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Bacteriophages (phages) are viruses which infect bacteria and are ubiquitous 
in nature. Phage research has undergone periods of interest and indifference, but are 
now common tools with some suggesting that they will become important as 
antimicrobial agents in food and in medicine. The first chapter of this thesis is in two 
parts. Chapter 1a reviews the discovery, basic biology, and applications of phages. 
They have varied uses such as in models for predator and prey dynamics studies, as a 
last resort in the fight against antibiotic resistant infections, in the treatment of illness 
and disease by faecal transplant, in food safety, in phage display and the expression of 
antibodies and peptides, and in metagenomics studies to understand human health and 
disease. In the chapters that follow four of these applications were investigated. 
Chapter 1b addresses the barriers that should be taken into account in order to use 
phages successfully in food and feed. These issues can also arise when using phages 
in phage therapy. 
Chapter 2 investigated a commercially available phage against Listeria 
monocytogenes, the causative agent of a serious foodborne illness. Phages can be used 
as clean label additives which are becoming more accepted than traditional additives 
by consumers. Phage alone and in combination with a commercially available 
bacteriocin, a ribosomally produced antimicrobial peptide, caused a significant 
reduction of L. monocytogenes in a food model.  
In Chapter 3 the effect of hormonal contraception on the human faecal virome 
was investigated in a pilot study. No differences in viral or bacterial diversity were 
found between men and women but viral diversity was found to be reduced in women 
using hormonal contraception compared to women not using hormonal contraception. 
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Clustering increased the discriminatory power of the virome data. This could be 
important for establishing inclusion or exclusion criteria for subjects or choosing 
healthy controls for studies. 
Chapter 4 addresses the isolation of phages and the analysis of single 
nucleotide polymorphisms (SNPs) in phage strains. Notwithstanding the importance 
of culture-independent methods for studying phages the isolation of phages is still 
necessary. No phages were isolated from the same source as bacterial strains but a 
number were isolated from environmental samples, illustrating the value of looking in 
different sources and new environments. 70 strains of Escherichia coli phage 
APCEc01 were isolated and compared to each other and the original sequenced 
genome of APCEc01. This highlighted the variation that occurs in genomes of the 
same phage and its possible impact.   
In Chapter 5 a jumbo phage was isolated against Klebsiella aerogenes, a 
member of the ESKAPE pathogens which are of concern due to their ability to cause 
hospital acquired and antibiotic resistant infections. The phage isolated was effective 
against K. aerogenes biofilms which are routinely found on medical devices. The 
phage in combination with Phage K was effective against a mixed biofilm of K. 
aerogenes and Staphylococcus aureus. 
 Phages have myriad applications in food and medicine. Since their discovery 
the number and breadth of applications have continued to grow. This research 
highlighted these uses and investigated a number of them in greater detail. This 
included the use of phage as useful tools in food safety, the first study highlighting the 
effect of hormonal contraception on the human gut virome, the isolation of a novel 
phage against a clinically relevant pathogen and its application as a tool to combat 
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biofilms, and an investigation into the isolation of phages and the incidence of single 











Bacteriophages (phages) are viruses of bacteria and therefore require a 
sensitive bacterial host for the production of new phages. Phages are the most 
abundant biological entities on earth and are found in almost every environment 
including the guts and homes of humans, in the guts of insects, and in oceans (1-4). 
They are also found in more extreme environments such as in hot springs, deep sea 
thermal vents, and arctic sea ice (5-7). Some estimates put viral numbers at 10 times 
that of bacterial cells worldwide (8). In some environments viral numbers can be up 
to 150 times greater than bacterial numbers. Viral abundances in oceans vary 
depending on the depth and environment, with the majority between 3.7X105 and 
6.4X107 per ml. Virus-like particles were estimated to be present in hot springs at 
concentrations ranging from 7X104 to 7X106 per ml (5). Viral abundance in human 
faeces has been estimated at 1.1X108 to 1.8X1010 per gram (9, 10). 
 
Discovery of phages 
Phages were independently discovered by Frederick Twort and Felix 
D’Herelle in 1915 and 1917, respectively (11). Twort discovered phages while 
carrying out experiments to investigate how viruses could be grown without the use 
of host cells. Twort believed that viruses from sources such as water, vegetation and 
faeces after incubation in water for periods of time and subsequent filtration could be 
grown outside of cells on artificial media consisting of an agar, egg or serum base with 
the addition of chemicals or extracts. Although this is now known to be false this 
experimentation led to the discovery of phages. After inoculating agar with unfiltered 
fluid used for vaccinating against small pox micrococcus contamination grew while 
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vaccinia virus, unsurprisingly, did not. It was observed that some micrococcus 
colonies took on a “glassy and transparent” appearance and could not be sub-cultured 
and grown on any media (12). These “glassy and transparent” colonies passed the 
attributes on to any colonies in which they came in contact and could be filtered and 
still retain this ability. Twort had discovered a virus of bacteria but was not confident 
in naming it so and simply said that it might be “an acute infectious disease of 
micrococci". The work was interrupted by Twort’s service during World War 1 (13). 
He did not continue with the investigation of what we now know to be bacteriophages 
after he returned to research. 
D’Herelle first viewed what we know to be phage plaques when culturing 
coccobacillus to infect and kill plagues of locusts as areas free of growth in confluent 
lawns of bacterial cells (14). He came to the opinion that two agents were present, one 
infecting the locusts and one inhibiting the growth of the bacterial culture that was 
filterable. The true discovery of phages by D’Herelle occurred when he was 
investigating a dysentery epidemic (11). Encouraged by his coccobacilli work 
D’Herelle followed the appearance of plaques from the filtered faeces of dysentery 
patients on cultures of bacteria isolated from the faeces of dysentery patients. At first 
he considered the clear spots could be the causative agent of the dysentery but 
reconsidered this after the feeding of filtered faeces of infected individuals failed to 
cause an infection in animals. He observed that plaques occurred during the recovery 
of patients and that the filterable agent could make a turbid bacterial culture clear. He 
had discovered a filterable virus that was parasitic on bacteria and named them 
bacteriophages. D’Herelle investigated them for their use in phage therapy and 
developed techniques which are still in use today. The areas free of growth seen in the 
coccobacillus cultures were not mentioned in his first communication about phages 
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but instead concentrated on his work regarding dysentery. D’Herelle denied having 
prior knowledge of Twort’s work and asserted that he only became aware of it in 1921 
after it was brought to his attention by other scientists. 
 
Phage biology 
Structure and taxonomy of phages 
Phages share a common structure of a filamentous nucleic acid core 
surrounded by a protein coat (15). The nucleic acid core can differ in being double-
stranded or single-stranded and consist of DNA or RNA. The protein coat consists of 
repeated identical subunits called capsomeres which give the virion a symmetrical 
structure which is prolate or icosahedral in shape. Icosahedral heads are essentially 
round in shape and are made up of identical capsomeres while prolate heads resemble 
an elongated icosahedral shape. The identical, repeated capsomeres reduce the number 
of different proteins which must be expressed by the phages to form new functional 
virions which is necessary as phages often have genomes which are smaller than would 
be expected to be necessary for the production of progeny. The entire infective particle 
is known as a virion. In general, phages consist of a head attached via a neck, 
surrounded by a collar, to the tail sheath and base plate which can then end in tail 
spikes or fibres (16, 17). Some do not have tail structures such as the Microviridae, 
which have circular head structures with no tail, or filamentous phages which are long 
and rod-shaped (15). 
Although the 16S rRNA gene can be used to classify bacteria phylogenetically 
phages have no conserved genes which can be used in a similar way (18). Phages have 
been historically classified based on a number of different parameters such as nucleic 
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acid composition, phage morphology and the bacterial host they infect. Each method 
of phage classification has its disadvantages, such as the lack of homology if using 
conserved genes and a lack of distinction using nucleic acid and morphological based 
classifications. The current taxonomy system for phages groups them together based 
on shared characteristics with further sub-division into families based on more closely 
related shared characteristics. Genus and sub-genus are characterised by genome 
configuration, host range and genome size. This system fails to take into account new 
information from metagenomics and proteomics and has led to calls for changes to 
reflect the growing field (18, 19). For example, despite the fact that they are so closely 
genetically related that they form functional hybrids P22 and lambda phage are placed 
in different families. It has been suggested that metagenomic sequencing data should 
be included in the taxonomy criteria. 
The order Caudovirales are double-stranded DNA tailed phages which consist 
of the families Myoviridae, Siphoviridae and Podoviridae among other phage families 
(Fig. 1) (20). Myoviridae have long contractile tails, Siphoviridae have long 
noncontractile tails and Podoviridae have short noncontractile tails. Phage tails are 
involved in the recognition of host cells, adsorption to the bacterial cell, penetration 
of the cell, and delivery of nucleic acid from the head into the bacterial host cell (21). 
Phage tails can end in a tail tip or more complex base plate structure with tail fibres or 
spikes which initiate infection after the tail fibres or spikes bind to the host cell. Phage 
receptor-binding proteins recognise bacterial protein or carbohydrate receptors on the 
bacterial cell. Common receptors on Gram negative bacteria include LPS, flagella 
proteins, pili, porins and other outer membrane proteins. Peptidoglycan and teichoic 
acid, components of the cell wall, are common receptors in Gram positive bacteria 
(22). Bacterial resistance to phage can occur by bacteria modifying their receptors but 
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also by the degradation of invading phage nucleic DNA (21). In turn phage can modify 
their receptor-binding proteins to overcome bacterial resistance. Phage receptor-
binding proteins are highly specific in their recognition of bacterial receptors and in 
this way play an integral role in determining the host range of a phage in conjunction 
with factors such as the presence of protective plasmids or prophage, phage resistance 
mechanisms and biochemical interactions (23). The host range of a phage can vary 
from a single bacterial strain to multiple bacteria from different genera. Phages are 
often described as having a broad or narrow host range but these terms are ambiguous 
in their description of the host range. Two phages infecting a number of strains or a 
number of species could both be described as having a broad host range. After 
recognition of receptors signalling occurs through the tail fibres or tail tip to the tail 
causing the ejection of nucleic acid from the head through the tail and into the host 
cell (24). In the case of T4 phage, a member of the Myoviridae family which all contain 
a sheath around the tail, the long-tail fibres recognise Escherichia coli and short-tail 
fibres located on the base plate bind irreversibly to the host cell causing a 
conformational change in the base plate from a high energy conformation to a low 
energy conformation. This energy change contracts the tail sheath causing the tail tube 
to enter the host cell where the phage DNA is introduced. 
Single-stranded DNA phages are grouped into eight families with two families 
infecting bacteria, Microviridae and Inoviridae (25, 26). Both families have circular 
genomes and replicate by rolling-circle replication. Microviridae have small 
icosahedral capsids while Inoviridae are filamentous phages. The Microviridae are 
further sub-divided into the genus Microvirus and the sub-family Gokushovirinae. 
Single-stranded DNA phages are less widely studied than the Caudovirales. The 
International Committee on Taxonomy of Viruses (ICTV) phage database contains 
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predominantly Caudovirales phages and also more Inoviridae phages than 
Microviridae phages. Conversely MetaVir, a web server for annotation of viral 
metagenomics datasets, contains a much higher percentage of single-stranded DNA 
phages than the ICTV database with the majority of these being Microviridae phages 
rather than Inoviridae phages.  
RNA phages are grouped into two families, Leviviridae and Cystoviridae (27). 
The Leviviridae are single-stranded RNA phages while the Cystoviridae are 
segmented, double-stranded RNA phages. Very few genomes are available for either 
RNA phage family, in part due to the focus on DNA phages in metagenomics but also 
because of difficulties in culturing RNA phages. Difficulties in culturing also occur 
with DNA phages. RNases in human and animal samples can degrade or damage RNA 
phages and make their discovery or study less likely (28). For this reason it has been 
suggested to separate RNA and DNA from samples and to eliminate RNases. There 
are also suggestions that some viruses have been misidentified as RNA viruses when 
they may actually be RNA phages. This draws attention to the need for better 
characterisation of RNA phages. Single-stranded RNA genomes can be negative or 
positive sense depending on their orientation and whether they require transcription 
before translation. Positive sense RNA can act directly as mRNA during replication. 
Phage genomes are often small and only consist of a few genes necessary for 
the replication of the phage genome and protein coats. Phages use the machinery of 
their host for replication. RNA phage genomes can reach up to ~4kb in length which 
is considerably smaller than double stranded DNA phages of which the smallest is 
~11kb (27, 29). Tailed phages with genomes larger than 200 kbp are termed jumbo 
phages (30). Jumbo phages are characterised by their large genomes and large virions. 
Tailed phages require at a minimum genes for DNA replication, transcription 
12 
 
regulation, DNA packaging, head, tail and tail fibres, and lysis (31). In addition to 
these core genes phages can carry genes to improve or aid phage and bacterial host 
survival. Bacterial virulence factors and toxins can also be phage encoded. 
Phage replication 
Phages require the machinery of a bacterial cell to express the proteins required 
to assemble new phages. The phage life cycle involves adsorption to a host cell, 
injection of nucleic acid into the host, replication of nucleic acid and production of 
phage proteins using the host machinery, virion assembly, and release (Fig. 2) (32). 
Phage life cycles vary and are described as lytic, lysogenic, pseudolysogenic, or 
chronic. Phages can be described as virulent or temperate with virulent phages 
undergoing a progeny phage producing lytic lifecycle while temperate phages can 
change between a progeny phage producing lytic lifecycle and a non-producing 
lysogenic lifecycle (33). As the name implies lytic replication requires the lysis of the 
bacterial host cell for the release of progeny phages (34). A lysogenic life cycle occurs 
when the phage genome is integrated as a prophage into the bacterial genome (33). 
Phage proteins are then expressed during the normal expression of the bacterial genes 
along with the bacterial proteins. Prophages have been found in ~60% of published 
bacterial genomes. A lysogenic life cycle can also occur when phages survive as 
plasmids in the host cell (34). Lysogeny may be useful when too few encounters will 
happen between phages and a permissive host, for instance when host abundance is 
too low or when too many phages are being removed from the system (32). This can 
occur when resources are limited (33). Phages use repressor genes to control the switch 
from lysogeny to lysis by repressing the lytic cycle. These repressors can also block 
the integration of any other phage genomes. The infection of a bacterial cell by 
multiple phages can occur and is called superinfection. The induction of prophages 
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can be triggered by impending host death which can be seen as DNA damage. 
Bacterial DNA damage can be caused by a range of chemical and physical methods 
including antibiotics targeting DNA replication, UV damage and reactive oxygen 
species. Prophage induction can also be triggered by molecules which signal that the 
phage is in a better location to find a receptive host (35). Cell lysis takes place using 
endolysins to break down the peptidoglycan and holins to damage the plasma 
membrane (32). When no cell lysis occurs phages can be released by budding or 
extrusion in what are termed chronic infections where phages are continually released. 
Pseudolysogeny is a poorly understood system whereby phage nucleic acid occupies 
the cell in a non-active state and does not establish a lysogenic or lytic lifecycle (36). 
This may be due to a starved or stressed bacterial state which does not provide enough 
energy or the correct conditions for phage replication. 
Phages in any form, lytic or lysogenic or something in between, can aid their 
host (37). Free phages kill related competitors allowing their hosts access to resources. 
Infection by prophages can protect hosts from infection by closely related phages.  
Phages are important for horizontal gene transfer between bacterial species and act as 
reservoirs of genetic diversity (38). Host bacterial genes can be accidentally packaged 
in phage heads instead of phage DNA. These phages lacking phage genes can then 
attach to new hosts and deliver the bacterial DNA that is then incorporated into the 
new genome. Also prophages can carry genes that are incorporated into the host 
genome with the prophage. Botulism, diphtheria, cholera, and illnesses caused by 
Shiga toxigenic E. coli are all caused by exotoxins, all of which are phage-encoded 
virulence factors. Virulence factors are not required by the phages for replication but 
aid the bacteria in proliferation and infection of a mammalian host. Phages can also 
carry antibiotic resistance genes between bacteria (39). 
14 
 
Bacterial resistance to phages 
On the other hand, phages can also hinder bacteria as evidenced by the many 
methods that bacteria use to stop phage infection (40, 41). Bacteria can resist phage 
infection by a number of methods such as preventing phage adsorption, superinfection 
exclusion, restriction-modification, CRISPR-cas, and abortive infection. Bacteria can 
stop or reduce adsorption by phages by modifying or completely removing receptors, 
reducing the number of receptors, masking receptors by the production of extracellular 
matrix, or the production of competitive inhibitors. Low phage adsorption rates can 
cause changes in phage dynamics. In phage dynamics models the rate at which the 
phage and bacterial populations change depends on five parameters - the infectivity of 
the phages, which is based on the adsorption rate; the burst size, which is the number 
of phage progeny produced from a single bacterial cell; the latent period, which is the 
time between adsorption and release of progeny phages; the rate at which the phages 
are inactivated or removed from the site of the infection; the maximum bacterial 
growth rate and two variables - the density of susceptible bacteria; and the density of 
phages (42). 
Superinfection exclusion is counted as a phage resistance system but is due to 
the presence of a phage in the host genome. It occurs when the presence of a phage in 
a host cell prevents infection by a second phage (43). Superinfection exclusion is 
carried out by the phage to avoid lysis of the host cell by the invading phage and the 
original phage being lost in the process.  
Bacteria use restriction-modification systems to protect against invading DNA 
in two ways using methylase and restriction endonuclease enzymes (41). Host DNA 
is methylated to protect against restriction. Upon entry into the cell phage DNA will 
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be recognized by a restriction enzyme, as it is unmethylated, and degraded. In some 
cases foreign DNA can be methylated upon infection by a bacterial methylase and 
avoid restriction.  
Bacteria can also use the CRISPR-cas system (Clustered Regularly Interspaced 
Short Palindromic Repeats loci, coupled to CRISPR-associated genes) for phage 
resistance (44). Upon interaction with a phage the bacteria integrates spacers derived 
from the phages DNA into the CRISPR locus between CRISPR repeats. Bacteria can 
insert multiple spacers to derive widespread resistance. The CRISPR locus provides 
specificity while the cas system provides the enzymatic function and degrades phage 
DNA. Bacteria use multiple systems together to protect against phage infection such 
as a combination of restriction-modification and CRISPR-cas (45).   
Abortive infection provides resistance by the abortion of phage infection; 
however, this also kills the infected cell (46). This limits the spread of phage by 
decreasing the number of progeny released. Abortive infection systems can interfere 
with phage DNA replication, RNA transcription, phage development, and 
morphogenesis (47).   
Phage overcoming resistant bacteria  
 Phage can also try to overcome bacterial phage resistance (48). Firstly, phage 
resistance itself can reduce bacterial fitness and the ability of bacteria to compete with 
phage-sensitive bacteria. Phage resistance can reduce the virulence of bacteria due to 
the loss or mutation of virulence factors (49). Through mutation phages can modify 
their receptor binding proteins to target alternative proteins to combat changing 
receptors (50). Phages can produce enzymes to break down extracellular matrices that 
protect receptors from recognition. Phages can modify restriction sites or place them 
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in an unrecognisable order, stimulate methylase enzymes to cause methylation of 
phage DNA so it is recognised as bacterial DNA, or modify DNA to avoid recognition 
by restriction modification systems. To avoid the CRISPR-cas system phages can use 
mutations in the protospacer or protospacer-adjacent motif or produce anti-CRISPR 
proteins that interfere with the system. Toxin-antitoxin systems are a subgroup of 
abortive infection systems that contain a toxin that induces cell death or dormancy and 
a neutralising antitoxin. Phages can avoid these systems by neutralising the toxin or 
mimicking the antitoxin. In other cases phages can prevent the activation of abortive 
infection systems or exchange genomic regions with prophages that are already 
present. 
 
Applications of phages 
Phage dynamics 
Phages can change the composition of bacterial communities through the 
predation of bacteria. Bacterial and phage co-adaptation leads to evolution of 
community members and aids in the maintenance of a diverse community and a large 
pangenome (51, 52). In the absence of phages bacterial diversity is dependent on the 
availability of substrates and bacterial substrate usage. Changes in substrates can cause 
diversity to be low as less adapted bacteria will be out-competed and users of the most 
commonly available substrate will overgrow. The presence of phages allows for the 
exploitation of less favoured niches and multiple bacterial lineages will be able to 
compete causing higher bacterial diversity. 
Antagonistic coevolution is the reciprocal development of predator and prey 
resistance and infectivity in response to one another (53). Antagonistic coevolution 
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increases community diversity. Phages and bacteria are often used as models for the 
study of antagonistic coevolution. Simplified benchtop experiments can be used to try 
and examine the importance and effects of phage dynamics in the gut. Phages increase 
bacterial fitness, by superinfection and introducing virulence or resistance genes, and 
competition. Phages can increase rates of bacterial evolution through stress response 
and genetic mutation (54). This increased evolution caused by the presence of phages 
has been suggested as a reason for the inter-individual variation seen between 
individuals (52, 55). Lysogenic cells have been found to be at a disadvantage in 
unstructured habitats and at an advantage in structured habitats, which could represent 
different areas of the human gut (56). Inaccessible areas such as crypts, biofilms, and 
the appendix could act as refuges for bacteria that prevent complete elimination and 
because of this prophage may have more of an effect than lytic phages (57). 
Phage therapy 
Although there was a period of interest in using phages to combat infectious 
disease, such as in the control of dysentery and during World War II, this ended due 
to the discovery and use of antibiotics (58). This was also due to the lack of strong 
scientific experimentation and literature for the use of phages as phage therapy and 
the lack of basic knowledge about phages (59). The majority of evidence for the use 
of phage therapy was small scale and based on largely anecdotal accounts. Another 
important issue was the efficacy of antibiotics, in that while they were so effective in 
the treatment of illness and saved the lives of so many it may have seemed unnecessary 
to look for an alternative (60). Political issues also had an effect on the use and trust 
placed in phage therapy. Phage therapy was mostly used by the Soviet Union and the 
German army during World War II and this lead to distrust around the use of it by the 
western world. Although phages have been studied deeply the lack of knowledge about 
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phages is still an issue when it comes to using phage therapy. Phage therapy is still in 
use in Georgia, Poland and Russia. 
Some estimates suggest that by 2050 ten million people will die every year due 
to antimicrobial resistant infections (61). The WHO has recently declared antibiotic 
resistance a global emergency, with alternatives treatments required immediately (62). 
In a 2015 Global Action Plan on antimicrobial resistance the WHO described 
antimicrobial resistance, which includes antibiotic resistance, as a threat to “the very 
core of modern medicine and the sustainability of an effective, global public health 
response to the enduring threat from infectious diseases”. The action plan also 
highlighted the shortage of emerging antimicrobials which could bring us from a pre-
antibiotic era to an antibiotic era to a post-antibiotic era in a matter of 100 years. The 
WHO pledged US$41.7 million to combating antimicrobial resistance for one 
financial year alone. The WHO has compiled a list of pathogens that are a priority in 
the fight against antimicrobial resistance (63). Mycobacterium tuberculosis is the top 
priority pathogen with carbapenem-resistant Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacteriaceae described as critical priorities. Vancomycin-
resistant Enterococcus faecium, clarithromycin-resistant Helicobacter pylori, 
fluoroquinolone-resistant Salmonella species, vancomycin-resistant or methicillin-
resistant Staphylococcus aureus, fluoroquinolone-resistant Campylobacter species 
and 3rd generation cephalosporin-resistant and fluoroquinolone-resistant Neisseria 
gonorrhoeae are described as high priority pathogens. Penicillin-non-susceptible 
Streptococcus pneumoniae, ampicillin-resistant Haemophilus influenzae and 
fluoroquinolone-resistant Shigella species are described as medium priority 
pathogens. The low number of new antibiotic compounds in development and the long 
time frame associated with their development and approval are of concern. The low 
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likelihood of approval means that only one or two in ten antibiotics will be approved 
for market and the average development time from Phase-1 safety trials to approval is 
about seven years. Many antibiotics in development are derivatives of well-established 
antibiotics and resistance will develop quickly. The low success rate of approval and 
the paucity of new classes of antibiotics means these will not be enough to combat the 
global antimicrobial resistance issue. The WHO report on antimicrobial resistance also 
draws attention to the importance of antibiotic use in animals adding to antimicrobial 
resistance. Antimicrobial resistance is a One Health problem meaning that the health 
of humans, animals and the environment are connected (64). Environmental bacteria 
can act as reservoirs of antimicrobial resistance genes that can be transferred to 
humans or animals. These genes can enter the environment through human and 
animals waste but also through the pharmaceutical industry. Combating a One Health 
problem requires an integrative approach through targeting of all of these areas. 
Research is growing in the use of phages as medical interventions. Phage 
therapy is a potential solution to antibiotic resistant bacteria for which all antibiotic 
options have been exhausted (65, 66). Historically the fact that phages do not affect a 
broad spectrum of bacteria like antibiotics was seen as a disadvantage of their use, but 
is now seen as a positive attribute due to their more limited impact on the surrounding 
microbiota and in fighting against the rise of antibiotic resistance. They are self-
replicating meaning small numbers of phages can be added and numbers will increase 
if the pathogen is present. Conversely the self-limiting nature means that if host 
numbers decrease phage numbers will also decrease. The disadvantages associated 
with phages can be overcome by selecting the correct phages. Phages should be lytic 
and non-temperate, and therefore unable to transfer virulence or antibiotic resistance 
genes. Phages should be nontoxic to the organism they are being used in and no toxins 
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or toxin genes should be present. To increase the host range of the therapy and to 
reduce the problem of resistance phages can be used in cocktails. Phages could also 
be used in combination with antibiotics (67). Although not many phages have 
undergone clinical trials, phages against a range of the priority pathogens have been 
used in phage therapy (68-71) and in-vivo models (72-76). 
Phages have been effective in compassionate use cases and individual cases in 
clinical trials but overall clinical trials did not prove efficacy of phages (77). For 
phages to be used commercially they will need to be produced under Good 
Manufacturing Practice (GMP) guidelines and infrastructure. This could be 
problematic as GMP production would greatly increase the cost. In the case of 
PhagoBurn, a Phase I and II clinical trial carried out in using a phage cocktail against 
burn wound infections, GMP production was suggested to be the cause of delayed 
patient recruitment and reduced phage titre.    
Endolysins 
 Endolysins are enzymes that degrade peptidoglycan, a constituent of the 
bacterial cell wall, produced late in the lytic phage life cycle of double stranded DNA 
phages to allow for the release of progeny phages (78). Peptidoglycan is composed of 
repeat polymers of the amino sugars N-acetylglucosamine and N-acetylmuramic acid, 
linked by β-1, 4 glycosidic bonds. Tetrapeptide side chains are attached to the lactyl 
group of the muramic acid by amide bonds. Endolysins are hydrolase enzymes and 
can be separated in to five groups N-acetylmuramidases (Iysozymes), endo-β-N-
acetylglucosaminidases, and lytic transglycosylases, which all cleave the glycosidic 
linkage of peptidoglycan; endopeptidases, which cleave the peptide moiety; and N-
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acetylmuramoyl-L-alanine amidases, which cut the amide bond between both 
moieties. 
 Endolysins have been suggested as tools as opposed to the use of whole 
phages. Endolysins have the advantage that they are modular in nature making 
engineering possible (79). Endolysins can be engineered for enhanced ability or host 
range. No resistance to endolysins has been detected (80). Endolysins also have the 
advantage of having increased host range compared to corresponding whole phages 
and temperate phages that are not suitable for phage therapy can be used as endolysins 
(81). Also the use of purified phage endolysins could avoid any issues of immune 
response caused by the use of whole phages. Endolysins have been effective in the 
treatment of natural cases of bovine mastitis caused by S. aureus, MRSA is a WHO 
high priority pathogen. Endolysins were also effective in the treatment of 
experimentally induced Streptococcus pneumoniae, a WHO medium priority 
pathogen, pneumonia in mice (82). Endolysins have been suggested as a treatment for 
Clostridium difficile infection (CDI), a common consequence of antibiotic therapy that 
is currently treated with antibiotics and commonly recurs (83). No lytic C. difficile 
phages have been isolated to date meaning they are unsuitable for phage therapy. 
Endolysins have been investigated for use in food safety, in foods such as soya milk 
and lettuce, similarly to whole phages to reduce contamination with bacterial 
pathogens (84). Endolysins have also been investigated for use in detecting bacterial 
pathogens, especially in food. Current methods for detection include plating on 
selective media, PCR, and antibody based detection. These methods can involve long 
incubation periods and expensive molecular techniques. The detection limit for 
antibody based detection methods can be high with low specificity of binding for 
pathogens. Endolysins contain conserved cell wall binding domains which recognise 
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their specific host. Cell wall binding domains can be fused to fluorescent proteins and 
used to probe for pathogens. They act as rapid and sensitive detection systems (80). 
Faecal transplant 
 Faecal transplants, the transfer of whole faeces or portion of the microbiota 
contained within it, are gaining interest for the treatment of human illnesses and 
conditions (85). Faeces is a complex collection of bacteria, plant viruses, animal 
viruses, phages, archaea, fungi, human colonic epithelial cells, protists, and 
metabolites produced in the human body. Metabolites are often produced by 
commensal bacteria rather than human cells. It is not clear what component is the 
active agent of changes associated with faecal transplants. Bacterial numbers have 
been estimated at nearly 1011 bacteria per gram of wet stool, but almost 50% of this 
number could be injured or dead cells. Viral numbers have been estimated at 108 to 
109 viruses per gram of wet stool but could be up to 1010 viruses per gram of stool 
(86). However, phage concentrations are greater in the mucous associated with the 
gastrointestinal tract than the gut lumen and therefore the faeces (37). Phages may act 
as non-host derived immunity for the mucosal surfaces by lysing or binding bacteria 
and reducing microbial colonization.  
 Faecal microbiota transplants (FMT) have been mostly used to treat CDI. The 
role of the virome has also been assessed in some of these cases. Draper et al. (87) and 
Zuo et al. (88) both found an increased abundance of Caudovirales, a decreased 
abundance of Microviridae, and an increased abundance of Anelloviridae in patients 
suffering from CDI compared to healthy controls. CDI is characterised by decreased 
bacterial diversity due to an overgrowth of C. difficile. It is possible that the success 
of FMT is not due to the presence or absence of particular members of a community 
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but is due to the introduction of a more diverse community of which phages are a 
significant part. The failure of FMT may be due to inadequate engraftment of the donor 
microbiota. Zuo et al. (88) found that FMT responders acquired more donor-derived 
contigs than non-responders. The importance of donor selection was also called to 
attention as a positive treatment outcome was more likely if the Caudovirales richness 
of the donor was higher than that of the recipient. In a follow up study to the treatment 
of CDI with FMT it was suggested that FMT could be regarded as much a viral therapy 
as a bacterial therapy as viruses are such a large component of faeces (89). In fact, 
sterile faecal filtrate has been used to successfully treat CDI, albeit in a small number 
of cases (90). The filtrate contained bacterial debris, viruses, proteins, antimicrobial 
compounds, metabolic products, and oligonucleotides. Patients were followed up for 
between six months and two years and five months and all remained symptom-free for 
the entire study period. More study is required in the long term effects of FMT to 
pinpoint what is happening to the microbiome that allows for remission of disease and 
what components are causing the changes. In addition to CDI FMT has been studied 
in the treatment of immune checkpoint inhibitor therapy-associated colitis, ulcerative 
colitis and in the eradication of multidrug-resistant Enterobacteriaceae in the gut (91-
93).  
 The choice of donors is of the utmost importance as faecal transplant can have 
unwanted or unexpected effects. Recently it was reported that two individuals who 
had received FMT from the same donor developed invasive infections, caused by 
extended-spectrum beta-lactamase producing E. coli, of which one was fatal (94). This 
has led to the introduction of new screening requirements for donors by the FDA (95). 
These new requirements require samples to be tested for multidrug resistant 
organisms, and subsequent exclusion if they are positive; exclusion of people at a 
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higher risk of multidrug resistant organisms carriage from being donors; screening of 
stored donor faeces before use; and for informed consent to include the risks of FMT, 
the risk of multidrug resistant organisms, and the donor screening and testing process. 
It would be possible to carry out these checks on donors of transplants composed 
solely of the viral fraction. 
Food safety 
Twelve phage preparations have been approved for use in food in the U.S. and 
granted Generally Regarded as Safe (GRAS) status by the U.S. Food and Drug 
Administration (Table 1) (96). These can be used to target a selection of pathogens 
commonly associated with food including Listeria monocytogenes, Salmonella, 
Shigella, and E. coli. Some are licensed for use in all foods, such as ListShield or 
SalmoPro, while other are licensed for use in specific foods such as PhageGuard which 
can be used in beef only.    
Phage display  
Phage display is the insertion of foreign DNA fragments into a gene of the 
phage coat protein and the subsequent expression of the foreign DNA fragments on 
the phage surface (97). Phage display can be used for antibodies or peptides. Phages 
displaying the peptide or antibody of interest are then selected by binding to the 
antigen of interest and washing to remove non-binding peptides or antibodies. Higher 
affinity binding peptides or antibodies can be selected by specific wash steps. Phages 
are then eluted and amplified using E. coli and can be used in a subsequent round of 
selection or analysis. An advantage of phage display is the direct linking of phenotype 
of the displayed peptide to the genotype. Phage display also lends itself to high 
throughput screening, through the creation of random libraries and screening, which 
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has led to its use in developing diagnostics and therapies. Phage display can be used 
to screen peptide libraries and whole cells (98). The screening of whole cells has many 
advantages such as cellular receptors are kept in their native state, peptides that 
mediate cellular uptake can be preferentially selected by washing, there is no selective 
pressure towards a specific macromolecule, and no previous knowledge is needed 
about which macromolecules to target. A common target for whole cell phage display 
screening are cancer specific peptides on tumours. Once isolated the tumour specific 
peptides can be used for tumour specific drug delivery by the attachment of the peptide 
directly to chemotherapeutic agents or indirectly to a drug carrier. They can also be 
used for in vivo and in vitro tumour diagnostics.  
Phage display can be used to identify bacterial surface proteins by screening 
for mimotopes (99). Mimotopes are mimics of epitopes and cause similar antibody 
responses to their epitope. This can be used for vaccine development when little is 
known about the pathogenesis of a bacteria or its surface proteins have not been 
identified. Mimotopes can be used to identify the epitope they are similar to by 
homology search to the bacterial genome. 
Phage display technology can be used to produce monoclonal antibodies and 
has many advantages over traditional hybridoma technology (100). Phage display does 
not require the use of animals, can be used to produce antibodies against toxins and 
conserved antigens which hybridoma technology cannot, and is also faster than 
hybridoma technology. Phage displayed antibodies can be easily engineered and will 
not contain any mouse antibodies which can cause reactions when used in humans. 
Adalimumab (Humira®) was the first antibody generated using phage display 
approved for use; it became the bestselling antibody drug and achieved more than ten 
billion USD global sales in 2013 (101). It is used in the treatment of inflammatory 
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autoimmune diseases by the binding of tumour necrosis factor to inhibit the 
proinflammatory cytokine cascade. 
Viral metagenomics studies 
As previously mentioned, there is no conserved gene that can be targeted for 
phage identification like the bacterial 16S rRNA gene. Although advances in 
molecular biology and metagenomics have increased knowledge of phages there is 
still a lot to be learned and some issues remain to be resolved (25). Shotgun 
metagenomics can be useful in cases where phages cannot be cultured, which often 
occurs when the host itself cannot be cultured. In metagenomics studies there can be 
a bias towards certain groups of phages based on the methods used. Even within the 
relatively small group of eight families of single stranded DNA phages considerably 
more is known about one family, the Microviridae. Very few RNA phages have been 
isolated and sequenced and they are rarely found in metagenomic studies. This bias 
can be due to a lack of RNA and ssDNA reference genomes that allow us to assign 
taxonomy to sequences but also some virome extraction and library preparation 
methods can bias the system. In one study a linker amplified shotgun library returned 
only double-stranded DNA viruses while multiple displacement amplification 
returned mostly single-stranded DNA viruses using the same sample (102). Viral DNA 
extraction methods can also affect sequencing outcomes (103). There are large 
numbers of sequences in metagenomic studies that cannot be identified or 
taxonomically categorised, this can be referred to as “viral dark matter” and can 
represent 60-95% of sequences in datasets (104). This may be due to the absence of a 
universal gene marker for phages and the relatively low number of phage sequences 
in publically available databases, in comparison to bacterial sequences. These 
unidentified sequences can make it difficult to mine information from data leading to 
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issues such as not being able to link bacterial hosts to phages or understanding the 
impact that phages have on a community. Another problem associated with viral 
metagenomics is the inability of some assembly programs to accurately assemble 
virome data (105). In some cases viromes simply cannot be assembled while in other 
cases multiple viromes can be misassembled together to form chimeric sequences that 
will be unidentifiable. Difficulties in assembly can be caused by bias in the processing 
and sequencing of viromes, unequal read coverage, the highly variable genome 
structure of phages due to horizontal gene transfer, and contamination by and 
subsequent inclusion of bacterial or human reads. The inclusion of prophage 
sequences in bacterial genomes and bacterial DNA in phage genomes from previous 
hosts can further complicate annotation (38, 39). Viral load has been shown to vary 
greatly between individual samples (86). Few studies have taken this in to account and 
often just rely on relative numbers rather than absolute. The correct choice of virome 
preparation protocol, assembly program and database are essential to an accurate viral 
metagenomics study. 
Metagenomics can be used to find things which were previously unknown such 
as crAssphage which was discovered using metagenomics data in 2014, despite never 
being cultured (106). CrAssphage has been found to account for up to 90% of the reads 
in the virus-like particle-enriched fraction of some gut metagenomes studies (107). 
Subsequently, crAssphage has been suggested to be a family of phages rather than a 
single phage as previously indicated. In 2018 a crAssphage was cultured for the first 
time and its host was confirmed as Bacteroides intestinalis (108). 
The human virome is highly specific to individuals (109). This makes looking 
for trends and changes difficult as the viromes of subjects vary so much. While the 
bacteriomes of monozygotic twins and their mothers were more similar than those of 
28 
 
unrelated individuals the viromes did not reflect this and were unique to individuals. 
While inter-individual variation was high, intra-individual variation was low over the 
period studied. This individuality was also seen by S. Minot et al. (55) who showed 
that over a two and a half year period 80% of viral contigs persisted in an adult subject. 
Phages were defined as “core” if found in more than 50% of people in a dataset, 
“common” if found in 20–25%, and “rare” representing phages rarely shared or unique 
to a person (110). Together the “core” and “common” phages were proposed as a 
healthy gut phageome. The selection of healthy controls in studying disease is 
important and it has been suggested that household controls would be the best choice 
as they would be the most similar (111). This was also highlighted for microbiome 
studies where members of a household were more similar than those not sharing a 
home (2). Viral metagenomics studies could be useful in identifying the cause of 
illnesses or as biomarkers of disease. For example, a significant increase in viral 
richness was seen in IBD sufferers compared to healthy controls (111). The viruses 
causing this increased richness differed for ulcerative colitis and Crohn’s disease 
sufferers. V. Pérez-Brocal et al. (112) found an association between some viruses and 
the onset of inflammatory symptoms which could be useful as biomarkers. The virome 
of tooth plaque was found to be significantly different between those with and without 
periodontal disease (113). 
Conclusion 
 Phages have a relatively short history, having been independently discovered 
in 1915 and 1917, but they have been playing an important role in bacterial evolution 
for billions of years. Understanding phage biology is crucial to their implementation 
as tools. Phages have relatively small genomes, require a bacterial host for replication, 
and can present a number of different lifecycles. Phage taxonomy is complicated by 
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their lack of conserved genes and the large variations between phages. Phages and 
their hosts are constantly evolving for infectivity and resistance to one another with 
varying levels of success. Phages are currently widely used but this could increase 
further over time as knowledge and need increases. Community dynamics can be 
studied through phage-host lab experiments and metagenomics studies. Changing 
attitudes and rising levels of antimicrobial resistance have renewed interest in phage 
therapy and brought to light the use of phages in food safety. Endolysins are also an 
option for these issues. Faecal transplants may be a powerful tool in the treatment of 
CDI and other illnesses for which there is no adequate treatment. Phage display is a 
tool for the production of peptides and antibodies for countless purposes. 
Metagenomics studies may be the key to understanding the causes or successful 
treatment of many conditions.  
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Figure 1. Morphologies of prokaryotic virus families. Figure sourced from H. W. 













Figure 2. Replication of phages during the lytic and lysogenic cycles. In short the lytic 
lifecycle involves phage adsorption, DNA injection, phage replication using the host 
machinery, phage protein assembly, DNA packaging, and release of progeny phages. 
Lysogeny occurs when the phage integrates into the bacterial host DNA and replicates 
with the host. Prophages can also re-enter the lytic cycle. Figure sourced from Davies, 






Table 1. U.S. Food and Drug Administration Generally Recognised as Safe (GRAS) 
Notices for phage preparations in food (96).  
GRN 
number 
Year Target Phage content Notifier Name Food 




218 2007 L. monocytogenes P100 EBI Food 
Safety 
(Micreos) 
Listex All foods 






Intralytix SalmoFresh All foods 
468 2013 Salmonella FO1a, 
S16 
Micreos Salmonelex  Pork, poultry 






Intralytix ListShield All foods 
603 2016 Salmonella    BP-63, 
BP-42 











Intralytix ShigaShield All foods 
724 
 




















   














Micreos PhageGuard Beef 
827 2019 E. coli 3 phage 
cocktail 
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 Bacteriophages (phages) can play a useful role as narrow spectrum 
antimicrobials in food safety and in food production. Consumer attitudes towards 
traditional additives have led to a search for natural, potentially clean label, 
alternatives. At the same time, the rise in antimicrobial resistance has created a need 
for alternative antimicrobials for disease prevention and treatment in animal 
husbandry. Phages represent a viable option for both of these applications. We 
highlight important barriers which should be considered to improve the chance of a 
positive outcome when using phages in food and food production. These include the 
feasibility of adding high concentrations of phages, the physico-chemical properties 
of the food or target, how and when phages are applied, and which phages are chosen.  
 
Introduction 
Bacteriophages (phages) are bacterial viruses and use bacteria to produce new 
phages. Phages can replicate using lytic or lysogenic lifecycles. Lytic phages replicate 
by attaching to a host cell, injecting phage nucleic acid, replicating the phage nucleic 
acid, assembling proteins, packaging nucleic acid with head and tail proteins, and 
lysing the host cell to release new phages (1). Lysogenic phages integrate into the host 
genome and replicate along with the host. Interest is growing in the use of lytic phages 
as biocontrol agents of foodborne pathogens in food and food production (2). Phages 
can be used in a number of ways in food and feed and can also be applied as pre or 
post-harvest interventions. Recently there has been a change in consumer attitudes 
towards how food should be processed and preserved with rising interest in the concept 
of “natural foods” and “naturalness” (3). The importance of consumers’ perception 
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should not be overlooked as it has a significant effect on willingness to buy a product 
and can even affect how individuals enjoy and experience that product (4). The 
importance of this changing consumer attitude has led to the introduction of the term 
“clean label”; these products aim to have simple ingredient lists free from “chemical-
sounding” terms and negatively perceived ingredients (5•). It has been found that 
consumers are more willing to accept additives from natural sources than the chemical 
additives that have been used for decades. This rise in clean label food has increased 
the demand for new methods to ensure food safety. Another reason for introducing 
phages is the problem of antimicrobial resistance. A WHO report on antimicrobial 
resistance drew attention to the contribution of antibiotic use in animals to 
antimicrobial resistance in general (6). Antimicrobial resistance has been termed a One 
Health problem and requires an integrative approach targeting the environment and 
the health of humans and animals (7). Historically the antibiotics used in treating 
livestock have been the same as, or closely related to, those used in human medicine 
and the use of long-term sub-therapeutic doses of antibiotics, as they have been used 




The success of phages for use in food and feed depends on the overcoming of 
a number of barriers. The number of phages used is of great importance; in general, 
the higher the concentration of phages the more significant the reductions in target 
bacteria. Bai, et al. (8••) found that a phage cocktail at multiplicity of infections 
(MOIs) of 103 and 104 significantly reduced the Salmonella Typhimurium load of 
cucumbers and lettuce. The cocktail at an MOI of 104 led to a greater and more 
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sustained reduction. Phage at MOIs of 1, 10 and 102 significantly reduced S. 
Typhimurium on lettuce with the reductions increasing as the phage concentration 
increased (9•). This was also evident using  SalmoFreshTM, an FDA approved 
Salmonella lytic bacteriophage preparation, on chicken fillets (10). SalmoFreshTM 
applied at MOIs of 102 and 103 both significantly reduced a combination of S. 
Typhimurium, S. Heidelberg and S. Enteritidis at an initial concentration of 3 log 
CFU/g on chicken fillets. SalmoFreshTM at an MOI of 103 was significantly better than 
phage at an MOI of 102. In other examples, a single phage was used to control 
Escherichia coli on raw and cooked beef (11), while ShigaShieldTM reduced Shigella 
levels in smoked salmon and yogurt (12••). In both cases the reduction was 
concentration dependent with the greatest reduction occurring at the highest phage 
titre tested. Using ListexTM P100, a commercially available phage against Listeria 
monocytogenes, a greater reduction was seen in tuna using an MOI of 102 than an MOI 
of 0.1 (13). The greatest effect was seen with a lower starting concentration of L. 
monocytogenes combined with a higher concentration of ListexTM P100. However, 
phage concentration is not a definitive indicator of a positive outcome. A  low titre 
phage cocktail decreased chickens’ mortality and morbidity in a natural outbreak of 
Avian Pathogenic E. coli (APEC) but not in experimentally infected chickens (14). 
This could have been due to the non-synchronous nature of the natural outbreak. In a 
natural outbreak all of the cases would be not at the same point in their infection cycle 
and the low titre phage cocktail may have controlled the infection at the early stages 
and interrupted the transmission. This would not have occurred in the experimental 





Feasibility of adding high phage concentrations 
The need for high numbers of phages for successful phage treatment brings up 
the question of the feasibility of generating phages at high enough titres to deploy in 
food or feed. Salmonella on post-chill chicken carcases has been suggested as a target 
as numbers do not usually exceed 3 log CFU/g (15). The inoculation of 25 g samples 
of turkey fillet with 500 µl of a 109 PFU/ml bacteriophage preparation was sufficient 
to significantly reduce S. Heidelberg over a seven day period and represented a 
reasonable volume of phage preparation to be applied. In a study of the application of 
FinalyseTM hidewash, ~3x1010 phage/head of cattle in one gallon of water was used 
(16). This was insufficient to reduce E. coli O157:H7 contamination of cattle hides 
and carcasses but given the one gallon quantity needed it may be difficult and cost 
prohibitive to increase the titre used. Recombinantly expressed endolysins isolated 
from phages could possibly be used in place of whole phages to avoid this issue (17), 
though once again the economic viability of this solution would have to be 
investigated. Issues with GMO legislative approval and consumer acceptance may 
limit the use of endolysins in food safety (18). 
 
Properties of the target matrix 
The properties of the targeted food or animal in question can be a barrier to 
phage success. The target matrix can affect the efficiency of phages. In a study of a 
single phage to reduce S. Typhimurium in whole milk, skimmed milk, energy drink, 
apple juice, and liquid egg the smallest effect of the phage was seen in liquid egg (19). 
Phage titre increased in all foods except for liquid egg in which a decrease occurred. 
The highly viscous matrix of egg limiting diffusion and homogeneous distribution of 
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the phage particles was suggested as a reason for this reduced activity and the decrease 
in phage numbers. Similarly when looking at a phage cocktail to reduce S. Enteritidis 
in milk, cabbage, and chicken breast the greatest effect was seen in milk (20). Again 
it was proposed that the liquid allowed greater diffusion of the phages. Using a single 
phage it was necessary to use an MOI of 105 to reduce S. Typhimurium load in liquid 
egg and fruit juice while an MOI of 107 was required to give a similar reduction in 
cooked beef and chicken (21). SalmonelexTM, a commercially available phage cocktail, 
was effective in reducing Salmonella on chicken (22). SalmonelexTM diluted in tap 
water was more effective than in filtered tap water with reduced calcium, magnesium, 
and sodium. Temperature can also affect the activity of phages. The antibacterial 
activity of ListShieldTM, a commercially available phage against L. monocytogenes, 
was reduced at 12˚C compared to 4˚C (23). When using phages to reduce 
Staphylococcus aureus during the manufacturing of cheese it was observed that phage 
titre decreased with decreasing pH (24). Antacids can be given before or in 
combination with phages in animal application to improve the survival of phages in 
the gut by increasing pH (25, 26).  
 
Application method of phages 
The method of phage application can also be a barrier to a positive outcome. 
Although dipping and spraying are common methods for phage application, they can 
have negative effects (27). Dipping and spraying can release phage particles into the 
environment, dipping liquid can be a source of cross contamination and spraying 
equipment may not be available in the processing environment. Different methods can 
be used to suit the situation or to expand the conditions of activity of the phages. 
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Microencapsulated phages significantly reduced E. coli on tomatoes and maintained 
the reduction for 5 days (28). Microencapsulation reduced the UV sensitivity of the 
phages and increased the survival of phages at pH 3-7 and extreme temperatures. Free 
phages, paper impregnated with phages, and encapsulated phages all immediately 
reduced E. coli on alfalfa seeds and sprouts (27). After five days free phages and 
encapsulated phages had a significant effect compared to untreated controls. This can 
be case dependent as in the same study free phages reduced L. monocytogenes by 3 
log CFU/g in cantaloupes while encapsulated phages reduced numbers by only 1 log 
CFU/g over the same period. This was suggested to be due to how the bacteria attached 
to different food matrices represented by cantaloupe and alfalfa sprouts. A phage 
cocktail applied to chicken feed was as effective as phage introduced by crop gavage 
and represents a much easier mode of inoculation (25). Phages can also be applied in 
more unexpected ways such as in the depuration of bivalves where phages were added 
to the depuration tank water (29). Longer treatment time was required in control tanks 
to obtain comparable reductions to those achieved when using phage tanks. 
 
When phages should be applied  
Phage interventions must be carried out at the correct stage of processing for a 
positive outcome and to avoid reintroduction of bacteria. For example, cucumbers that 
were sprayed with SalmoFreshTM and then sliced did not show a significant reduction 
in S. Newport while unsliced cucumbers did show a significant reduction (30). It is 
believed that insufficient numbers of phages were transferred by cutting to achieve a 
significant reduction. A cocktail of six phages reduced the symptoms of 
Pectobacterium atrosepticum soft rot in potato tubers significantly (31•). However, 
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phage alone increased the disease severity in uninfected control tubers. This was 
suggested to be caused by the presence of enzymes or metabolites from phage 
production. This could limit the use of phages as a prophylactic treatment but not as 
an intervention as the cost to uninfected tubers could outweigh the benefit of reduction 
of symptoms in uninfected tubers. Regarding the issue of reinfection pigs can become 
infected with Salmonella after just two hours in a contaminated abattoir environment 
so would need to be treated at the correct time to avoid this (32). To reduce 
Campylobacter in chicken, interventions should be performed at multiple stages as 
Campylobacter can re-enter the food due to its ubiquitous nature on farms (33).  
 
Phage selection 
There are a number of disadvantages associated with the use of phages but this 
barrier can be overcome by careful selection of phages. The emergence of phage 
resistant bacteria is a risk (34). To decrease the issue of resistance treatments can be 
rotated or cocktails of phages can be used instead of single phages. Phages should only 
be applied when there is no risk of treated bacteria being reintroduced into the 
processing environment and causing issues with resistance. The highly specific nature 
of phages to their host has historically been viewed as a disadvantage in that they may 
only infect a limited number of strains (35). This view is changing as it is recognised 
that their specificity limits negative effects to the surrounding bacterial community. 
For example, it would be possible to use phages to reduce enteropathogenic or Shiga 
toxigenic E. coli during milk fermentation without compromising the performance of 
starter cultures (36). Cocktails of multiple phages can also be used to increase the 
number of strains targeted (37•). Phages can carry virulence genes or antibiotic 
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resistance genes but this can be largely avoided by using lytic rather than lysogenic 
phages (38). There are also concerns about the immunogenicity of phages and the 
cytotoxicity which could result by lysis of target bacteria. Phages have been found to 
cause no adverse reactions in rats and mice suggesting they are safe for human use 
(39, 40). Phages against Staphylococcus aureus in cheddar manufacture did not 
increase enterotoxin production (41). Phages are constantly encountered by humans 
since they are found naturally in the gut of humans (42), on their skin (43), in animals 
(44), in sewage treatment systems (45), and during the breakdown of food 
fermentations (46) among others. 
 
Conclusion  
Phages show promise for use in controlling bacterial pathogens as additives 
from natural sources, which may be more readily accepted by consumers than 
traditional additives, and also in the growing fight against antibiotic resistance. Phages 
may only reduce bacterial populations in food and not eliminate them completely, but 
this is not a serious issue. Criteria are put in place by groups, such the European Union, 
for acceptable levels of pathogens in food depending on the pathogen, food, and 
intended consumer with some required to be absent and some acceptable at low levels 
(47). There is zero tolerance for Salmonella in foods such as pre-cut vegetables, L. 
monocytogenes in food for infants and for medical purposes, and E. coli O157:H7 on 
sprouts. Phages reduced S. Typhimurium in whole milk and skimmed milk to 
undetectable, and therefore authorised, levels (19). Phages reduced L. monocytogenes 
to undetectable levels on tuna and Spanish dry cured ham (13, 23). Coagulase-positive 
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staphylococci are permitted in cheeses during manufacture up to 104 CFU/g. Phages 
have been successful in reducing S. aureus in cheddar cheese to safe levels (41). 
Bacteria use a number of methods to defend against phage infection at various 
points in the infection process (48). Bacteria can inhibit phage adsorption by altering 
or blocking receptors. Superinfection exclusion occurs when a prophage causes the 
expression of proteins which stops phage injection. Restriction modification 
methylates host DNA and cleaves invading unmethylated DNA. Bacteria using the 
CRISPR-Cas system (clustered, regularly interspaced, short palindromic repeat) 
integrate small fragments of invading DNA and cleave DNA with this sequence. 
Abortive infection limits the spread of the phage by the death of infected host cells. 
Care must be taken in the application of phages and their use to ensure they achieve a 
favourable outcome before they become a widely used and accepted aid in food 
processing. Phage concentration, the feasibility of adding a high concentration of 
phages, the properties of the food or animal to be treated, how phages are applied, 
when they are applied, and what phages are used are all barriers which must be 
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Tables and figures 
Table 1. The application of phages to eradicate target microbes. In the case of ListShieldTM against L. monocytogenes in Spanish dry cured ham 
bacterial numbers increased after treatment at 12˚C but decreased after treatment at 4˚C, this increase was represented by a (+) (23). 











Applied to surface 1.1-1.9 log CFU/cm2  
2.8-3.9 log CFU/cm2 
0.7-1.2 log CFU/cm2 
2.5-2.8 log CFU/cm2 
(8) 
LPST10 S. Typhimurium Lettuce 1 
10 
102 
Applied to surface 0.7-1.7 log10 CFU/cm2
1.1-1.7 log10 CFU/cm2 




S. Typhimurium, S. Heidelberg, 
S. Enteritidis 
Chicken breast fillets 102 
103 
Applied to surface 0.6 log CFU/g 
1.1 log CFU/g 
(10) 







Applied to surface 1 log CFU/cm2
2.7 log CFU/cm2 
1 log CFU/cm2 

















Mixed in to food 
0.16 log CFU/g 
0.50 log CFU/g 
1.098 log CFU/g 
0.07 log CFU/g 
0.26 log CFU/g 








Applied to surface 0.62 log CFU/g 
1.11 log CFU/g 
1.08 log CFU/g 
2.35 log CFU/g 
(13) 
phi F78E Avian pathogenic E. coli Experimentally infected 
chickens 
30 Oral gavage and 
spraying 
No reduction in 






Oral gavage and 
spraying 
Decreased mortality to 
below 0.5% in no more 
than 3 weeks 
SalmoFreshTM S. Heidelberg Turkey breast 104 Applied to surface 1.3 log CFU/g (15) 
FinalyseTM E. coli Live cattle ~3x1010 
phage/head of 
cattle in one 






Applied to hide surface 6.6 % reduction in 
prevalence 
(16) 




Liquid egg  
108 Mixed in to liquid 4.45 log CFU/ml 
4.32 log CFU/ml 
2.09 log CFU/ml 
2.06 log CFU/ml 




S. Enteritidis  Milk 
Cabbage 
Chicken breast 
104 Applied to surface 
Applied to surface 
Mixed in to liquid 
4 log CFU/sample 
3.86 log CFU/sample 
2.5 log CFU/sample 
(20) 








Mixed in to liquid 
Mixed in to liquid 
Spraying 
Spraying 
1.96 log CFU/ml 
2.06 log CFU/ml 
2.03 log CFU/ml 




S. Newport, S. Typhimurium, 
S. Heidelberg, S. Enteritidis  
Skinless chicken legs and 
thighs 
103 Applied to surface in 
tap water 
Applied to surface in 
filtered water 
0.39 log CFU/cm2 
 
0.23 log CFU/cm2 
(22) 





Applied to surface 4˚C 
Applied to surface 12˚C 
Applied to surface 4˚C 
Applied to surface 12˚C 
Applied to surface 4˚C 
1.5 log CFU/cm2
+1.5 log CFU/cm2 
2 log CFU/cm2 
+3 log CFU/cm2 








S. aureus Fresh cheese 6 Added during cheese 
manufacture 




C. jejuni Live chickens 15 In feed 
Oral gavage 
1.96 log CFU/g 
1.69 log CFU/g 
(25) 


















Applied to surface 
Encapsulated phage 
Applied to surface 
Encapsulated phage 
Impregnated paper 
3 log CFU/g 
1 log CFU/g 
1.5 log CFU/g 
1.3 log CFU/g 






E. coli Tomatoes 104 Spraying 
microencapsulated 
phage 
2.5 log CFU/tomato (28) 
phT4A, 
ECA2 
E. coli Cockles 1 Added to depuration 
tank water 
0.6 log CFU/g (29) 
SalmoFreshTM S. Newport Cucumbers 7.9X104 Sprayed before slicing 
Sprayed unsliced 
1 log CFU/sample 
 








Pectobacterium atrosepticum Potatoes 102 Phage wash Reduction in disease 
incidence 61.3% 
(31) 
DT6 E. coli Milk 2.4X104 Added during milk 
fermentation 
1.1 log CFU/ml (36) 




S. aureus Cheddar cheese 150 Added during cheese 
manufacture 










The Effect of a Commercially Available Bacteriophage and 















Lewis R, Bolocan AS, Draper LA, Ross RP, Hill C. 2019. The Effect of a 
Commercially Available Bacteriophage and Bacteriocin on Listeria monocytogenes in 




Changing consumer attitudes show an increased interest in non-chemical 
antimicrobials in food preservation and safety. This greater interest of consumers in 
more ‘natural’ or ‘clean-label’ food interventions is complicated by concurrent 
demands for minimally processed, ready-to-eat (RTE) foods with long shelf lives. 
Two viable interventions are bacteriophage (phage) and bacteriocins, a number of 
which have already been approved for use in food safety. Listeriosis is a serious 
foodborne infection which affects at-risk members of the population. Listeriosis 
incidence has increased between 2008 and 2015 and has a case fatality rate of up to 
20% with antibiotic intervention. Here, we tested an intervention to attempt to control 
a pathogenic Listeria monocytogenes strain in a food model using two of these 
alternative antimicrobials. Phage P100 on its own had a significant effect on L. 
monocytogenes ScottA numbers in coleslaw over a 10-day period at 4˚C (P≤0.001). A 
combination of P100 and Nisaplin® (a commercial formulation of the lantibiotic 
bacteriocin, nisin) had a significant effect on the pathogen (P≤0.001). P100 and 




Listeria monocytogenes is a small (0.5–2 µm in length), Gram positive rod-
shaped bacteria, and the causative agent of listeriosis (1-3). Listeriosis is a serious 
foodborne illness which can occur as sporadic cases or as outbreaks, and most 
commonly affects the most susceptible members of the population; namely, neonates, 
the immunocompromised, the elderly, and pregnant women. The majority of listeriosis 
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cases manifest one of three clinical syndromes: Maternofetal or neonatal listeriosis, 
blood stream infection, or meningoencephalitis. Listeria is of significant concern, 
despite the fact that fewer than 2300 cases were reported in the European Union 
(EU)/European Economic Area (EEA) per year between 2008 and 2015 (4). This 
concern is due to an overall annual case fatality rate of 12-20%, the involvement of at 
risk groups, and an increase in confirmed cases between 2008 and 2015. L. 
monocytogenes has been associated with a wide range of foods such as meat, seafood, 
vegetables, egg products, dairy products, and ready-to-eat (RTE) foods (5, 6). Interest 
is growing in biopreservation: The use of the anti-microbial properties of micro-
organisms and their metabolites for the preservation of food (7). This is, in part, due 
to the growing popularity of ready-to-eat (RTE) and minimally processed foods, which 
often carry an increased risk of microbiological contamination and are usually not 
cooked before consumption. Another reason for the rising interest in biopreservation 
is the trend towards ‘clean label’ and more ‘natural’ foods because of rising consumer 
distrust in traditional, artificial additives and preservatives (8). Bacteriophages 
(phages) are attracting interest for use in food preservation and food safety (9). Phages 
are effective at killing bacteria, are specific to their host, and, as a result of their 
ubiquity in nature, are commonly encountered and ingested, making them attractive 
for use in food safety. The anti-Listeria phage Listex P100 contains a single phage, 
P100, and was granted Generally Regarded as Safe (GRAS) status by the American 
Food and Drug Agency (FDA) in 2006 (10). Bacteriocins are another alternative to 
traditional additives and preservatives for food safety (11). Bacteriocins are 
ribosomally synthesised antimicrobial peptides with a broad or narrow spectrum of 
action produced by bacteria. Many bacteriocins are produced by lactic acid bacteria 
used in food fermentations that have been granted Generally Regarded as Safe 
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(GRAS) status by the FDA or have been granted Qualified Presumption of Safety 
(QPS) by The European Food Safety Authority (EFSA) (12). Nisaplin® containing 
nisin has been approved as a food preservative. Here, the activity of two commercially 
available ‘clean label’ antimicrobial compounds were investigated against L. 
monocytogenes, a foodborne pathogen of great importance and increasing incidence, 
in coleslaw. The objectives of this study were to [1] investigate the effect of P100 
alone at a high MOI (multiplicity of infection) in coleslaw, [2] find a suitable 
combination of concentrations of P100 and Nisaplin®, and [3] investigate the efficacy 
of the combination in comparison to an untreated control, P100 alone and Nisaplin® 
alone. 
 
Materials and Methods 
Bacteriophage Propagation and Bacteriophage Assays 
Bacterial strains were grown in TSB (tryptic soy broth) and TSA (tryptic soy 
broth 1.5% agar w/v) at 37˚C. Plaque assays were carried out by overlaying 4 ml TSA 
(0.4% agar w/v) supplemented with Calcium boroglucinate (final concentration 10 
mM). Plates were incubated at 30˚C for 24 h. P100 was isolated from Listex. P100 
was propagated on L. monocytogenes strain 33116 ATCC 19117. To propagate P100, 
plaque assays were carried out. After 24 h incubation, 5 ml SM buffer (50 mM Tris-
HCl; 100 mM NaCl; 8.5 mM MgSO4; pH 7.5) and 2% (v/v) chloroform were added 
to plates with confluent plaques and incubated at room temperature for 10 min. Phage 
suspension was removed from the plates, centrifuged at 4700 X g for 10 min at 4˚C in 
a swing-bucket centrifuge, and filtered twice through a 0.45 µm pore diameter filter. 
Chloroform was removed using a VivaSpin® 6 column. 
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Host Range of P100 
The host range of P100 was established by carrying out plaque assays and 
comparing the phage titre on the strain to be tested to the phage titre on strain 33116 
ATCC 19117 (Table 1) (Titre on test strain/Titre on strain 33116 ATCC 19117). 
Coleslaw Food Trial with P100 
Coleslaw was purchased from a supermarket. L. monocytogenes ScottA was 
grown overnight in TSB at 37˚C, centrifuged at 5500 X g for 20 min, and the resulting 
pellet resuspended in PBS. Resuspended ScottA was then diluted to ~107 CFU/ml in 
PBS and 100 µl added per 10 g of coleslaw. P100 was diluted to ~108 PFU/ml in SM 
buffer. The control group was treated with 1 ml SM buffer per 10 g of coleslaw, and 
the test group was treated with 1 ml diluted P100 per 10 g of coleslaw. Bacteria and 
phage were added immediately after one another. PBS and SM buffer were added in 
place of ScottA and P100 as negative controls, which also served as a means for 
sterility monitoring throughout the experiment. Coleslaw was manually mixed for 1 
min after these additions; 10 g samples of coleslaw were aliquoted and stored at 4˚C 
for 10 days. Then, 1 ml of liquid was pipetted off from the top of the coleslaw sample 
and used for spread plating of undiluted coleslaw to count low numbers of ScottA and 
diluting to count P100. To count P100, 500 µl of coleslaw liquid was added to 4.5 ml 
SM buffer, vortexed, centrifuged at 4700 X g for 10 min at 4˚C in a swing-bucket 
centrifuge and filtered through a 0.45 µm pore diameter filter, and spot assays carried 
out against ScottA. To count ScottA, 90 ml PBS was added to 10 g of coleslaw and 
stomached for 90 s, and then serial dilutions were prepared in PBS. Oxford agar and 
Oxford Listeria Selective Supplement were used to count ScottA by spread plating 
100 µl of the relevant dilution. Plates were incubated at 37˚C for 24 h. To check for 
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resistance, colonies were streaked on Oxford agar and Oxford Listeria Selective 
Supplement from Day 8 and Day 10 food trial count plates and spot assays carried out 
in triplicate against P100 lysates. 
Rate of Resistance to P100 
The rate that resistance to P100 occurs was assessed using the efficiency of 
lysogeny protocol of Dalmasso, et al. (42). Plates were incubated at 30°C for 24 h. 
The percentage of bacteriophage insensitivity was calculated as follows: (CFU on 
phage seeded plates/CFU on phage-free control plates) X 100. Twenty colonies were 
picked from the phage seeded plate and spot assays carried out to evaluate the 
colonies’ sensitivity to P100. 
P100 and Nisaplin® Checkerboard Assay in Broth 
P100 and Nisaplin® checkerboard assay was performed in TSB as per Draper, 
et al. in triplicate (43). A 2-fold serial dilution of Nisaplin® was made horizontally in 
sterile water (50 µl) in a 96-well microtitre plate. A 10-fold serial dilution of P100 was 
made vertically in SM buffer in a microtitre plate and 50 µl added vertically to the 
Nisaplin® dilution plate. Bacteria were grown overnight, subcultured into TSB, and 
allowed to grow to an OD600 nm of ~0.5. Bacteria were then diluted and 100 µl added 
to each microtitre well, resulting in a final concentration of 105 CFU/ml. The final 
concentrations of Nisaplin® were from 0 to 1600 µg/ml and P100 from MOI 0 to MOI 
100, with the first well containing no antimicrobial agents. Wells containing media 
without bacteria were used to check for sterility. Growth was assessed visually after 





P100 and Nisaplin® Checkerboard Assay in Coleslaw Liquid 
Fresh coleslaw was centrifuged at 5400 X g for 5 min at 4˚C in a swing-bucket 
centrifuge to separate solid and liquid parts. Then, 1 ml of coleslaw liquid was added 
to 24-well plates. ScottA was grown overnight in TSB at 37˚C, centrifuged at 5500 X 
g for 20 min, and the resulting pellet resuspended in PBS. Resuspended ScottA was 
then diluted to ~107 CFU/ml in PBS and 10 µl added per 1 ml of coleslaw. The starting 
concentration of ScottA in coleslaw liquid was ~105 CFU/ml. A 1:10 serial dilution of 
P100 was made horizontally in SM buffer in a microtitre plate. In a second microtitre 
plate, Nisaplin® dilutions were made in sterile water. Next, 10 µl of P100 and 20 µl 
of Nisaplin® was added per 1 ml of coleslaw. The plate was stored at 4˚C for 24 h. 
After 24 h, 20 µl from each sample was serially diluted in 180 µl PBS in 96-well 
plates, and 10 µl of coleslaw dilutions were pipetted on Oxford agar and Oxford 
Listeria Selective Supplement and allowed to dry. Plates were incubated at 37˚C for 
24 h. The combination of P100 and Nisaplin® was evaluated using the Fractional 
Inhibitory Concentration (FIC) index (43). The FIC looks at the interaction of 
antimicrobial compounds in the inhibition of a bacterial strain. It is defined by the 
equation: FIC = FICX + FICY = (X/MICX) + (Y/MICY). (MICx) is the minimum 
inhibitory concentration of the antimicrobial alone, while (X) is the lowest level of 
antimicrobial X in combination with another to achieve an inhibitory effect. FIC index 
results are interpreted as follows: FIC ≤ 0.5 is synergy, 0.5 < FIC ≤ 0.75 is partial 






Coleslaw Food Trial with P100 and Nisaplin® in Combination 
P100 and Nisaplin® combination food trial was carried out as per the P100 
food trial with some adjustments. ScottA was diluted to ~107 CFU/ml in PBS and 100 
µl added per 10 g of coleslaw, as previously described. P100 was diluted to ~107 
PFU/ml in SM buffer. A 500 µg/ml stock solution of Nisaplin® was prepared in sterile 
water, and 500 µl SM buffer and 500 µl sterile water per 10 g of coleslaw was added 
to the negative control samples. Then, 500 µl diluted P100 and 500 µl sterile water 
was added per 10 g of coleslaw to the P100 only samples; 500 µl SM buffer and 500 
µl Nisaplin® stock solution per 10 g of coleslaw was added to the Nisaplin® only 
samples; and 500 µl diluted P100 and 500 µl Nisaplin® stock solution per 10 g of 
coleslaw was added to the P100 and Nisaplin® samples. Samples were stored at 4˚C 
for 10 days. To check for resistance, colonies were streaked on Oxford agar and 
Oxford Listeria Selective Supplement from Day 10 food trial count plates and spot 
assays carried out in triplicate against P100 lysates. To test for Nisaplin® sensitivity 
spot assays were carried out using 10 µl of 50 µg/ml solution of Nisaplin® on strain 
overlays similarly to phage spot assays. 
Statistical Analysis 
Bacterial and phage counts were determined by triplicate plating and all 
experiments were independently performed three times. Results are presented as mean 
values of these three experiments, and error bars in the figures indicate standard error 
of the mean (SEM). For CFU/g, graphs values were normalised before plotting. For 
coleslaw treated with P100 at MOI of 50, Student’s t-test (unpaired, two-tailed) was 
used to determine the significance of differences between controls and phage-treated 
samples. For coleslaw treated with P100 and Nisaplin® in combination, one-way 
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Host Range of P100 
P100 is suited to use in food safety due to its broad host range (13). A range of 
strains of Listeria were tested for sensitivity to P100 (Table 1). These strains were 
originally isolated from a range of sources. P100, as expected, showed activity against 
many, but not all, pathogenic and non-pathogenic Listeria strains. 
Coleslaw Food Trial with P100 
Coleslaw was experimentally contaminated with ScottA at 7.1X105 CFU/g. 
Over a 10-day period at 4˚C, ScottA was reduced approximately 10-fold to 7.6X104 
CFU/g in the untreated control (Fig. 1A). The addition of phage P100 at an MOI of 50 
significantly reduced ScottA in coleslaw stored under the same conditions (P≤0.001). 
A significant reduction in ScottA was obvious within 2 h after phage addition 
(P=0.0014) and numbers continued to fall for the first 48 h. Specifically, within 2 h of 
addition of P100, the ScottA numbers were reduced from 7.1X105 to 2.0X104 CFU/g 
(Supp. Table 1). Listeria numbers remained low throughout the test period. The 
reductions were statistically significant at each sampling day, with an overall reduction 
from 7.1X105 CFU/g to an undetectable level (less than 30 colonies) after 10 days 
(Supp. Table 1). P100 titre was tested throughout the 10-day trial (Fig. 1B). P100 titre 
remained high, at between 3.8X107 PFU/g and 1.6X107 PFU/g, during the 10-day trial. 
All 15 isolates were grown from individual colonies from Day 8 and all 20 colonies 
from Day 10, and were tested for resistance to P100 by spot assay (Supp. Table 2). 
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Less than 30 colonies were present on Day 8 and Day 10, so were not counted and 
used for statistical analysis; however, they were picked and tested for resistance to 
P100. No isolates were resistant to P100 after 8 or 10 days of the trial. All colonies 
showed similar efficiency of plaquing of P100 as naïve sensitive ScottA, which had 
not been included in the food trial. 
The rate that resistance to P100 occurs was assessed against ScottA. The 
bacterial counts on phage seeded plates and on phage-free control plates were 4.7X102 
CFU/ml and 4.0X108 CFU/ml, respectively. This gave a resistance rate of 0.0001%. 
Twenty colonies from the phage seeded plate were tested for sensitivity to P100 by 
spot assay (Supp. Table 3). Eleven of the 20 colonies were resistant to P100 and 
formed no plaques or zones on spot assay. Six of the 20 colonies showed reduced 
sensitivity to P100 (efficiency of plaquing<0.4) compared to naïve ScottA. Three of 
the 20 colonies were more sensitive to P100 (efficiency of plaquing>1) than naïve 
ScottA. 
P100 and Nisaplin® Checkerboard Assays in Broth and Coleslaw 
The minimum inhibitory concentration (MIC) of P100 and Nisaplin® was 
investigated in TSB incubated at 30˚C for 24 h. The starting concentration of ScottA 
in broth and coleslaw was ~105 CFU/ml. The MIC of P100 alone trended towards an 
MOI of 100. The MIC of Nisaplin® alone trended towards 400 µg/ml. No synergistic 
effect was seen when P100 and Nisaplin® were used in combination in checkerboard 
assays in broth. 
To prepare for a food trial using P100 and Nisaplin® in combination against 
ScottA in coleslaw, a checkerboard assay was carried out in coleslaw stored at 4˚C for 
24 h (Table 2). Survival was measured by counting CFU/ml of each combination. The 
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MIC for P100 occurred at an MOI of 10, while the MIC of Nisaplin® alone was 50 
µg/ml. The combination of P100 at an MOI of 1 and Nisaplin® at a concentration of 
25 µg/ml reduced the amount of each antimicrobial required to inhibit ScottA growth. 
The FIC of P100 at an MOI of 1 in combination with Nisaplin® at a concentration of 
25 µg/ml was 0.6, which represents partial synergy against ScottA. Based on this data, 
the concentrations of P100 at an MOI of 2.5 and 25 µg/ml Nisaplin® were chosen for 
a food trial using P100 and Nisaplin® in combination. 
Coleslaw Food Trial with P100 and Nisaplin® in Combination 
Coleslaw was experimentally contaminated with ScottA at 9.4X105 CFU/g. 
Over the 10-day period at 4˚C, ScottA in the untreated control was reduced to 7.4X104 
CFU/g, representing a reduction of more than 1 log (Fig. 2A). The combination of 
P100 at an MOI of 2.5 and 25 µg/ml Nisaplin® significantly reduced (P≤0.001) the 
ScottA burden in coleslaw stored at 4˚C over a period of 10 days. Again, as seen with 
the P100 alone at an MOI of 50, a reduction in ScottA was visible 2 h after the 
antimicrobials were added, and reductions continued until the end of the 10-day 
period. Within 2 h of P100 and Nisaplin® addition, ScottA numbers were reduced 
from 9.4X105 to 1.0X105 CFU/g (Supp. Table 4). ScottA numbers were reduced to 
1.2X102 CFU/g by day 10. 
P100 alone also significantly reduced the ScottA numbers in coleslaw 
(P≤0.001) over the 10-day period. This reduction was visible 2 h after P100 addition 
(9.4X105 to 2.5X105 CFU/g). There was no statistically significant difference in the 




Nisaplin® alone did not significantly reduce ScottA numbers over the 10-day 
period (P>0.05). However, Nisaplin® did significantly reduce ScottA numbers over 
the first 5 days (P<0.01). The reduction was not significant on days 6, 8, 10, or overall 
(P>0.05). ScottA numbers were reduced (9.4X105 to 2.0X105 CFU/g) within 2 h after 
Nisaplin® addition. 
Ten colonies from each test group on Day 10 were tested for resistance to P100 
and Nisaplin® by spot assay (Supp. Table 5). No colonies were found to be resistant 
to P100 after 10 days of the trial. All colonies showed similar efficiency of plaquing 
of P100 to naïve ScottA, which had not been included in the food trial. No colonies 
were found to be resistant to Nisaplin® after 10 days of the trial. All colonies showed 
similar Nisaplin® zones of inhibition to naïve ScottA, which had not been included in 
the food trial.  
 
Discussion 
The “Commission Regulation (EC) No 2073/2005 of 15 November 2005 on 
microbiological criteria for foodstuffs” outlines the acceptable levels in the EU for 
common pathogenic bacteria in a range of foods and at different points in their 
manufacturing and storage. The limit for L. monocytogenes is 100 CFU/g in RTE 
foods able to support the growth of L. monocytogenes, other than those intended for 
infants and for special medical purposes, when products are placed on the market or 
an absence in 25 g before the food has left the immediate control of the manufacturer. 
In this experiment, 100 CFU/g was chosen as a cut off as it would be unlikely for food 
to leave a processing plant at the starting levels of contamination used in this 
experiment, and this level would probably only occur after days of growth. The Food 
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Safety Authority of Ireland (FSAI) “Survey on verification of compliance with 
Commission Regulation (EC) No 2073/2005 (12NS1)” in 2014 discussed the issue of 
categorisation of foods in terms of which EU criteria should apply. In the FSAI survey, 
coleslaw fell into food category 1.2, but if it had a shorter shelf-life (<5 days), it would 
have fallen into food category 1.3 and, therefore, L. monocytogenes would have been 
permitted at 100 CFU/g instead of a complete absence in 25g. The average L. 
monocytogenes contamination of foods varies greatly and it has been found in foods 
from 102 to >106 CFU/g (18). 
The difference in results of the checkerboard assays in broth and coleslaw 
could be due to temperature and pH. The concept of hurdle technology, the 
combination of a number of methods of preservation, is often used in food safety (19). 
Alone, each hurdle may not be effective, but in combination, they can reduce bacterial 
growth. These hurdles can include temperature, pH, salt concentration, water activity, 
and preservatives. The pH of coleslaw is 3.9-4.5 (20, 21), while the pH of TSB is 7.3. 
The TSB checkerboard was carried out at 30˚C compared to the coleslaw 
checkerboard, which was carried out at 4˚C. The low storage temperature and pH of 
coleslaw aid in reducing bacterial growth in the product. The temperature used for the 
experiment and the lower pH of the coleslaw may have reduced the MICs of P100 and 
Nisaplin® alone and in combination in coleslaw compared to TSB. Also, it has been 
seen that nisin has increased activity against L. innocua at pH 5 compared to pH 7, 
which could have contributed to the difference between the checkerboard assays in 
broth and coleslaw (22). The differences in results between food trials could be due to 
the effect of different foods and conditions on P100 activity. P100 had a significant 
effect on the growth of L. monocytogenes in melon and pear slices, but not on apple 
slices (23). The same effect was seen in juices, in that P100 had a significant effect on 
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the growth of L. monocytogenes in melon and pear juice but not in apple juice. Phage 
titre decreased in apple juice but stayed constant in melon and pear juice. The pH of 
apple slices and juice were determined to be 3.76 and 3.70, respectively, which is 
outside the range recommended by EFSA of pH 5.5-9.5 and an optimum of 7.7 (24). 
The MICs of P100 and Nisaplin® indicated by the checkerboard assay using TSB or 
coleslaw differed greatly. The checkerboard in broth indicated a much higher MIC for 
P100 and Nisaplin® against ScottA and suggests that no synergistic killing effect 
would occur between them, while the same analysis using coleslaw indicated MICs 
10 times lower for P100 and 8 times lower for Nisaplin®, with a synergistic effect. 
This could have been due to the increased growth of ScottA in broth, as it was carried 
out at a more optimum temperature for Listeria growth or that the growth media itself 
is optimised for rapid bacterial growth. 
The liquid or solid nature of food can affect the diffusion of phages (25). 
Phages can become bound to components of the food, and therefore unable to bind to 
the bacterial target. The volume of liquid present can also be an issue as, if too low a 
volume is present, phage will not be able to diffuse, but too great a volume can 
represent too large of a barrier for phage to cross. Also a low concentration of bacteria 
in food may mean that bacteria and phage may never meet by diffusion if phage 
concentration is low. It has been estimated that it would take in the order of 1000 years 
for 1 phage and 1 bacterium to meet within 1 ml of liquid (25). Therefore, in general, 
a high concentration of phage must be used to ensure a high likelihood that phage 
encounter the target bacterium. A lower concentration of phage may be required if 
bacterial numbers are high, as seen in our study. 
It was not clear if phage killing over a period of 10 days was concentration-
dependent. P100 at an MOI of 50 (P≤0.001) or 2.5 (P≤0.001) significantly and 
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similarly reduced ScottA numbers in coleslaw over a 10-day period at 4˚C, a 5.85 log 
reduction and a 5.97, respectively. In comparing the reduction in ScottA between Day 
0 and Day 1, where the greatest killing effect occurred, there was little difference in 
the killing between an MOI of 50 and an MOI of 2.5 (5.85 log reduction and 5.96 log 
reduction, respectively). A concentration-dependent killing of L. monocytogenes by 
P100 has been observed previously. In catfish fillets, P100 at a concentration of 2X103 
PFU/g did not reduce L. monocytogenes numbers inoculated at ~4.3log10 CFU/g, but 
2X105 PFU/g and 2X107 PFU/g both worked, with 2X107 PFU/g showing even greater 
reduction (26). This was also seen in tuna slices, where P100 at a concentration of 
5X108 PFU/ml was better at reducing L. monocytogenes numbers inoculated at 100 
CFU/g than P100 at 3˚C at a concentration of 105 PFU/ml, representing MOIs of 106 
and 103, respectively (27). This trend was repeated in tuna slices at 3˚C inoculated 
with 6 log/g L. monocytogenes and treated with 5X108 PFU/ml and 105 PFU/ml, 
representing MOIs of 100 and 0.1, respectively, but the differences were not as 
pronounced. In some cases, P100 did not have a significant effect on L. monocytogenes 
at the end point of the trial, but was significant at points throughout the trial. 
The reduction in ScottA was time-dependent; in both cases ScottA did not 
reach the EU regulation for L. monocytogenes in RTE foods until Day 10 of the trial. 
It should be borne in mind that we used an initial contamination level far in excess of 
anything that would be likely to occur in normal food production, and so we would 
expect excellent control with lower initial contaminating levels. As previously 
mentioned, in all cases, the greatest reduction in ScottA occurred in the first day after 
phage addition with a 5.85 log reduction with an MOI of 50, 5.96 log reduction with 
an MOI of 2.5 alone, and 5.97 log reduction 9.3X105 CFU/g with an MOI of 2.5 in 
combination with Nisaplin®. After this point, the reduction was at a similar rate to 
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that of negative controls. A similar rapid and dramatic reduction has previously been 
seen in trials using P100 in cabbage, smoked salmon, seafood, and hotdogs (28). L. 
monocytogenes decreased from 1X103 CFU/g by up to 1000-fold in hot dogs, 100-fold 
in mixed seafood and cabbage, and 50-fold in smoked salmon between Day 0 and 1, 
and this level of reduction was not seen again in each food during the 6-day trial. A 
rapid 10-fold reduction from 104 CFU/g of L. monocytogenes after the addition of 
P100 in combination with Lactobacillus sakei was also seen in cooked ham (29). 
When looking at the effect of phage contact time on bacterial reduction, Soni, 
Nannapaneni, and Hagens found that a contact time of 30, 60, or 120 min was more 
effective than 15 min contact time in reducing bacterial load on catfish fillets (26). 
However, contact times of 30, 60, or 120 min were no more effective than one another. 
The titre of P100 at an initial MOI of 50 and MOI of 2.5 was stable throughout the 
experiment. The titre of commercially available Listex is 2X1011 PFU/ml and it can 
be added to food at a concentration of 1X109 PFU/g, although it should be added with 
the estimated reduction in mind (24). P100 could have been added at a higher titre to 
investigate if reduction would have occurred faster and reached the recognised EU 
food safety cut off earlier in the shelf life of the product. 
In this experiment, Nisaplin® alone did not significantly reduce ScottA 
numbers over the 10-day trial (P>0.05). A significant reduction was not expected, as 
Nisaplin® alone was added at sub MIC levels as established by a checkerboard assay 
in coleslaw and, of course, once again, we must note the extraordinarily high initial 
contamination levels. A combination of P100 and Nisaplin® was significantly better 
than Nisaplin® alone (P≤0.05). Leverentz, et al. found Nisaplin® to be effective at 
reducing L. monocytogenes in sliced melon and apple pieces, but P100 in combination 
with Nisaplin® was more effective (30). Figueiredo and Almeida found that nisin and 
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P100 individually inhibited growth of L. monocytogenes in RTE sliced ham (31). A 
combination of P100 and nisin was significantly better at inhibiting growth of L. 
monocytogenes than nisin alone, but not P100 alone. In the trial carried out here, P100 
and Nisaplin® in combination were no more effective at reducing ScottA than P100 
alone (P>0.05). 
The EFSA Panel on Biological Hazards (24) mentions the conditions of use of 
P100 to be between 1 and 35˚C, with an optimum temperature of 30˚C. P100 would 
not form plaques on L. monocytogenes 33116 ATCC 19117 at 37˚C, but would at 
30˚C. This is consistent with the study of Tokman, et al. (32). The importance of the 
active temperature range of a phage should not be overlooked when developing phages 
for food safety, as phages may be required for use at refrigeration temperatures, at 
room temperature (in processing plants and in non-refrigerated foods), and at higher 
temperatures for lab assays. 
A potential consequence of using phage in biopreservation and phage therapy 
is the possible emergence of phage resistant mutants (33). This can be addressed in a 
number of ways. Firstly, bacterial mutants can often lose their phage-resistant 
phenotype when the phage is removed (34), because the evolution of phage resistance 
can reduce bacterial fitness or virulence (35). Phages also have the ability to evolve 
past bacterial resistance mechanisms (36). Methods to limit the emergence or reduce 
the impact of phage-resistant bacteria include the use of phage cocktails (37), the 
sequential use of different phages (28), the use of phage immediately before packaging 
to avoid the reintroduction of contamination that may have become phage resistant, 
and thorough cleaning of equipment to avoid phage resistant mutants forming and 
being introduced to food (38). Phage-treated products should not be entered back into 
the production line, such as in “old-young smearing”, where mature cheeses are used 
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to inoculate cheese that is in production (39). Phage can also be used in combination 
with other compounds, such as essential oils, to avoid bacterial resistance (40). 
The advantage of using a combination of antimicrobial compounds, or even a 
phage cocktail, can be seen from results of the rate of resistance to P100 assay and the 
coleslaw trial using P100 and Nisaplin® in combination. Using an initial MOI of 50 
or 2.5, no colonies resistant to P100 at an MOI of 50 were found after 8 or 10 days. 
The efficiency of plaquing of colonies from Day 8 and Day 10 were similar, with no 
major increase or decrease in efficiency of plaquing occurring between Day 8 and Day 
10. However, colonies from the rate of resistance to P100 assay were found to have 
reduced sensitivity to P100-highlighting the fact that resistance can occur to P100, 
albeit only rarely. L. monocytogenes mutants resistant to 50 µg/ml nisin were 
previously found at a frequency of 10-6 to 10-8 (41). Based on these prospective 
mutation rates to P100 and Nisaplin®, the chance of a strain developing resistance to 
both P100 and Nisaplin® is extremely low. Therefore, the advantage of a combination 
lies in that any cells resistant to one antimicrobial that is present will be inhibited by 
the other and vice-versa. 
 
Conclusions 
Three objectives were outlined at the start of this study. They were [1] to 
investigate the effect of P100 alone at a high MOI in coleslaw against a pathogen of 
interest, [2] to find a suitable combination of concentrations of P100 and Nisaplin® to 
act against the pathogen of interest in coleslaw, and [3] to investigate the efficacy of 
the combination in comparison to an untreated control, P100 alone and Nisaplin® 
alone. P100 at an MOI of 50 significantly reduced L. monocytogenes numbers 
90 
 
(P≤0.001) in heavily contaminated coleslaw over a 10-day period and reached EU safe 
limits for L. monocytogenes in RTE-foods. A checkerboard assay was carried out and 
a combination of P100 at an MOI of 2.5 and 25 µg/ml Nisaplin® was selected as a 
combination against L. monocytogenes in coleslaw. This combination was then used 
in a food trial against L. monocytogenes. P100 alone significantly reduced L. 
monocytogenes numbers (P≤0.001), as did P100 and Nisaplin® in combination 
(P≤0.001). Nisaplin® alone had no significant effect on L. monocytogenes numbers. 
P100 and Nisaplin® in combination was more effective than Nisaplin® alone, but not 
P100 alone. No resistance to P100 or Nisaplin® was encountered at any point. 
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Tables and figures 
Table 1. Listeria strains used and their sensitivity to phage P100. Efficiency of 
plaquing is represented as a fraction with standard error of the mean (SEM) of three 
separate experiments. If no P100 plaques formed on a strain, efficiency of plaquing is 
represented by (-). 
Strain Equivalent 
Names 





 Guinea pig (14) 1/2a 1.22 ± 0.4 
L. monocytogenes 33116 ATCC 19117 Animal (15) 4d 1 ± 0 
L. monocytogenes 33120 ATCC 19118 Animal (15) 4e 0.92 ± 0.54 
L. innocua DPC 3372   - 0.83 ± 0.25 
L. monocytogenes 33176 20240-954 Animal (15) 1/2b 0.72 ± 0.31 




4b 0.70 ± 0.03 
L. monocytogenes 
ScottA 
33013 Clinical (Massachusetts 
outbreak, 1983) (15) 
4b 0.70 ± 0.03 
L. monocytogenes 
EGDE 
 Rabbit (16)  1/2a 0.61 ± 0.2 
L. monocytogenes 33007 RM2218 Food (15) 4b 0.59 ± 0.22 
L. monocytogenes 33186 20674-01 Animal (15) 1/2b 0.49 ± 0.25 
L. monocytogenes 
ATCC 15313 
 Rabbit (17) 1/2c 0.29 ± 0.02 
L. monocytogenes 
ATCC 19112 
 Human CSF (14) 1/2c 0.24 ± 0.06 
L. monocytogenes 6179  Cheese;  
production 
environment (16) 
1/2a 0.002 ± 0.001 
L. grayi CD671 ATCC 25400 Corn stalks (15) - - 
L. monocytogenes 33028 OB001102 Food (15) 1/2b - 
















Figure 1. A. Effect of P100 on ScottA reduction in coleslaw stored at 4˚C over a 10-
day period. Error bars represent SEM. Coleslaw was spiked with bacteria (7.1X105 


















































Table 2. ScottA CFU/ml during P100 and Nisaplin® checkerboard assay in coleslaw. 
MIC of P100 alone and Nisaplin® alone are shown in bold. FIC values were 
calculated. FIC index results are interpreted as follows: FIC≤0.5 is synergy, 
0.5<FIC≤0.75 is partial synergy, 0.75< FIC≤1.0 is additive, FIC>1.0 is indifferent, 
and FIC>4 is antagonistic. The partially synergistic combination of P100 and 




P100 P100 P100 P100 P100 
MOI 0 MOI 0.01 MOI 0.1 MOI 1 MOI 10 
Nisaplin® 
0 µg/ml 










4.2 × 104 8.0 × 104 2.0 × 104 <1.0 × 104 
FIC 0.6  
Partial synergy 
<1.0 × 104 







<1.0 × 104 
FIC 1.001 
Indifferent
<1.0 × 104 
FIC 1.01 
Indifferent
<1.0 × 104 
FIC 1.1  
Indifferent 
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Figure 2. A. Effect of P100 and Nisaplin® in combination on ScottA reduction in 
coleslaw stored at 4˚C over a 10-day period. Coleslaw was spiked with bacteria 
(9.4X105 CFU/g) and phage (~2.6X106 PFU/g). Error bars represent SEM. P100 titre 
was also measured throughout the experiment of B. P100 MOI 2.5 alone and C. P100 





Supplementary Table 1. Effect of P100 on ScottA in coleslaw food trial stored at 4˚C 
over a 10 day period. P100 titre was also measured throughout the experiment. 
 













Day CFU/g  
ScottA no P100 ScottA with phage P100 
0 7.10E+05 7.10E+05 
0.16 7.10E+05 2.00E+04 
1 5.70E+05 1.70E+03 
2 4.60E+05 1.20E+03 
3 3.50E+05 8.30E+02 
4 3.10E+05 3.70E+02 
5 2.50E+05 4.00E+02 
6 2.30E+05 1.50E+02 
8 1.20E+05 2.90E+02 














Supplementary Table 2. Efficiency of plaquing of 15 colonies picked from Day 8 and 
15 colonies picked from Day 10 of P100 at an MOI of 50 treated coleslaw food trial 
to check for resistance to P100. Efficiency of plaquing is represented as a fraction with 
SEM of 3 separate experiments. 
Colonies picked from P100 at an 
MOI of 50 food trial 
Efficiency of plaquing 
 
Untreated Scott A 1±0 
Day 8_1 0.81±0.1 
Day 8_2 0.67±0.1 
Day 8_3 0.89±0.11 
Day 8_4 0.71±0.04 
Day 8_5 0.95±0.15 
Day 8_6 0.84±0.17 
Day 8_7 0.84±0.17 
Day 8_8 0.89±0.11 
Day 8_9 0.75±0.05 
Day 8_10 0.89±0.11 
Day 8_11 0.92±0.21 
Day 8_12 0.83±0.26 
Day 8_13 1±0.19 
Day 8_14 1.03±0.17 
Day 8_15 0.95±0.15 
Day 10_1 0.95±0.15 
Day 10_2 1±0.19 
Day 10_3 0.95±0.15 
Day 10_4 0.92±0.21 
Day 10_5 1±0.19 
Day 10_6 1±0.19 
Day 10_7 1.25±0.14 
Day 10_8 1.14±0.25 
Day 10_9 1.14±0.25 
Day 10_10 1.03±0.18 
Day 10_11 1.08±0.21 
Day 10_12 1.08±0.21 
Day 10_13 1.14±0.25 
Day 10_14 1.33±0.17 
Day 10_15 1.28±0.31 
Day 10_16 1.17±0.25 
Day 10_17 1.22±0.28 
Day 10_18 1.28±0.31 
Day 10_19 1.17±0.25 




Supplementary Table 3. Efficiency of plaquing of colonies isolated from phage seeded 
plates in the rate of resistance to P100 assay. Efficiency of plaquing is represented as 
a fraction. If no P100 plaques formed on a colony isolated from the rate of resistance 














Colonies isolated from 
efficiency of lysogeny plate 
Efficiency of plaquing  























Supplementary Table 4. Effect of P100 and Nisaplin® in combination against ScottA 
in coleslaw food trial stored at 4˚C over a 10 day period. P100 titre was also measured 















Day CFU/g  
No P100 No Nisaplin® P100 only Nisaplin® only P100 and Nisaplin®
0 9.40E+05 9.40E+05 9.40E+05 9.40E+05 
0.16 9.40E+05 2.50E+05 2.00E+05 1.00E+05 
1 5.10E+05 2.70E+04 7.40E+04 8.20E+03 
2 4.60E+05 1.20E+04 5.70E+04 4.40E+03 
3 3.50E+05 5.90E+03 5.50E+04 3.10E+03 
4 2.80E+05 3.70E+03 4.70E+04 1.60E+03 
5 2.40E+05 2.20E+03 3.20E+04 8.00E+02 
6 2.00E+05 1.50E+03 1.80E+04 4.80E+02 
8 1.20E+05 3.60E+02 2.80E+04 2.60E+02 
10 7.40E+04 2.10E+02 1.40E+04 1.20E+02 
Day PFU/g 
P100 only P100 and Nisaplin® 
0.16 2.70E+06 2.50E+06 
1 3.10E+06 3.70E+06 
2 3.20E+06 3.70E+06 
3 4.00E+06 4.70E+06 
4 3.70E+06 3.70E+06 
5 3.10E+06 3.50E+06 
6 2.60E+06 3.10E+06 
8 2.70E+06 2.50E+06 
10 3.10E+06 2.60E+06 
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Supplementary Table 5. Efficiency of plaquing and Nisaplin® sensitivity of colonies 
picked from Day 10 of combination food trail of Nisaplin® alone, P100 alone and P100 
and Nisaplin® in combination. Efficiency of plaquing is represented as a percentage 
with SEM of 3 separate experiments. 
 
 Colonies picked from 





Nisaplin® zone of 
inhibition diameter  
(mm) 
Untreated ScottA 1±0 10.06 
P100 alone_1 0.90±0.05 10.04 
P100 alone_2 0.89±0.06 10.15 
P100 alone_3 1±0 9.9 
P100 alone_4 0.93±0.07 10.56 
P100 alone_5 0.98±0.1 9.47 
P100 alone_6 0.98±0.1 10.08 
P100 alone_7 0.93±0.07 9.75 
P100 alone_8 1±0 9.38 
P100 alone_9 1±0 10.15 
P100 alone_10 1±0 9.86 
Nisaplin® alone_1 1±0 10.45 
Nisaplin® alone_2 1±0 10.49 
Nisaplin® alone_3 0.95±0.05 10.45 
Nisaplin® alone_4 1±0 10.4 
Nisaplin® alone_5 0.78±0.06 10.52 
Nisaplin® alone_6 0.93±0.07 9.71 
Nisaplin® alone_7 0.94±0.06 10.37 
Nisaplin® alone_8 1±0 10.39 
Nisaplin® alone_9 0.93±0.07 9.77 
Nisaplin® alone_10 1.05±0.05 10.07 
P100 and Nisaplin®_1 0.95±0.05 9.55 
P100 and Nisaplin®_2 0.83±0.02 10.09 
P100 and Nisaplin®_3 0.95±0.05 10.09 
P100 and Nisaplin®_4 0.85±0.08 10.27 
P100 and Nisaplin®_5 0.90±0.05 9.57 
P100 and Nisaplin®_6 0.95±0.05 9.67 
P100 and Nisaplin®_7 0.95±0.05 9.7 
P100 and Nisaplin®_8 0.90±0.05 9.19 
P100 and Nisaplin®_9 0.89±0.06 9.79 




The effect of hormonal contraceptives on the gut phageome over the 
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Metagenomics has been used to study the microbiota in both healthy and 
diseased humans across a number of variables in terms of diet, age and medication. 
Hormonal contraception is one of the most widely used group of medications but we 
are not aware of any studies investigating their effect on the microbiome, and 
particularly the viral component, the virome. In this pilot study women using hormonal 
contraception showed reduced virome diversity compared to women not using 
hormonal contraception. No differences were seen in 16S bacteriome data. Virome 
differences were more pronounced when viral data was clustered. Clustering was used 
to overcome viral inter-individual variation and the problems associated with viral 
‘dark matter’ (viruses with no counterparts in databases). Viromes can therefore reveal 
subtle differences that 16S studies may overlook. These findings suggest that 
hormonal contraceptive use should be taken into account when interpreting 
metagenomic data.  
 
Introduction 
The role of the gut microbiome in human health has recently emerged as a 
vibrant area of research. The gut microbiome has been demonstrated to impact on 
conditions such as obesity, asthma and diabetes (1-3). One component of the 
microbiome are bacteriophages, viruses of bacteria, which are the most common 
biological entities on earth. Their important role in shaping bacterial composition of 
the gut microbiome of humans is being increasingly recognised. Bacteriophages and 
their potential role within the human gut have been studied in several cohorts, such as 
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in twins and their mothers (4), in faecal microbiota transplantations for Clostridium 
difficile infections (5) and in Inflammatory Bowel Disease (IBD) (6). 
Estrogens are steroid hormones produced in the ovaries, adrenal glands and 
adipose tissue (7). Estrogens can act locally or circulate to target organs. The 
estrobolome has been described as the bacterial genes in the human gut microbiome 
capable of producing products that metabolise estrogens. Many small but important 
links have been drawn between changes in the gut microbiota and differences in sex 
hormone levels and gender. The estrobolome plays an important role as a regulator of 
circulating and excreted estrogen levels by the conjugation and deconjugation of 
estrogens. Estrogens have been shown to play a role in neural development, bone 
density, cardiovascular health, gut epithelial barrier integrity, epithelial thickness in 
the reproductive tract and decreasing vaginal pH (8). Colonic transit time has been 
shown to be shorter in men than women but no difference was found in the colonic 
transit time of menopausal and premenopausal women (9). 
Polycystic ovary syndrome (PCOS) is a hormonal condition affecting women 
of reproductive age characterised by hyperandrogenism, oligo- or anovulation and 
polycystic ovaries on ultrasound (10). Estrogen without the opposing effect of 
progesterone, due to chronic anovulation, can increase the risk of endometrial cancer 
development in women with PCOS. Many women with PCOS are prescribed 
hormonal contraception to reduce this risk. PCOS patients show a reduction in 
phylogenetic diversity and microbiome profile shifts in comparison to healthy controls 
(11). In a letrozole induced PCOS rat model administration of Lactobacillus or faecal 
microbiota transplantation improved the estrous cycles and ovarian morphologies of 
PCOS induced rats and significantly altered hormone levels towards that of healthy 
controls (12).   
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Hormone levels during the menstrual cycle are dynamic, with a decrease in 
estrogen and progesterone levels during the late luteal (pre-menstrual) phase with 
estrogen and progesterone levels at their lowest level during menstruation (13). Many 
women report gastrointestinal symptoms associated with the menstrual cycle. In a 
study of 156 healthy women, 73% reported at least one symptom including abdominal 
pain, constipation, diarrhoea, nausea, or vomiting pre-menstrually while 69% reported 
at least one of these symptoms during menses (14). This is an increase on the rates 
suggested by Moore, et al. whereby around one third of healthy women reported 
perimenstrual gastrointestinal symptoms while almost half of women suffering from 
functional bowel disorders reported perimenstrual gastrointestinal symptoms (15). It 
is also noteworthy that there is a female predominance associated with IBS, with 
women making up two-thirds of those with Inflammatory Bowel Syndrome (IBS) 
(16). Women with IBS or IBD report more and worse perimenstrual gastrointestinal 
symptoms than healthy women, but it is unknown whether this is a flare of disease 
symptoms or menstrual symptoms (16). Heitkemper, et al. reported that the 
perimenstrual gastrointestinal symptoms of IBS women taking oral contraceptives did 
not differ from those of IBS women not taking oral contraceptives (17). 
Another time of significant hormonal change occurs during pregnancy with 
physiological hyperestrogenemia and hyperprogesteronemia (13). There are 
conflicting accounts as to whether the gut microbiome changes during pregnancy. 
Koren, et al. suggested that the gut microbiota changes during pregnancy between the 
first and third trimesters (18). Between the first and third trimesters a decrease in the 
abundance of Faecalibacterium occurred and in the majority of women an increase in 
the abundance of Proteobacteria was observed. These changes were associated with 
inflammation. This was suggested to promote metabolic changes which are beneficial 
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during pregnancy for energy storage and growth of the foetus. Conversely DiGiulio, 
et al. found no difference in the gut microbiota during pregnancy (19). 
There is little information available comparing the gut microbiota of healthy 
hormonal contraceptive users and controls. Progesterone and estrogen were identified 
as covariates associated with microbiome composition, although stool consistency was 
a confounder (20). However, work has been carried out investigating the vaginal 
microbiota. Maintenance of the vaginal pH is important for vaginal health and is 
controlled by the interaction of estrogen and the vaginal microbiota (21). Estrogen 
production causes the deposition of glycogen in the vaginal epithelium which is then 
metabolised to organic acids, mostly lactic acid, by the vaginal microbiota (22). This 
low pH and the antimicrobial nature of the bacteria are protective against colonisation 
by pathogens. The vaginal microbiota can be classified into 5 groups with different 
groups being associated with premenopausal women, perimenopausal women and 
postmenopausal women. These groups are often dominated by Lactobacillus species. 
The vaginal microbiota of hormonal contraceptive users has been studied, with greater 
vaginal microbiota stability observed in hormonal contraceptive users (23). The 
vaginal microbiota of hormonal contraceptive users was more likely to be dominated 
by Lactobacillus than controls. Hormonal contraceptive users have been reported to 
be at a lower risk of bacterial vaginosis than controls. Oral contraceptive use has been 
associated with an increased risk of developing Crohn’s disease, while oral 
contraceptive use in conjunction with smoking has been associated with an increased 
risk of developing ulcerative colitis (24).  
In order to investigate the potential effect of hormonal contraceptives on the 
gut microbiome of humans, a pilot study was performed. We compared the faecal 
bacterial (by 16S) and viral composition of ten men and ten women, five of whom 
111 
 
were using hormonal contraception. A decrease in diversity of the microbiome 
associated with the use of hormonal contraceptives was observed in the faecal 
phageome but not the bacteriome, showing that the phageome can be more 
discriminatory than bacterial 16S data. 
 
Materials and methods 
Selection of faecal samples 
All study participants provided written, informed consent. The study was 
approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals, 
University College Cork. Male faecal samples were collected at one time point. 
Female faecal samples were collected at 3 time points over a one month period. The 
hormonal contraceptive using women were age matched with non-hormonal 
contraceptive users. Samples were collected at approximately menstrual cycle days 1, 
13, and 21.  
Faecal metagenomics 
Preparation of faecal viral suspensions, extraction of viral DNA and library 
preparation was performed as per Shkoporov, et al. (51). This consisted of steps 
including the homogenisation of faecal samples in SM buffer, separation of viruses 
from faecal solids, virus concentration using NaCl/PEG precipitation, chloroform 
extraction to remove bacterial cells and PEG, DNase and RNase treatment, Proteinase 
K digestion and purification of viral nucleic acid by phenol:chloroform extraction and 
spin columns. Before library preparation viral nucleic acid was amplified using 
SuperScript IV Reverse Transcriptase followed by Illustra GenomiPhi, pooled and 
passed through a QIAGEN Blood and Tissue Purification kit. Reverse transcriptase 
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treatment was included to convert RNA and ssDNA viruses into dsDNA, suitable for 
library preparation (51). GenomiPhi was necessary to obtain sufficient DNA for 
library preparation due to low concentrations of extracted DNA. However, reverse 
transcriptase treatment can amplify bacterial rRNA contamination and GenomiPhi can 
preferentially amplify short single-stranded DNA such as members of the 
Microviridae. DNA concentrations were equalised and library was prepared using 
Nextera XT library preparation (Illumina, San Diego, CA, USA) as described by the 
manufacturer. Metagenomic sequencing was performed using the Illumina MiSeq 
platform. 
16S rRNA extraction, library preparation, and sequencing was carried out by 
others.  
Metagenomic sequencing analysis 
Quality of raw reads was visualized with FastQC v0.11.5. Adaptor removal 
and read trimming was carried out using Trimmomatic v0.32 (52). A quality score of 
20 was applied over a sliding window of 4 and a minimum length filter of 60 to retain 
reads following read trimming. Host sequences were identified and removed with 
Kraken v0.10.5 using the human genome. Levels of bacterial and archaeal 
contamination were estimated with sortMeRNA v2.1 (53) by aligning forward reads 
to the SILVA database. Assemblies were performed individually with the 
metaSPAdes assembler (54). Redundant contigs, at 90% identity across 90% of their 
length, between samples were removed. Contigs less than 1kb were filtered out and 
the resulting non-redundant contigs were submitted to VIRsorter in viromes mode. 
BLAST search of the contigs against the RefSeq Virus database was also performed. 
Contigs that were predicted as viral by VIRsorter or which had a significant hit against 
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the RefSeq Virus database were included for further analysis. The final database also 
included the remaining contigs which had no significant BLAST hit against the nt 
database and were greater than 3kb long. End-to-end alignments of sample reads were 
then performed against the contig database using Bowtie2 v2.1.0 and a count table 
was generated using SAMtools v0.1.19. 
Clustering  
vContact was used to form clusters with contigs grouped based on protein 
similarity (39). Individual genomes were analysed as representatives of viral clusters. 
The largest fully circular sequence from each chosen cluster was annotated. VIGA was 
used to annotate genomes as performed by Shkoporov, et al. (45). Genomes were 
visualised using GView and manually coloured (55). Genomes were screened for 
CRISPR spacers using BLASTn modified for short sequences against CRISPR spacers 
from Pasolli, et al. (56). Figure was drawn in ggplot2 in R. 
Statistical analysis 
Statistical analysis was performed using R v3.4.1. Alpha diversity was 
estimated using the Chao1 and Shannon diversity indices from vegan (package version 
2.4-3). Means and standard deviation are presented. Between group comparisons were 
performed using the Mann-Whitney test for two-group comparisons or the Kruskal-
Wallis test for more than two groups. The Hellinger transformation was used for data 
transformation. Bray-Curtis distances were calculated and used as input for Principal 
Component Analysis (PCA) using the princomp function in base R. Permutational 
Multivariate Analysis of Variance (PERMANOVA) and Analysis of Similarity 
(ANOSIM) were performed to assess all grouping variables using 99,999 
permutations in vegan. Comparison between use of hormonal contraception and not 
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was performed with DESeq2 v1.16.1(57). Plotting was performed using ggpubr 




Metagenomic sequencing of the viromes of ten women and ten men was 
carried out. Viral DNA from the faeces of ten healthy men was extracted and 
sequenced at one time point. Viral DNA from the faeces of the ten women was 
extracted and sequenced at three time points over a one month period to include the 
early follicular, late follicular and late luteal phases of the menstrual cycle. Five 
women were using hormonal contraception and five were not. A non-redundant 
database of 2409 putative viruses was generated and raw virome reads mapped to the 
assembled database (Fig. 1A). Contigs ranged in size from 1031 bp to 263205 bp 
(mean size 12633 bp). There were 345 circular contigs and 2064 non-circular contigs 
(Fig. 1B). The mean size of the circular contigs was 15447 bp (range 3006 bp to 
196493 bp), although circular contigs demonstrated a bimodal distribution. The mean 
size of non-circular contigs was 12163 bp (range 1031 bp to 263205 bp). The number 
of contigs that were classified according to the various databases are as follows; 456 
contigs were predicted viral by VIRsorter, 128 were identified by BLAST against the 
refseq viral database, 1451 contigs had greater than 3 pVOGs predicted (prokaryotic 
Virus Orthologous Groups) and 345 were predicted as circular genomes (Fig. 1A). 
There was significant overlap in these contigs and 1635 unique contigs were classified 




After the final putative virus database was generated vContact was used to 
form clusters of contigs grouped on protein similarity (Fig. 1A). Clusters were filtered 
to remove clusters only present in one individual or with an overall abundance of less 
than 0.001%. This reduced the number of clusters from 994 to 212 but retained greater 
than 98% of the reads, suggesting that the removed reads would contribute very little 
to the overall picture. 
Alpha diversity 
No differences were seen in alpha diversity of the bacteriome using Chao1 
between any groups including men and women (Fig. 2A), the three phases of the 
menstrual cycle (Fig. 2A), or women using hormonal contraception and women not 
using hormonal contraception (Fig. 2B). 
 Unclustered viral contigs showed no difference in alpha diversity as measured 
by Chao1 between men and women or the three phases of the menstrual cycle (Fig. 
2C). However, women using hormonal contraception had significantly reduced 
diversity compared to women not using hormonal contraception (P=0.00049) (Fig. 
2D). No difference was observed between the three phases of the menstrual cycle for 
all women combined.  However, when the phases were divided between women using 
hormonal contraception and women not using hormonal contraception we observed a 
significant reduction in diversity in women using hormonal contraception in the late 
luteal phase (P=0.022) (Fig. 2D).  
 Clustered viral data showed no difference in alpha diversity as measured by 
Chao1 between men and women or the three phases of the menstrual cycle (Fig. 3A). 
Again, women using hormonal contraception had reduced diversity compared to 
women not using hormonal contraception (P=0.00022) (Fig. 3B). Clustered viral data 
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showed no difference between the three phases of the menstrual cycle for all women 
combined but did show a significant reduction in women using hormonal 
contraception during the late follicular (P=0.037) and late luteal phases (P=0.022) 
(Fig. 3B). 
No differences were seen in alpha diversity of the bacteriome using Shannon 
between men and women or the three phases of the menstrual cycle (Fig. 4A). Unlike 
Chao1, Shannon showed reduced diversity in women using hormonal contraception 
(P=0.02) compared to women not using hormonal contraception (Fig. 4B). No 
difference was observed when the phases were split into women using hormonal 
contraception and women not using hormonal contraception (Fig. 4B). 
Unclustered viral contigs showed no difference in alpha diversity as measured 
by Shannon between men and women or the three phases of the menstrual cycle (Fig. 
4C). Women using hormonal contraception had reduced diversity that was 
approaching statistical significance (P=0.056) compared to women not using 
hormonal contraception (Fig. 4D). When the phases were split into women using 
hormonal contraception and women not using hormonal contraception there was a no 
reduction in diversity in women using hormonal contraception in any of the three 
menstrual cycle phases (Fig. 4D). 
Clustered viral data showed no difference in alpha diversity as measured by 
Shannon between men and women or the three phases of the menstrual cycle (Fig. 
4E). There was significantly reduced diversity found in women using hormonal 
contraception (P=0.042) compared to women not using hormonal contraception (Fig. 
4F). As with unclustered viral contigs when the phases were split into women using 
hormonal contraception and women not using hormonal contraception there was a no 
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reduction in diversity in women using hormonal contraception in any of the three 
menstrual cycle phases (Fig. 4F). 
Beta diversity  
 The three time points of each woman clustered together using Bray-Curtis beta 
diversity of bacterial and clustered viral data (Fig. 6A, B). Beta diversity did not 
differentiate gender, hormonal contraceptive use status or time point (Fig. 6A, B). 
Women not using hormonal contraception clustered together on the left hand side of 
the heat map while women using hormonal contraception clustered together on the 
right hand side (Fig. 6C). Men were interspersed equally between women not using 
hormonal contraception and women using hormonal contraception. Five men were 
located towards the left between women not using hormonal contraception, one man 
was located between the women using hormonal contraception and women not using 
hormonal contraception and four men were located to the right of the heat map 
between women using hormonal contraception. This could represent the similar 
diversity seen between men and women not using hormonal contraception and 
between men and women using hormonal contraception.    
Differentially abundant clusters and contigs  
 Lefse analysis was used to test for differentially abundant viral clusters and 
bacterial contigs. A number of viral clusters were suggested to be differentially 
abundant in women using hormonal contraception and women not using hormonal 
contraception (Fig. 7A). A number of bacterial contigs were differentially abundant in 
women using hormonal contraception and women not using hormonal contraception 
(Fig. 7B). The differentially abundant clusters were then correlated with all bacterial 
OTUs (Fig. 7C).  
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Analysis of individual genomes as representatives of viral clusters 
The largest fully circular sequence from representatives of a selection of viral 
clusters were annotated (Fig. 8A). Circular genomes were selected to ensure genomes 
were complete. Clusters representing the phage families Myovirus (cluster 87), 
Siphovirus (cluster 19), Podovirus (cluster 117), Inovirus (cluster 750), and 
Microvirus (cluster 94) were selected. An animal virus Circovirus (cluster 90) and a 
human virus Papillomavirus (cluster 964) were also selected. Bacterial hosts were then 
inferred using CRISPR spacers targeting the viral cluster (25) (Fig. 8B). 
 
Discussion 
The first publication of the metagenomic analysis dedicated to the human gut 
virome appeared in 2003 (26). Since then many studies have investigated changes and 
alterations in the gut microbiome and the virome. Virome studies have examined many 
areas such as differences between the luminal and mucosal gut viromes of mice (27), 
differences in the viromes of children born by spontaneous vaginal delivery and 
caesarean section (28) and compared the gut viromes of healthy controls and irritable 
bowel disease patients (29). Gut microbiome studies have explored the gut 
microbiome in a range of situations including the development of the microbiome over 
time in infants (30), the effect of immunosuppressants (31) and in geographically and 
culturally distinct areas (32).  
Sex hormones have many roles in the body. Oral contraceptives, of all types, 
have been associated with an increase in estrogen and sex hormone binding globulin 
and a decrease in testosterone and Dehydroepiandrosterone sulfate (DHEAS) (33). 
Estrogen may modulate the mucosal immune system and maintain intestinal barrier 
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function while testosterone modulates immune function. The vaginal microbiota is 
dominated by Lactobacillus spp indirectly as a result of estrogen production (34). 
Estrogen stimulates glycogen deposition in vaginal epithelial tissue which is 
metabolised by human α-amylase to maltose, maltotriose and α-dextrines, which are 
then metabolized to lactic acid by Lactobacillus. In a non-obese diabetic mouse model 
of type 1 diabetes, the transfer of the microbiota of adult male mice to immature female 
mice protected female mice from the onset of type 1 diabetes (35). It can be seen that 
changes in the microbiota can play a role in autoimmune disease. We therefore carried 
out an observational pilot study on the effect of hormonal contraception on the human 
gut microbiome, and particularly the virome. 
There are many difficulties associated with classification of viral reads due in 
part to the lack of widely conserved gene markers and the fact that the majority of 
publically available databases are mostly composed of bacterial genomes (36). A large 
number of viral reads often end up unclassified. Care must be taken to include as many 
viral reads as possible without including non-viral reads (37). Another issue associated 
with viral metagenomics is the inter-individual variability of people. Minot, et al. 
showed that even when a dietary intervention was introduced inter-individual variation 
was still greater than intra-individual variation, however viromes did become more 
similar than before the intervention (38). Beta diversity of the viromes within 
individuals over a one year period has been found to be more similar than between 
individuals (4). Co-twins and their mothers showed more gut bacterial similarity than 
unrelated individuals while the gut viromes of co-twins and their mothers showed no 
more similarity than unrelated individuals. This was also apparent in the data presented 
here where the beta diversity of the three time points of each woman were closely 
grouped (Fig. 6B). Viral clustering can be used to overcome the issues of inter-
120 
 
individual variability and viral dark matter (39, 40). Clustering can also be helpful to 
infer details about badly annotated cluster members from other more annotated 
members. In our study prospective hosts were suggested by CRISPR analysis (Fig. 
8B) which could be helpful in identifying potential hosts for related cluster members. 
In this case clustering of data supported the results obtained with unclustered viral data 
but also identified more instances of reduced diversity. Clustered viral data showed 
reduced diversity during the late luteal and late follicular phases while unclustered 
viral contigs only showed reduced diversity during the late luteal phase.  
 No differences were seen in the 16S rRNA diversity of age-matched men and 
women in this study which contradicts previous studies. Mahnic and Rupnik found 
Shannon diversity to be higher in women than men (41). A combination of gender and 
age explained 2.2% of the inter-individual bacterial community variation using Bray-
Curtis distances. However, Haro, et al. also found no significant difference in alpha 
diversity between men and women (42). No difference in the relative abundance of 
specific taxa between men and women was found at phylum level but there were 
differences at genus level. In another study when the confounding effect of stool 
consistency was taken into effect the impact of gender was greatly reduced (20). 
Estrogens showed anti-commensal activity against representative strains of the gut 
microbiota but the effect was not significant due to the small number of drugs tested 
(43). Perhaps in the pilot study carried out here bacterial diversity differences would 
have been evident at a species or strain level.  
In this study 16S rRNA did not show differences between women using 
hormonal contraception and women not using hormonal contraception, but virome 
data did separate the two groups. There was a suggestion of clustering by hormonal 
contraceptive status in the heat map of viral clusters (Fig. 6C). The heat map also 
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supported the difference between women using and not using hormonal contraception. 
Men were not shown to be different to either group of women in the clustered heat 
map or using Chao1 alpha diversity (Fig. 3B). This inability of 16S data to show 
differences where virome data can has previously been seen in McCann, et al. where 
16S rRNA did not show differences between caesarean section and standard vaginal 
delivered infants but virome data did discriminate the two cohorts (28). 16S rRNA 
shotgun metagenomic sequencing can miss differences between datasets due to low 
taxonomic resolution (44). The shorter the fragment the less accurate the taxonomic 
resolution; longer sequences are required for high taxonomic determination. Therefore 
the virome can be a more sensitive indicator of change.  
Some viral clusters were suggested to be differentially abundant in women 
using hormonal contraception and women not using hormonal contraception. Bacterial 
correlations and CRISPR analysis agreed on host prediction (Fig. 7C and Fig. 8B). 
Cluster 14 was annotated to be crAssphage. Cluster 14 was correlated with Alistipes 
and CRISPR analysis predicted Bacteroides fragilis and Parabacteroides distasonis 
as hosts.  Bacteroides was determined experimentally to be the host of crAssphage in 
2018 (45). It has been proposed that crAssphage is actually a family of phages, with 
four subfamilies, which could have varying Bacteroidetes hosts which would support 
these results (46). Cluster 19 was identified as a Siphovirus with CRISPR analysis 
predicting the host as Ruminococcus bicirculans and correlating with Lachnospira 
which are both members of the order Clostridiales. It appears as if there was an 
overabundance of gram positive bacterial species associated with women using 
hormonal contraception as seen with Lefse analysis (Fig. 7B). Gram negative species 
appeared to be more common in women not using hormonal contraception. 
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This pilot study cannot determine if changes in the virome caused by the use 
of hormonal contraception are beneficial or detrimental to health. Virome changes can 
be significant in human health. Norman, et al. found the gut virome to be altered in 
IBD patients compared to household controls in a manner that was not explained by 
changes in the gut microbiome (6). Virome richness was reduced in IBD patients and 
virome changes were specific to ulcerative colitis and Crohn’s disease patients. It was 
suggested that these changes could contribute to inflammation in the gut and the 
symptoms associated with the condition. In a study comparing twins discordant for 
malnutrition and concordant healthy twins viral contigs could be used to discriminate 
between concordant healthy twins and the “healthy” and malnourished twins of the 
discordant pair (47). Although they showed no symptoms of malnutrition the 
“healthy” discordant twin had features of an at-risk microbiota. 
When choosing subjects and healthy controls for a microbiome study the 
impact of many factors are taken into account (48). Following the results of this pilot 
study, the question could be raised of whether or not the use of hormonal contraception 
or the onset or conclusion of taking hormonal contraception should be treated like age, 
diet, sex, or antibiotic use. Also it should perhaps be considered just how long the 
women have been using hormonal contraception (49). Women who have just started 
taking or stopped taking hormonal contraception could have an altered microbiota that 
is in flux or may have stopped due to negative effects. This could represent an 
underlying condition causing the negative effects or a microbiome such as the 
“healthy” discordant twin in the study previously mentioned (47). A National Health 
Statistics Report regarding 22,682 women between 2006 and 2010 reported that 82% 
of women had used the contraceptive pill at some time (50). One quarter of the women 
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interviewed who had taken the hormonal contraceptive pill had stopped due to side 
effects. 
 No effect of gender was observed on the diversity of 16S rRNA or viral data. 
This is contrary to published reports of increased bacterial diversity in women 
compared to men. However, women using hormonal contraception were found to have 
reduced viral diversity compared to women not using hormonal contraception. Men 
showed similar diversity to both groups of women. Similar trends were observed in 
unclustered viral contigs and viral clustered data with differences more pronounced in 
viral clustered data. Viral clustering was used to overcome issues of inter-individual 
variation and viral dark matter. This study highlights the importance of phages as a 
more sensitive tool for showing differences in data sets. The effect of hormonal 
contraceptive use was visible in the virome portion of the human gut microbiome when 
no effect was visible in the bacteriome. This study was carried out as a small, pilot 
study and included a limited number of subjects. It would be interesting to establish if 
shotgun metagenomics of the bacterial fraction of the microbiome or more subjects 
would make the effect of hormonal contraception visible in the bacteriome or if the 
virome is a more discriminatory tool for viewing change. 
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Figure 1. A. Flow chart of metagenomic analysis. B. Coverage and length of circular 
and non-circular predicted viral contigs. The y-axis shows the number of sequence 
reads, the x-axis shows contig length. Circular contigs are shown in red and non-


























Figure 2. Chao1 Alpha diversity A. 16S rRNA comparing men, women and the three 
phases of the menstrual cycle. B. 16S rRNA comparing men, women using hormonal 
contraception, and women not using hormonal contraception over the three phases of 
the menstrual cycle. C. Unclustered viral contigs comparing men, women and the three 
phases of the menstrual cycle. D. Unclustered viral contigs comparing men, women 
using hormonal contraception, and women not using hormonal contraception over the 















Figure 3. Chao1 Alpha diversity of clustered viral contigs comparing A. Men, women, 
and the three phases of the menstrual cycle B. Men, women using hormonal 
contraception, and women not using hormonal contraception over the three phases of 
































Figure 4. Shannon Alpha diversity A. 16S rRNA comparing men, women, and the 
three phases of the menstrual cycle. B. 16S rRNA comparing men, women using 
hormonal contraception, and women not using hormonal contraception over the three 
phases of the menstrual cycle. C. Unclustered viral contigs comparing men, women, 
and the three phases of the menstrual cycle. D. Unclustered viral contigs comparing 
men, women using hormonal contraception, and women not using hormonal 
contraception over the three phases of the menstrual cycle.  E. Clustered viral contigs 
comparing men, women, and the three phases of the menstrual cycle. F. Clustered viral 
contigs comparing men, women using hormonal contraception, and women not using 



















Figure 5. Beta diversity comparing A. 16S rRNA men and women. B. 16S rRNA men, 
women using hormonal contraception, and women not using hormonal contraception. 
C. 16S rRNA men and the three phases of the menstrual cycle. D. Unclustred viral 
contigs data men and women. E. Unclustered viral contigs men, women using 
hormonal contraception, and women not using hormonal contraception. F. Unclustred 




















Figure 6. A. PCoA of Bray-Curtis beta diversity of individuals over three time points 
for women and one time point for women and men of 16S. B. PCoA of Beta diversity 
of individuals over three time points for women and one time point for women and 
men of viral clusters. Men are shown as triangles, women are shown as circles. C. 











Figure 7. A. Lefse analysis of viral clusters that explain differences between women 
using hormonal contraception and women not using hormonal contraception. B. Lefse 
analysis of bacterial groups that explain differences between women using hormonal 
contraception and women not using hormonal contraception. C. Heat map of viral 
clusters that were differentially abundant in women using hormonal contraception and 
women not using hormonal contraception correlated with bacterial OTUs.  
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Figure 8. A. Genome maps of representatives of viral clusters. B. CRISPR spacers 






Analysis of single nucleotide polymorphisms in multiple strains of 





















Screening for new bacteriophages (phages) will be vital as increasing 
consumer interest in natural products and alternatives to traditional antibiotics is likely 
to result in an ever-increasing requirement for alternative therapies. This study 
involved the isolation of phages from seven different environments against a number 
of target strains. One novel phage was isolated, together with many previously 
identified phages that were re-isolated from the seven sources using 240 bacterial 
strains as targets, including 163 bacterial strains newly isolated in this study. 
Interestingly, 70 strains of phage APCEc01 were isolated against Escherichia coli 
from maize silage, grass silage, and sheep faeces. We performed single nucleotide 
polymorphisms (SNPs) analysis on these 70 phage isolates. Compared to the original 
phage genome first published in 2016 we identified 1174 different SNPs. These 
occurred in a range of annotated genes and hypothetical proteins. Areas of high and 
low SNP concentration were mapped within the genome. The number of SNPs did not 
correlate with the source of the phage. 
 
Introduction  
Bacteriophages (phages) are important biological tools that can potentially be 
used in a number of fields. Despite the increasing importance of sequencing-based, 
culture-independent, methods for phage identification, the isolation of phages is still 
as important as ever. Consumers are turning away from artificial or traditional 
additives and preservatives and often choosing those that they perceive as “natural” 
(1). Increasing numbers of products are advertised using this term. Consumers can 
also tend to attribute negative effects to non-natural interventions over “natural” 
ingredients. Foodborne illness causes significant morbidity, mortality and economic 
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loss every year (2). For this reason, alternative antimicrobial compounds for food 
safety are required, of which phages are a good option. Some phages have been 
investigated solely in research settings while others have been developed as 
commercial products such as the anti-Listeria product Listex, and Agriphage that 
targets phytopathogenic bacteria. Phages can be used at various stages of food 
processing to ensure food safety, such as in the reduction of contamination from 
livestock during production, during processing, and during storage. The rise in 
antibiotic resistance and the shortage of newly developed antibiotics has led to 
research into alternative antimicrobials for infections (3). Antimicrobial resistance is 
one of the greatest threats to global health. Antibiotic resistance is a naturally 
occurring phenomenon, but has been exacerbated by human activities such as overuse 
and misuse of antibiotics in human and animal health. Phages have been investigated 
to address this need and are seen as a viable option. Phage taxonomy is still very 
dependent on phage characteristics which require the culturing of phages, such as 
phage virion morphology for family level classification and the bacterial host for 
naming of phages (4). 
We were interested in the natural variation between strains of phages isolated 
from multiple environments. Phages can encounter different selective pressures based 
on their environment and their mutation and evolution can be affected by this (5). The 
selective pressures can be due to the conditions of the environment itself or the bacteria 
present within it. Genetic similarity between phages can represent relatedness and 
shared evolution (6). Isogenic strains are often developed to use in evolution and 
mutation studies (7). Similar or identical phages are placed under selective pressures 
and allowed to evolve. The mutations and physiological effects associated with these 
pressures can then be tracked. We aimed to look at the occurrence and relatedness of 
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phage strains within and between different sources. This is one of the first studies to 
isolate and compare isogenic phage strains in this way. 
Also of note is that sequencing and annotation can group nearly identical 
phages together and lose valuable information. For example, SPAdes is a commonly 
used assembly program in metagenomic studies. SPAdes forms a high-quality, 
representative, consensus sequence for almost identical sequences rather than lower 
quality sequences for individual strains (8). However, this can conceal variation 
between individual strains. These variations can be of physiological importance. In 
certain cases a single nucleotide polymorphism (SNP) can alter host range (9). The 
replication of phages is dependent on encountering a susceptible host. The less 
genetically related a host is to the original host the less likely the phage is to infect that 
host. The most commonly isolated phages have a narrow host range, limited to strains 
within a genus or species (10). Polyvalent phages infecting multiple species are less 
common. Phages are more likely to evolve under strong selective pressure, for 
example broad host range phages are more likely to evolve under competition for hosts 
(9). While having a broad host range could be seen as an evolutionary advantage, many 
phages persist and replicate despite having an apparently narrow host range. Bacterial 
hosts in turn evolve resistance to phages. Adaptation to a broader host range may have 
consequences. For example, mutants with increased host range have been found to 
have reduced infectivity towards their original hosts (11).  
A selection of 86 phages isolated from human faeces, cow slurry, sheep faeces, 
maize silage, and grass silage, targeting 52 bacterial strains from a bank of laboratory 
strains and independently isolated from a healthy human faecal sample, were 
sequenced and analysed. All phage genomes were sequenced to determine the levels 
of variation across the genomes of multiple strains of the same phage.  
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Materials and methods 
Isolation of bacterial hosts  
Written consents were given according to study protocol APC055, approved 
by the Cork Research Ethics Committee (CREC). A healthy human faecal sample (1 
g) was suspended in 5 ml of 1 X PBS and 5 ml 40% glycerol and homogenised by 
vortexing for 5 min. Bacterial strains were isolated by diluting the faecal suspension 
in PBS and spread plating 100 µl of dilutions 10-3-10-8 on MacConkey agar (Merck), 
Violet Red Bile agar (Merck), Brain Heart Infusion agar (Oxoid), MRS agar (Oxoid) 
and LB agar (Oxoid). Agar plates were incubated at 37˚C aerobically, and also under 
facultative anaerobic conditions using a gas jar with an Anaerocult A (Merck). 
Colonies of different morphology, size and colour were isolated from various different 
agar plates. Strains were streaked on their respective agar plates in triplicate to purify 
cultures for phage screening. A bank of known strains was also selected to be used for 
screening (Table 2). Bacterial strains were identified by 16S rRNA sequencing 
analysis using BLASTn. The 16S rRNA DNA was amplified by colony PCR using 
primers: F8-Fw: 5’-AGAGTTTGATCMTGGCTC-3’ and R1509-Rv: 5’-
GNTACCTTGTTACGACTT-3’. 
Isolation and purification of phages 
Human faecal and farm environmental samples (2 cow slurry, 2 sheep faeces, 
1 maize silage and 1 grass silage) were collected and lysates were prepared 
immediately. Lysates were prepared from samples using the following method. 
Sample (1g) was suspended in 10 ml of SM buffer (50 mM Tris-HCl; 100 mM NaCl; 
8.5 mM MgSO4; pH 7.5). Samples were homogenised by vortexing for 5 min, before 
centrifuging twice at 4,700X g for 10 min at 4˚C in a swing-bucket centrifuge to 
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remove large particulates and bacterial cells. Lysates were filtered twice through a 
0.45 µm pore diameter filter. Bacterial strains were grown overnight in BHI at 37˚C 
with shaking (for aerobes) or without shaking (for facultative anaerobes). The overlay 
method was used for spot and plaque assays. BHI (1% agar w/v) was used as the base 
agar in a 100 mm X 15 mm petri dish. Plaque assays were performed by adding 400 
µl of 1M CaCl2 (final concentration 10mM), 100 µl of phage lysate and 100 µl of an 
overnight culture of bacterial host to 4 ml of soft BHI agar (0.5% agar w/v) kept at 
50˚C. This mixture was poured on top of the BHI (1% agar w/v) base agar and allowed 
to solidify. Spot assays were performed by adding 400 µl of 1M CaCl2 (final 
concentration 10mM) and 200 µl of an overnight culture of bacterial host to 4 ml of 
soft BHI agar (0.5% agar w/v) kept at 50˚C. This mixture was poured on top of the 
BHI (1% agar w/v) base agar and allowed to solidify. 10 µl of phage sample lysates 
were pipetted on the agar and allowed to dry. Plates were incubated at 37°C for 24 to 
48 h. Single plaque purification by propagation of a single plaque and plaque assay 
was carried out 3 times. After isolation phages isolated using anaerobic conditions 
were grown under aerobic conditions. 
Extraction of viral DNA 
A 20 ml phage lysate with 4 ml of 2.5M NaCl and 50% polyethylene glycol 
(PEG) solution (final conc 0.4M NaCl and 8% (w/v) PEG) added was stored at 4˚C 
on ice overnight. Samples were centrifuged at 4700X g for 20 min at 4˚C in a swing 
bucket rotor. Supernatants were removed and pellets were dried for 5 min by inverting 
tube. Pellets were resuspended in 400 µl SM buffer (50 mM Tris-HCl; 100 mM NaCl; 
8.5 mM MgSO4; pH 7.5). 40 µl of 10X Nuclease Buffer (50 mM CaCl2; 10 mM 
MgCl2), was added and treated with 20 U of DNase I and 10 U of RNase I (final 
concentrations; Ambion) for 1 hr at 37˚C. Nucleases were inactivated at 70˚C for 10 
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min before samples were treated with 2 µl of freshly prepared 20 mg/µl Proteinase K 
for 20 min at 56˚C. Phage DNA extractions were performed using Norgen BioTek 
Corp Phage DNA Isolation Kit as described by the manufacturer starting at addition 
of Lysis Buffer B. The Elution Buffer (50 µl) was passed through the column twice to 
maximise DNA recovery. 
Viral DNA amplification, library preparation and sequencing 
Viral DNA concentrations were equalised before paired-end Nextera XT 
library preparation (Illumina, San Diego, CA, USA) as described by the manufacturer. 
Metagenomic sequencing was performed using the Illumina MiSeq (Illumina Inc., San 
Diego, CA, USA) by generating 300 bp paired-end read libraries following the 
manufacturer's instructions. 
Phage genome annotation 
 Sequencing reads of phages were quality filtered and assembled into contigs 
using SPAdes (meta) (38). Redundancy was removed at 99% identity over 99% of the 
length. BLASTn NT database was used to compare sequences to that of known phages 
(39). Genomes were annotated using VIGA (https://github.com/EGTortuero/viga; 
(40)) and visualised using GView (41). 
SARL analysis 
 Spot assays and plaque assays were carried out as previously described. The 
efficiency of plaquing was calculated by dividing the titre of each phage on the strain 
to be tested by the titre of that phage on strain APC 317. 
The presence or absence of phage DW2 in the longitudinal data of subject 918 
was tested using bowtie2 (v2.3.4.1) with default parameters. 
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SNP analysis of APCEc01 genomes 
 Reads were aligned to the reference genome APCEc01, from Dalmasso, et al. 
2016 (12), using Bowtie2 (v2.3.4.1) with default parameters and output in SAM 
format. SAMtools (v1.7) was used to convert SAM files to BAM files and to sort BAM 
files. Bcftools (v1.7) was used to obtain coverage information (mpileup) and to call 
SNP variants (call--ploidy), outputting a VCF file for each sample. Vcfutils.pl 
(varFilter) was used to filter SNP variants by read quality and coverage, outputting 
filtered VCF files. Information contained in VCF files was extracted to build SNP 
tables for nucleotide and amino acid level. A GFF file for APCEc01 was used to match 
functional annotation with SNP data and also to label each SNP as either synonymous 
(no amino acid change) or non-synonymous (amino acid change). GView (v1.7) was 
used to generate a circular annotated genome that included SNP information. Barplots 
of synonymous and non-synonymous SNPs per gene were normalised by gene length 
and visualised in R (v3.6.1). Heatmaps were generated using pairwise SNP counts 
(nucleotide) as input and default parameters for the heatmap.2 function from the 
made4 package in R (v3.6.1). PCoAs were generated in R (v3.6.1) and coloured based 
on isolation site. Box and whisker plot of number of SNPs compared to the original 
APCEc01 genome from 2016 was prepared using GraphPad Prism 5.  
 
Results 
Isolation of bacterial strains and screening for phages in a human faecal sample 
163 bacterial strains were isolated from a healthy human faecal sample and 
triple streaked to ensure pure cultures were obtained (Fig. 1 and Table 1). 37 colonies 
were isolated on MacConkey agar, 47 on BHI agar, 46 on MRS agar, and 24 on LB 
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agar. All were identified to be Enterobacteriaceae. As these were sequenced by 16S 
PCR they were not identified to strain level. 162 were identified as Shigella/E. coli 
and one as Klebsiella aerogenes. Seven strains were not identified. Due to the inability 
of 16S sequencing to distinguish between Shigella and E. coli the top three BLAST 
hits were included for each strain. These included Shigella sonnei, E.fergusonii, 
Shigella flexneri, E.marmotae, Shigella boydii, Shigella dysenteriae. All 240 strains, 
the newly isolated 163 together (Fig. 1) with a bank of 77 known strains representing 
various pathogens (Table 2), were screened by spot on lawn assays for phage present 
in faecal filtrate obtained from the same healthy human (Fig. 1). One spot was visible 
on Staphylococcus aureus APC317 and plaque purified three times. One phage 
(designated SARL) was isolated against S. aureus APC317.  
Staphylococcus aureus phage DW2 analysis 
SARL was sequenced and was found to resemble a previously described phage 
named DW2 (9) (Fig. 2). Another staphylococcal phage, CS1, was isolated in the same 
study as DW2 (10). SARL, DW2 and CS1 were compared (Table 3). SARL, DW2, 
and CS1 infected the same strains and had similar efficiencies of plaquing. SARL, 
DW2, and CS1 on strain S. aureus APC 2053 were positive on spot assay but plaques 
in plaque assays were hazy and unclear. 
The subject from which SARL was isolated took part in a longitudinal study 
of the human gut virome over a twelve-month period (11). SARL was not detected in 
the faecal virome at any of the twelve time points, suggesting that this phage is not a 





Screening for phages in environmental samples  
The same 240 strains were used to screen for phages in environmental samples 
including maize silage, grass silage, cow faeces, and sheep faeces by spot on lawn 
assays (Fig. 1). 155 spots were visible against 76 bacterial strains and purified by three 
rounds of plaquing and picking individual plaques. Multiple plaques were picked from 
a single strain in some cases. 155 putative phages were isolated against 76 bacterial 
strains. We chose 85 phages for sequencing against 51 strains (Table 1). The majority 
were against Shigella/E. coli apart from two phages which were against Klebsiella 
aerogenes. These were selected to include a phage against as many individual bacterial 
strains as possible. One phage isolated was a novel phage against Klebsiella aerogenes 
which is discussed further in Chapter 5. Phages JL1, vB_EcoM_JS09, 
vB_Kpn_IME260, OSYSP, and Pet-CM3-4 were previously described phages 
targeting various Enterobacteriaceae including E. coli and Klebsiella aerogenes (Fig. 
1). Genome maps were drawn for each phage (Fig. 3). Seventy strains of APCEc01 
were isolated using Escherichia coli strains (Fig. 1). 
Number of SNPs in APCEc01 genomes 
 70 strains of the phage APCEc01 were independently isolated from maize 
silage, grass silage, and sheep faeces. When the 70 sequenced genomes were compared 
to the reference genome isolated from a human faecal sample in 2016 (12), 1174 
different SNPs were identified (Table 4). Any changes which were present in all 70 
genomes but not the original genome was not considered a SNP, this was essentially 
a SNP in the original APCEc01 genome and so was discounted. There were 64 SNPs 
in intergenic regions and 1110 SNPs in coding regions. Of the SNPs in coding regions 
286 were non-synonymous and 824 were synonymous. 88 non-synonymous SNPs 
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occurred in one genome only and 58 non-synonymous SNPs occurred in 69 genomes. 
367 synonymous SNPs occurred in one genome only and 220 synonymous SNPs 
occurred in 69 genomes. 
 Overall the most common substitution for A was G (A→G 167/271, A→T 
64/271, A→C 40/271) (Table 4). The most common substitution for C was T (C→T 
234/307, C→A 51/307, C→G 22/307). The most common substitution for G was A 
(G→A 190/258, G→T 54/258, G→C 14/258). The most common substitution for T 
was C (T→C 237/338, T→A 59/338, T→G 42/338). These trends were also seen if 
non-synonymous substitutions and synonymous substitutions were considered 
separately. In the case of intergenic substitutions A to C substitution and A to T 
substitution were equally likely. No G to C substitutions or T to G substitutions were 
evident in intergenic regions but were in non-synonymous substitutions and 
synonymous substitutions.  
SNPs did not cluster based on the source  
The maximum number of SNPs compared to the original genome was 653 
SNPs in A43M (Fig. 4A). After this the maximum was 527 in A1G2. The minimum 
number of SNPs was 387 in A1M1. The median number of SNPs was 486. Genomes 
isolated from maize silage, grass silage, and sheep faeces all had varying numbers of 
SNPs. PCoA analysis of pairwise distance between SNPs of 69 APCEc01 genomes, 
excluding A43M, showed no greater similarity between phage strains isolated from 
the same environment than strains isolated from different environments (Fig. 4B). 
A43M and the original APCEc01 genome were excluded as their divergence skewed 
the PCoA and their inclusion did not add any information as to whether the sources 
affected the incidence of SNPs. A43M showed the greatest variation between it and 
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other strains of APCEc01 isolated (Fig. 5A). When compared A43M showed between 
600 and 800 SNPs between it and all of the other genomes analysed. When all other 
genomes were compared there were less than 300 SNPs found between any two 
genomes (Fig. 5B). Reduced numbers of SNPs were not seen when comparing 
genomes from the same source compared to different sources. No two genomes were 
identical. Based on the heat maps and PCoA we can establish that genomes do not 
cluster based on the SNPs associated with their source.  
SNPs distribution across the genome  
SNPs appeared to cluster rather than be regularly interspersed throughout the 
genome (Fig. 6). There were areas of the genome where no SNPs were present, such 
as in a stretch of hypothetical genes between 111000 bp and 117000 bp. A higher 
concentration of SNPs occurred between the start of the genome and 20000 bp. There 
was also a high concentration of SNPs between 148000 bp and 163000 bp. Fewer 
SNPs were found between these areas of SNPs from 163000 bp to 2000 bp which 
included a DNA helicase and a primase. Few SNPs were found in a collection of genes 
associated with the baseplate from 71000 bp to 78000 bp, including baseplate hub 
subunit, baseplate subunit, and baseplate tail tube initiator. Synonymous and non-
synonymous SNPs were mostly co-occurring. Non-synonymous SNPs were present 
without synonymous SNPs in the same position in much fewer cases. We also noted 
a large number of hypothetical genes within the genome. Based on GenBank 
annotation APCEc01 contained 273 genes of which 55 were hypothetical proteins and 
104 were phage proteins. Of the 115 genes that contained SNPs 31 were hypothetical 
proteins, 33 were annotated as phage proteins, and 51 had more detailed annotations. 
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SNPs were detected in 118 genes (Fig. 7). The number of SNPs per gene was 
normalised based on the length of genes. Of these 118 genes, 31 were classified as 
hypothetical proteins and 35 as encoding a phage protein. A number of genes only 
contained non-synonymous SNPs including phage holin, KEGG_ENZYME:2.4.1.18, 
phage baseplate hub subunit, phage major capsid protein, phage rl lysis inhibition 
regulator, thioredoxin, KEGG_ENZYME:2.7.7.6, phage DNA polymerase clamp 
subunit Gp62, seven phage proteins, and three hypothetical proteins. Molybdenum 
ABC transporter, phage ModA/ModB ribosyltransferase, transcriptional regulator, 
phage rIIA lysis inhibitor, phage nucleoid disruption protein Ndd, acridine resistance, 
DNA topoisomerase, KEGG_ENZYME:3.1.26.4, phage outer membrane lipoprotein 
Rz1, phage T4-like protein, phage RNA ligase, phage portal vertex of the head, phage 
baseplate wedge subunit, putative phospholipase, thioredoxin, sp spackle periplasmic 
protein, nine phage proteins, and 12 hypothetical proteins contained only synonymous 
SNPs. The other genes had a mix of synonymous and non-synonymous SNPs with the 
majority having a preponderance for synonymous SNPs.  
The occurrence of multiple SNPs at a single site and SNPs associated with stop codons 
 Only in five cases were two different SNPs found at the same site (Table 5). 
At 18612 bp, in the phage endonuclease, both were synonymous changes which did 
not affect the glycine amino acid. At 18613 bp, in the phage endonuclease, A was 
changed to C in 66 genomes and from A to T in one genome. These were both non-
synonymous changes from isoleucine to leucine and from isoleucine to phenylalanine, 
respectively. At 18615 bp, in the phage endonuclease, T was changed to A in 66 
genomes but and T to G in one genome. The T to A change was synonymous, 
isoleucine, and the T to G change was non-synonymous from isoleucine to methionine. 
At 18633 bp, in the phage endonuclease, both were synonymous changes which did 
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not affect the threonine amino acid. At 34283 bp, in a hypothetical protein, T was 
changed to A in one genome and from T to C in one genome. These were both non-
synonymous changes changing from aspartic acid to valine and glycine, respectively. 
Non-synonymous substitutions introduced stop codons in four cases (Table 5). 
This occurred in the middle of a Phage rIIA lysis inhibitor gene (16006 bp) in two 
genomes. It occurred in the middle of a Putative tail fiber protein gene (27658 bp) in 
67 genomes. It occurred in a hypothetical protein (53678 bp) in one genome. It also 
occurred in the middle of a phage protein gene (118117 bp) in 26 genomes. A non-
synonymous substitution changed a stop codon to glutamic acid in a phage protein 
(41219 bp). There was also a substitution introduced into a stop codon but it was non-
synonymous so did not have an effect. This occurred in 46 genomes and was located 
at the end of a phage protein gene (143547 bp). 
 
Discussion 
We began this study with the assumption that there would be a higher chance 
of finding a phage and host pair if both came from the same environment. No phages 
were isolated using the same source for bacterial host and phage isolation, and only 
one was found using a bank of laboratory strains (Fig. 1). This lack of success is not 
unprecedented. In the isolation of DW2 and CS1 only five out of twenty different 
farmyard slurry samples gave plaques against S. aureus DPC 5246 (13). Restriction 
analysis indicated that only two distinct phages were present, DW2 and CS1. In a study 
of the isolation of phages from silage on dairy farms 114 Listeria phages were isolated 
(16). Based on host range and genome size re-isolation of the same phages was 
indicated. Vongkamjan, et al. also noted that certain serotypes of Listeria acted as 
157 
 
hosts more often than others suggesting that bacterial choice for screening is 
important. Only nine phages were isolated when screening 86 waste water samples 
against 88 S. aureus strains (17). Six were subsequently excluded due to their 
lysogenic lifecycle or low lytic activity. During the isolation of phages for phage 
therapy against clinically relevant pathogens only one phage was isolated against one 
S. aureus strain after 117 enrichment attempts (18). No phages were isolated against 
the other nine S. aureus strains used. Multiple phages were isolated from the same 
source but these were judged to be the same based on the plaque appearance. Mattila, 
et al. also found that the probability of isolating a phage varied based on the pathogen 
of interest (18). Phage isolation was successful almost 90% of the time against 
Salmonella strains but only 30% of the time against Enterococcus faecium/faecalis 
strains. This can occur if the host that the phage is isolated against is not be the most 
effective or most recent natural host (19). To date only temperate phages, but no 
virulent phages, have been isolated against Clostridium difficile, the causative agent 
of C. difficile infection (20). Similarly, no virulent Bifidobacterium phages have been 
isolated although a number of temperate phages have been identified (21). Therefore, 
the choice of host is important for phage isolation and the isolation of the same phages 
multiple times is common. 
The inability to isolate phages from the same environment that their host was 
found in may be due to how we isolate phages. A number of things must be taken in 
to account when screening for phages. Phage screening can be carried out using direct 
plating or enrichment before plating (22). Samples can be concentrated by filtration or 
precipitation before screening. Direct plating and enrichment have both been effective 
in isolating phages. Direct plating requires higher concentrations of phage particles in 
the samples being screened than samples being used for enrichment. Enrichment can 
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negatively bias isolation towards faster growing phages or phages that propagate better 
in liquid culture and miss slower growing phages or phages that perform better in 
environmental situations. Conversely, this can act as positive selection for the fastest 
and fittest phages. Enrichment can be effective in increasing the number of phages 
isolated from a source. By using enrichment Jurczak-Kurek, et al. isolated 83 potential 
phages from two sewage samples from a wastewater treatment plant (23). Using 
morphological and physiological analysis 13 phages were determined to be 
duplications and discounted. Concentration of samples can be carried out before direct 
plating to give a more accurate representation of an environment than enrichment. 
Faster growing or less pathogenic “surrogate” strains can be used for screening to 
make the process faster and easier (24). These surrogates can also be used solely for 
propagation rather than isolation. Obviously, no phages can be isolated against 
unculturable bacteria. Most phages have been isolated using a single host but the use 
of multiple hosts combined can aid in the isolation of broader host range phages (22). 
There are a number of negatives associated with the most common methods 
for investigating phages such as plaque and spot assays. They can be labour intensive, 
the bacterial hosts may not form confluent lawns, spot assays can show false positives 
due to phage binding but no infection (lysis from without), and plaque assays can show 
false negatives due to incorrect media or low infection productivity. Plaque formation 
can be media dependent. For example, jumbo phages, with genomes greater than 
200000 bp and large phage virions form small plaques in agarose concentrations 
commonly used in screening (25). These small plaques may not be visible. The large 
virion size does not allow for diffusion through higher agarose concentrations so lower 
concentrations must be used for larger, visible plaques to form. Jumbo phage have also 
been found to not lyse liquid bacterial cultures like smaller phages.   
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Not finding a phage in the same source as its host may have also been 
indicative of phage and bacterial community dynamics. Phage and bacterial numbers 
in a community are dependent on one another with phages helping to maintain 
bacterial diversity (26). Areas of the human gut, for example the lumen and mucosa, 
can represent different environments and different dynamics models can be present 
within them. Phages may not have been isolated as their numbers were low. Phages 
present in high numbers would have been available for isolation but their bacterial 
hosts perhaps were only present in low numbers so would not be isolated. 
When the same faecal sample was screened for phages against a bank of 77 
known strains only one phage was isolated and it was determined to be a previously 
sequenced and described phage, DW2 (13) (Fig. 2). In our study, DW2 and CS1 had 
very similar host ranges (Table 3). This was in contrast to O'Flaherty, et al. who found 
DW2 and CS1 to have some similarities in host range but also to infect some different 
hosts and have differing EOPs. SARL was not detected in the virome of 12 monthly 
samples of the same subject. However, the longitudinal study took place over a year 
after SARL was isolated from the subject. It is possible that it was present but at very 
low abundance and the metagenome coverage was too low to detect it. Another 
possibility is that it was not replicating in the gut and was simply passing through and 
was of food or environmental origin (27). Or it too may have been due to community 
dynamics as mentioned in relation to the isolation of phages and their bacterial hosts 
from the same source. 
A number of previously identified phages were re-isolated in this study (Fig. 
3). Phage JL1 is a 43,457 bp Siphoviridae phage first isolated against Escherichia coli 
O157:H7 (Accession Number JX865427) (28). JL1 was isolated from sewage. Phage 
vB_EcoM_JS09 is a 169,148 bp Myoviridae phage first isolated against 
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enterotoxigenic E. coli (Accession Number KF582788) (29). vB_EcoM_JS09 was 
isolated from sewage samples from a pig farm. Phage vB_Kpn_IME260 is a 123,490 
bp phage first isolated against Klebsiella pneumoniae (Accession Number KX845404) 
(30). vB_Kpn_IME260 was isolated from sewage water. Phage OSYSP is a 110,901 
bp phage first isolated against E. coli O157:H7 from waste water (Accession Number 
MF402939) (31). Phage Pet-CM3-4 is a 171, 975 bp Myoviridae phage first isolated 
against Cronobacter malonaticus (Accession Number LT614807). Pet-CM3-4 was 
isolated from waste water.  
APCEc01 was first isolated from the faecal sample, used in a metagenomic 
study, of an elderly patient in long-term care with no known health disorders 
(Accession Number KR422352) (15). Two other phages, APCEc02 and APCEc03, 
were isolated from other individuals in the same metagenomic study. APCEc01 was 
isolated from a faecal sample with a higher E. coli/Shigella content than the samples 
from which APCEc02 and APCEc03 were isolated, 2% compared to 0.07% and 
0.24%, respectively. APCEc01 is a 168,771 bp Myoviridae phage first isolated against 
E. coli strain APC 106. No genes suggesting a temperate lifestyle were found. 
APCEc01 applied for 24 hours at a concentration higher than 107 PFU/well reduced 
biofilm activity by at least 4-fold. APCEc01 was considered to have a narrow host 
range in comparison to the other two phages isolated at the same time, targeting only 
three of the 15 E. coli strains tested compared to APCEc02 which targeted five strains 
and APCEc03 which targeted nine strains. APCEc01 infected E. coli strains APC 104, 
APC 105, and APC 106 and a Shigella sonnei strain isolated from a patient with 
shigellosis. This ability to infect more than one species may help to explain why 
APCEc01 was such a dominant phage and was found so many times in our experiment. 
E. coli is commonly found in farm environments which could also have explained the 
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number of APCEc01 strains isolated (15). The samples of maize silage, grass silage, 
cow faeces, and sheep faeces were from the same farm so APCEc01 could have been 
transferred between these places and contributed towards its presence in multiple 
areas. APC 104, APC 105, and APC 106 were included for phage screening in this 
study. The GC content of APCEc01 at 37.7% is lower than that of E. coli, which is 
around 50%, suggesting that elements of the genome may have been acquired from 
phages infecting hosts with a lower GC content or could have evolved from an 
ancestor that infected a host with a lower GC content (15). APCEc01 and 
vB_EcoM_JS09 have been placed in the same clade, Rb69virus (32). SPAdes is 
commonly used in phageomic studies and forms consensus sequences for very similar 
sequences and can mean that the variation between individual strains is lost. For our 
analysis all of the individual strain sequences of APCEc01 isolated in this study were 
used.  
Different phages show different rates of mutation or evolution. In a 
metagenomics study of the human gut virome over a 2.5 year period temperate phages 
showed lower mutation rates, consistent with replication by accurate bacterial DNA 
polymerases in the integrated prophage state, than lytic phages (33). The single 
stranded DNA phage belonging to the Microviridae showed high substitution rates 
and up to 4% variation over a 2.5 year period. Substitutions occurred at a steady rate 
as well as in response to a change in selective pressure. Podoviridae, Myoviridae, and 
Siphoviridae had medium substitution rates. This rapid evolution was suggested as a 
contributor to the inter-individual nature of human gut viromes. The International 
Committee on Taxonomy of Viruses defines different Microviridae species as having 
as little as 3.1% divergence. Two viruses belonging to the same species differ from 
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each other by less than 5% at the nucleotide level according to the International 
Committee on the Taxonomy of Viruses (4).  
Synonymous SNPs exhibit extremely low mutation rates and are expected to 
be evolutionarily neutral or near so, therefore providing useful markers for studying 
population genetics and the epidemiology of bacterial pathogens (34). For genes in 
which only synonymous SNPs were found, such as topoisomerase and RNA ligase, it 
could be possible that non-synonymous changes would negatively affect their 
expression or operation and so only synonymous SNPs have survived (Fig. 7). Not all 
phage genes undergo mutation at the same rate (19). This was visible when SNP counts 
were normalised based on gene length (Fig. 7). The head genes do not often undergo 
horizontal gene transfer (17). The proteins produced by the head genes must interact 
in a complex way during the formation of new phages. Newly evolved genes may 
produce proteins that cannot interact adequately. This does not mean that these genes 
undergo less mutation it simply means that in these areas mutations that are 
unsuccessful or non-functioning are selected against. A phage baseplate wedge 
subunit was found to have low levels of only synonymous changes which could have 
occurred for similar reasons to phage head genes undergoing low levels of horizontal 
gene transfer (Fig. 7). A phage rIIA lysis inhibitor gene was found to have only non-
synonymous SNPs and in one case this introduced a stop codon. Similarly, the 
introduction of stop codons in genes could be indicative that these genes can be altered 
without affecting the function of the proteins they encode. There is also the possibility 
that these introduced stop codons, or those in the original genome, will not function 
due to processes such as stop codon readthrough in which stop codons function as 
sense codons (35). 
163 
 
SNPs can have important effects on physiology. Non-core phage genes, which 
are not shared between all members of a group, can aid in the exploitation of a niche. 
For example, temperate phages can use the diversity-generating retroelements (DGR) 
system to diversify tail fibres (36). This can be used to overcome bacterial resistance 
mechanisms, such as the mutation of bacterial surface receptors, by introducing up to 
1014 tail fibre variations. A change in the class of the amino acid is more likely to 
affect function than a change to the same class (37). A phenotypic change may require 
the interaction of a number of genetic changes and environmental conditions. Phages 
experimentally coevolved with P. fluorescens increased host range over time and those 
with the broadest host range were found to have the most non-synonymous changes 
(38). These were mostly located in the phage tail fibre gene. It was suggested that these 
non-synonymous mutations had an epistatic effect as the changes could not be linked 
directly to infection of a specific host. The effect of competition and selective pressure 
was evident in the study by Scanlan, et al. where phages that were evolved in the 
presence of non-evolving hosts did not show mutations in select genes while those in 
the presence of evolving phages did (38). Evolution of phage infectivity is a 
combination of phage genomics and host sensitivity. Conversely, phages can also 
evolve a reduced host range (39). Phages have been found to increase their host range 
with as few as one to three mutations in target genes (40). The host range or growth 
of the individual APCEc01 strains was not assessed in this study but it would be useful 
to carry this out in the future and to see if any substitutions changed any aspects of the 
phage growth.  
Although many phage genes have been annotated the function of many is still 
unknown (41). SNPs may be present in a gene we class as non-coding or of unknown 
function but that is simply because we have not established its role yet. This was 
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evident in the data presented here where a number of SNPs occurred in hypothetical 
proteins or genes with ambiguous names such as phage protein for which no function 
has been determined (Fig. 7). Similarly, a number of hypothetical proteins were found 
to have no SNPs (Fig. 6). We cannot predict why this occurred if no function can be 
assigned. Therefore, the effect of SNPs in these areas cannot be predicted or even 
suggested highlighting the need for greater basic phage research. 
It could be possible that SNPs occurred in phage regions targeted by the 
CRISPR/Cas system of its host. SNPs in the proto-spacer or the proto-spacer adjacent 
motif (PAM) of phages can allow phages to overcome CRISPR/Cas associated 
immunity (42). The PAM is a conserved sequence immediately next to the protospacer 
that is used by the bacteria to discriminate between its own nucleic acid and that of 
invading phages. This could explain why SNPs were found in blocks and not equally 
dispersed throughout the genome. It could also explain why in a number of cases the 
exact same SNP was found in a number of strains as phages with PAM mutations were 
found to be dominant over wild type phages (42). Coevolution can occur by the 
reciprocal acquisition of new CRISPR spacers by the bacterial host and mutation in 
these regions by the phage (43). It would be interesting to look if the SNPs in the 
APCEc01 genome are in regions targeted by the CRISPR/Cas system. 
One aspect of this study concentrated on the importance of bacterial strain 
selection and environmental source for screening for phages. It drew attention to the 
difficulty in isolating new and unreported phages. A number of previously known 
phages were re-isolated together with a single novel phage. The second part of this 
work looked at the occurrence of SNPs in strains of a single phage isolated from 
various environmental sources. Up to 800 SNPs occurred between some genomes 
including instances where stop codons were introduced and amino acids were 
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changed. It was also significant to see where SNPs did and did not occur which can 
highlight the importance of these genes or their requirement to be conserved. The large 
number of hypothetical proteins and genes known only as phage proteins also showed 
how much is left to learn about the genomes of phages. These changes could be 
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Tables and figures 
 
 
Figure 1. Workflow of bacterial strain isolation from faeces and screening of faecal 




Table 1. Phages isolated and sequenced. Bacteria in brackets are laboratory strains and 
were not isolated in this study. Phages were named using the convention “A/N-
bacterial host strain number-M/G/S1/S2/C1”. A=aerobic isolation, N=anaerobic 
isolation. M=maize silage, G=grass silage, S1=sheep faeces sample 1, S2=sheep 
faeces sample 2, C1=cow faeces sample 1. For some samples an extra number was 
added to the end if multiple phages were isolated from the same source against the 
same bacterial host. 




A1G1 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
A1G2 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
A1M1 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
A1M2 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey Not sequenced 
A1M3 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey Not sequenced 
A4G1 Shigella sonnei/Shigella flexneri/E.fergusonii MacConkey Not sequenced 
A4G2 Shigella sonnei/Shigella flexneri/E.fergusonii MacConkey APCEc01 
A4M Shigella sonnei/Shigella flexneri/E.fergusonii MacConkey APCEc01 
A5G Shigella sonnei/Shigella flexneri/E.fergusonii MacConkey Not sequenced 
A5M1 Shigella sonnei/Shigella flexneri/E.fergusonii MacConkey APCEc01 
A5M2 Shigella sonnei/Shigella flexneri/E.fergusonii MacConkey Not sequenced 
A7G Shigella sonnei/E.fergusonii/Shigella flexneri BHI APCEc01 
A7M Shigella sonnei/E.fergusonii/Shigella flexneri BHI APCEc01 
A8G Shigella sonnei/E.fergusonii/Shigella flexneri BHI Not sequenced 
A8M Shigella sonnei/E.fergusonii/Shigella flexneri BHI APCEc01 
A10G Not sequenced BHI Cronobacter phage Pet-CM3-4 
A21S2 E.marmotae/E.fergusonii/Shigella boydii MacConkey Not sequenced 
A22M1 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
A22M2 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey Not sequenced 
A22S2 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey Not sequenced 
A24M Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
A24S21 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey Not sequenced 
A24S22 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey Not sequenced 
A25M Not sequenced MacConkey APCEc01 
A25S21 Not sequenced MacConkey APCEc01 
A25S22 Not sequenced MacConkey Not sequenced 
A25S23 Not sequenced MacConkey APCEc01 
A26M1 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
A26M2 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey Not sequenced 
A27M Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey Not sequenced 
A27S21 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
A27S22 Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
A30M Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
A35M Shigella sonnei/E.fergusonii/Shigella flexneri MRS APCEc01 
A35S2 Shigella sonnei/E.fergusonii/Shigella flexneri MRS Not sequenced 
A37M E.fergusonii/Shigella boydii/E.fergusonii MRS Not sequenced 
A41M  E.fergusonii/Shigella sonnei/E.fergusonii MRS Not sequenced 
A41S2 E.fergusonii/Shigella sonnei/E.fergusonii MRS Enterobacteria phage JL1 
A43M Shigella sonnei/E.fergusonii/Shigella flexneri MRS APCEc01 
A43S2 Shigella sonnei/E.fergusonii/Shigella flexneri MRS Not sequenced 
A44M E.fergusonii/Shigella boydii/Shigella 
dysenteriae 
MRS Not sequenced 
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A44S2 E.fergusonii/Shigella boydii/Shigella 
dysenteriae 
MRS Not sequenced 
A45M Shigella flexneri/Shigella sonnei/E.fergusonii MRS APCEc01 
A46S2 E.fergusonii/Shigella boydii/Shigella 
dysenteriae 
MRS Not sequenced 
A50M Shigella sonnei/Shigella flexneri/Shigella 
dysenteriae 
LB APCEc01 
A50S2 Shigella sonnei/Shigella flexneri/Shigella 
dysenteriae 
LB APCEc01 
A51S2 E.fergusonii/Shigella sonnei/E.fergusonii LB Enterobacteria phage JL1 
A53M Shigella sonnei/E.fergusonii/Shigella flexneri LB APCEc01 
A53S2 Shigella sonnei/E.fergusonii/Shigella flexneri LB Not sequenced 
A59M1 Shigella sonnei/E.fergusonii/Shigella flexneri VRBA APCEc01 
A59M2 Shigella sonnei/E.fergusonii/Shigella flexneri VRBA APCEc01 
A59S2 Shigella sonnei/E.fergusonii/Shigella flexneri VRBA APCEc01 
A61M Shigella sonnei/E.fergusonii/Shigella flexneri VRBA APCEc01 
A61M1 Shigella sonnei/E.fergusonii/Shigella flexneri VRBA Not sequenced 
A61S2 Shigella sonnei/E.fergusonii/Shigella flexneri VRBA APCEc01 
A66M Shigella sonnei/E.fergusonii/Shigella flexneri VRBA Not sequenced 
A66S2 Shigella sonnei/E.fergusonii/Shigella flexneri VRBA Not sequenced 
A67C11 E.fergusonii/Shigella sonnei/E.fergusonii VRBA Enterobacteria phage JL1 
A67C12 E.fergusonii/Shigella sonnei/E.fergusonii VRBA Enterobacteria phage JL1 
A67S2 E.fergusonii/Shigella sonnei/E.fergusonii VRBA Enterobacteria phage JL1 
A68M Shigella sonnei/E.fergusonii/Shigella flexneri BHI APCEc01 
A68S2 Shigella sonnei/E.fergusonii/Shigella flexneri BHI APCEc01 
A70M Shigella sonnei/E.fergusonii/Shigella flexneri BHI Not sequenced 
A70S2 Shigella sonnei/E.fergusonii/Shigella flexneri BHI APCEc01 
A71M1 E.fergusonii/Shigella boydii/E.fergusonii BHI Not sequenced 
A71M2 E.fergusonii/Shigella boydii/E.fergusonii BHI APCEc01 
A73M Not sequenced MRS Not sequenced 
A73S2 Not sequenced MRS Not sequenced 
A74S2 E.fergusonii/Shigella boydii/Shigella sonnei MRS APCEc01 
A77M Shigella sonnei/E.fergusonii/Shigella flexneri MRS Not sequenced 
A77S2 Shigella sonnei/E.fergusonii/Shigella flexneri MRS APCEc01 
A78M Shigella flexneri/Shigella sonnei/E.fergusonii BHI APCEc01 
A78S2 Shigella flexneri/Shigella sonnei/E.fergusonii BHI Not sequenced 
A81G Not sequenced BHI Not sequenced 
A81M Not sequenced BHI Not sequenced 
A81S11 Not sequenced BHI Not sequenced 
A81S12 Not sequenced BHI Not sequenced 
A85M Shigella flexneri/Shigella sonnei/E.fergusonii BHI APCEc01 
APC104G (E. coli  APC104)  APCEc01 
APC105G (E. coli  APC105)  APCEc01 
APC105M1 (E. coli  APC105)  APCEc01 
APC105M2 (E. coli  APC105)  Not sequenced 
APC106G1 (E. coli  APC106)  Not sequenced 
APC106G2 (E. coli  APC106)  Not sequenced 
APC106M (E. coli  APC106)  APCEc01 
MG1655G (E. coli  MG1655)  APCEc01 
MG1655M1 (E. coli  MG1655)  Not sequenced 
MG1655M2 (E. coli  MG1655)  Escherichia phage OSYSP 
SARL (S. aureus APC317)  DW2 
N1M1 Klebsiella aerogenes MacConkey Klebsiella phage vB_Kpn_IME260 
N1M2 Klebsiella aerogenes MacConkey Novel N1M2 
N9G E.fergusonii/Shigella flexneri/Shigella sonnei BHI APCEc01  
N9M1 E.fergusonii/Shigella flexneri/Shigella sonnei BHI APCEc01 
N9M2  E.fergusonii/Shigella flexneri/Shigella sonnei BHI Not sequenced 
N17G Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
N17M Shigella sonnei/E.fergusonii/Shigella flexneri MacConkey APCEc01 
N18M Not sequenced MacConkey Not sequenced 
N19G1 Shigella flexneri/Shigella sonnei/E.fergusonii MacConkey Not sequenced 
N19G2 Shigella flexneri/Shigella sonnei/E.fergusonii MacConkey Not sequenced 
N22G1 E.fergusonii/Shigella flexneri/Shigella sonnei MacConkey Not sequenced 
N22G2 E.fergusonii/Shigella flexneri/Shigella sonnei MacConkey Not sequenced 
175 
 
N22M  E.fergusonii/Shigella flexneri/Shigella sonnei MacConkey APCEc01 
N26M  Shigella flexneri/Shigella sonnei/E.fergusonii MacConkey APCEc01 
N27M Shigella flexneri/Shigella sonnei/E.fergusonii MacConkey APCEc01 
N28G Shigella flexneri/Shigella sonnei/E.fergusonii MacConkey APCEc01 
N28M Shigella flexneri/Shigella sonnei/E.fergusonii MacConkey Not sequenced 
N29G  E.fergusonii/Shigella boydii/Shigella sonnei MacConkey Enterobacteria phage JL1 
N30M  E.fergusonii/Shigella boydii/Shigella sonnei MacConkey Not sequenced 
N31G E.fergusonii/Shigella flexneri/E.coli MacConkey Enterobacteria phage JL1 
N32M  E.fergusonii/Shigella boydii/Shigella flexneri MacConkey APCEc01 
N33M E.fergusonii/Shigella boydii/Shigella flexneri MacConkey APCEc01 
N36M E.fergusonii/Shigella boydii/Shigella flexneri BHI APCEc01 
N37M1 Shigella flexneri/E.fergusonii/E.fergusonii BHI APCEc01 
N37M2 Shigella flexneri/E.fergusonii/E.fergusonii BHI Not sequenced 
N38G Not sequenced BHI Enterobacteria phage JL1 
N39G E.fergusonii/Shigella flexneri/Shigella sonnei BHI Not sequenced 
N41M Shigella flexneri/Shigella sonnei/E.fergusonii BHI APCEc01 
N43M Shigella flexneri/Shigella sonnei/E.fergusonii BHI Not sequenced 
N48G Shigella flexneri/Shigella sonnei/E.fergusonii BHI APCEc01 
N48M Shigella flexneri/Shigella sonnei/E.fergusonii BHI Not sequenced 
N50G E.fergusonii/E.marmotae/Shigella boydii MRS APCEc01 
N50M E.fergusonii/E.marmotae/Shigella boydii MRS Not sequenced 
N51M Shigella flexneri/E.fergusonii/E.fergusonii MRS APCEc01 
N54G Not sequenced MRS Not sequenced 
N54M1 Not sequenced MRS Not sequenced 
N54M2 Not sequenced MRS Not sequenced 
N55G E.fergusonii/Shigella flexneri/Shigella sonnei MRS APCEc01 
N58G Shigella flexneri/E.fergusonii/E.fergusonii MRS Enterobacteria phage JL1 
N58M1 Shigella flexneri/E.fergusonii/E.fergusonii MRS Not sequenced 
N58M2 Shigella flexneri/E.fergusonii/E.fergusonii MRS Not sequenced 
N59M1 Not sequenced MRS Not sequenced 
N59M2  Not sequenced MRS Not sequenced 
N62G Shigella flexneri/E.fergusonii/E.fergusonii LB Escherichia phage vB_EcoM_JS09 
N62M1 Shigella flexneri/E.fergusonii/E.fergusonii LB Not sequenced 
N62M2 Shigella flexneri/E.fergusonii/E.fergusonii LB Not sequenced 
N64G Shigella flexneri/Shigella sonnei/E.fergusonii LB Not sequenced 
N64M Shigella flexneri/Shigella sonnei/E.fergusonii LB APCEc01 
N65G1 Shigella flexneri/Shigella sonnei/E.fergusonii LB Not sequenced 
N65G2 Shigella flexneri/Shigella sonnei/E.fergusonii LB APCEc01 
N65G3 Shigella flexneri/Shigella sonnei/E.fergusonii LB Not sequenced 
N65M1 Shigella flexneri/Shigella sonnei/E.fergusonii LB APCEc01 
N65M2  Shigella flexneri/Shigella sonnei/E.fergusonii LB APCEc01 
N66M1 E.fergusonii/Shigella flexneri/Shigella sonnei LB APCEc01 
N66M2 E.fergusonii/Shigella flexneri/Shigella sonnei LB Not sequenced 
N67G Shigella sonnei/E.fergusonii/Shigella flexneri LB Not sequenced 
N67M1 Shigella sonnei/E.fergusonii/Shigella flexneri LB APCEc01 
N67M2 Shigella sonnei/E.fergusonii/Shigella flexneri LB Not sequenced 
N67M3 Shigella sonnei/E.fergusonii/Shigella flexneri LB APCEc01 
N68G Shigella dysenteriae/Shigella sonnei/Shigella 
flexneri 
LB Escherichia phage vB_EcoM_JS09 
N68M Shigella dysenteriae/Shigella sonnei/Shigella 
flexneri 
LB Not sequenced 
N69G Shigella sonnei/Shigella flexneri/E.fergusonii LB APCEc01 
N69M1 Shigella sonnei/Shigella flexneri/E.fergusonii LB APCEc01 
N69M2 Shigella sonnei/Shigella flexneri/E.fergusonii LB Not sequenced 
N73G Shigella sonnei/E.fergusonii/Shigella flexneri BHI APCEc01 
N73M1 Shigella sonnei/E.fergusonii/Shigella flexneri BHI Not sequenced 





Table 2. A bank of known strains was selected to be used for phage screening. 
Strain designation  Other designations Strain 
APC 53 DPC 6085, NCIMB700577, NCDO0577 Bacillus cereus 
APC 54 DPC 6086, NCIMB700578, NCDO0578 Bacillus cereus 
APC 55 DPC 6087, NCIMB700579, NCDO0579 Bacillus cereus 
APC 56 DPC 6088, NCIMB700827, NCDO0827 Bacillus cereus 
APC 57 DPC 6089, NCIMB8079, ATCC7004 Bacillus cereus 
APC 58 DPC 6334, Bel 17Bc Bacillus cereus 
APC 59 DPC 6336, Bel Bc33 Bacillus cereus 
DPC 8079  Bacillus cereus 
APC 1762 UCC 5002 Bacillus subtilis 
APC 1640  Enterococcus casseliflavus 
APC 1039 EC618 Enterococcus faecalis 
APC 1749 DPC 5152 Enterococcus faecalis 
APC 1025 EC251 Enterococcus faecium 
APC 1026 EC289 Enterococcus faecium 
APC 1029 EC300 Enterococcus faecium 
APC 1030  EC357 Enterococcus faecium 
APC 1031 EC520 Enterococcus faecium 
APC 1032 EC533 Enterococcus faecium 
APC 1035 EC548 Enterococcus faecium 
APC 1036 EC562 Enterococcus faecium 
APC 1038 EC587 Enterococcus faecium 
APC 1043 EC725 Enterococcus faecium 
APC 1044 EC748 Enterococcus faecium 
APC 1641  Enterococcus faecium 
Lactobacillus salivarius 6482 Lactobacillus salivarius 
APC 317  DPC 5245 S. aureus 
APC 993 ST290 S. aureus 
APC 994 ST291 S. aureus 
APC 995 ST295 S. aureus 
APC 996 ST299 S. aureus 
APC 998 ST355 S. aureus 
APC 1003  ST528 S. aureus 
APC 1004 ST530 S. aureus 
APC 1007 ST535 S. aureus 
APC 1009 ST544 S. aureus 
APC 1010 ST550 S. aureus 
APC 1012 35197 S. aureus 
APC 1019 25949 S. aureus 
APC 1022  Newman S. aureus 
APC 1024 RF122 S. aureus 
APC 1055 LMG14694, ATCC 13813, CCRC 
10787, CCUG 4208, CIP 103227, DSM 
2134, JCM 5671, NCFB 1348, NCTC 
8181 
Streptococcus agalactiae 
APC 1759   Streptococcus agalactiae 
APC 1755  Streptococcus dysgalactiae 
APC 119 DPC 6143, 4001 Streptococcus mutans 
APC 120 DC 6144, 4021 Streptococcus mutans 
APC 121 DPC 6145, 4070 Streptococcus mutans 
APC 122 DPC 6150, 4009 Streptococcus mutans 
APC 123 DPC 6151, 4030 Streptococcus mutans 
APC 124 DPC 6152, 4037 Streptococcus mutans 
APC 125 DPC 6153, 4039 Streptococcus mutans 
APC 126 DPC 6154, 4040 Streptococcus mutans 
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APC 127 DPC 6155, 4055 Streptococcus mutans 
APC 128 DPC 6156, 4058 Streptococcus mutans 
APC 129 DPC 6157, 3007 Streptococcus mutans 
APC 130 DPC 6158, 3013 Streptococcus mutans 
APC 131 DPC 6159, 3017 Streptococcus mutans 
APC 132 DPC 6160, 1038 Streptococcus mutans 
APC 133 DPC 6161, 1054 Streptococcus mutans 
APC 134 DPC 6162, NCTC10449, ATCC 25175, 
SIMS, DSM 20523, ATCC 25175, IFO 
13955, NCDO 2062 
Streptococcus mutans 
APC 135 DPC 6543 Streptococcus mutans 
APC 1756 DSM 2071 Streptococcus pyogenes 
APC 1757 DSM11728 Streptococcus pyogenes 
APC 1758 NCDO2381 Streptococcus pyogenes 
APC 104 DPC 6009 Escherichia coli 
APC 105 DPC 6050 Escherichia coli 
APC 106 DPC 6051 Escherichia coli 
APC 109 DPC 6054, P1432 Escherichia coli 
APC 110 DPC 6055, AR12900 Escherichia coli 
APC 115 DPC 6472 Escherichia coli 
APC 1220 HM605 Escherichia coli 
Escherichia coli 042 Escherichia coli 
Escherichia coli Nissle  Escherichia coli 
Esherichia coli UTI89 Escherichia coli 
APC 1977 MG1655 Escherichia coli 
APC 176 DPC 6452 Salmonella typhimurium  
APC 181 DPC 6547 Salmonella typhimurium  









Figure 2. Genome map of phage SARL. A comparison was carried out and it was 








Table 3. Sensitivity of strains to SARL, DW2 and CS1 on the basis of efficiency of 
plaquing (EOP). (-) no clearing in spot assay. (+) clearing in spot assay but no plaques 
in plaque assay. EOP values are given for each phage. MRSA - Methicillin resistant 
S. aureus. MSSA - Methicillin sensitive S. aureus. hVISA - heterogenous vancomycin 
resistant S. aureus. 
APC 
designation 
Strain Other name Sensitivity 
designation 
SARL DW2 CS1 
APC 317 S. aureus DPC 5245 MSSA 1 1 1
APC 409 S. aureus DPC 5247 MSSA 1.06 1.28 1.17
APC 2053 S. aureus 3594(II)ST36 MRSA + + + 
APC 993 S. aureus ST290 MRSA - - - 
APC 994 S. aureus ST291 MRSA - - - 
APC 995 S. aureus ST295 MRSA - - - 
APC 996 S. aureus ST299 MRSA - - - 
APC 1003 S. aureus ST528 MRSA - - - 
APC 1004 S. aureus ST530 MRSA - - - 
APC 1007 S. aureus ST535 MRSA - - - 
APC 1009 S. aureus ST544 MRSA - - - 
APC 2044 S. aureus 0.1345(II)ST5 MRSA - - - 
APC 2045 S. aureus 3596(IIV)ST8 MRSA - - - 
APC 2047 S. aureus 3488(VV)ST8 MRSA - - - 
APC 2048 S. aureus 3144(IIV)ST8 MRSA - - - 
APC 2049 S. aureus E1038(IV)ST8 MRSA - - - 
APC 2050 S. aureus E1185(IV)ST12 MRSA - - - 
APC 2051 S. aureus E1174(IV)ST22 MRSA - - - 
APC 2052 S. aureus 0242(IV)ST30 MRSA - - - 
APC 2054 S. aureus E1139(IV)ST45 MRSA - - - 
APC 2055 S. aureus 0.1239(III)ST239 MRSA - - - 
APC 2061 S. aureus 3581(1A)ST247 MRSA - - - 
APC 2062 S. aureus 0.1206(IV)ST250 MRSA - - - 
APC 1012 S. aureus 35197 hVISA - - - 
APC 1022 S. aureus Newman MSSA - - - 
APC 1024 S. aureus RF122 MSSA - - - 
APC 79 S. epidermidis DPC6010 n/a - - - 




























Figure 3. Genome map of phages isolated from environmental sources. A. 
Enterobacteria phage JL1 B. Escherichia phage vB_EcoM_JS09 C. Klebsiella phage 
vB_Kpn_IME260 D. Escherichia phage OSYSP E. Cronobacter phage Pet-CM3-4. 
Green lines represent pVOGs. Blue arrows represent genes on the forward strand. Red 






Table 4. Number of SNPs and changes in nucleotide broken down by group. 








A→C  40  3  12  25  
A→G 167 7 44 116 
A→T 64 3 18 43 
C→A  51 5 23 23 
C→G  22 2 13 7 
C→T  234 13 33 188 
G→A 190 8 45 137 
G→C  14 0 10 4 
G→T  54 6 24 24 
T→A  59 4 17 38 
T→C  237 13 29 195 
T→G 42 0 18 24 





















Figure 4. A. Box and whisker plot of number of SNPs of 70 isolated APCEc01 
genomes compared to original APCEc01 genome from 2016. B. PCoA of pairwise 
distance between SNPs of 69 APCEc01 genomes (excluding A43M and original 































































Figure 5. A. Heat map comparing SNP count between 70 APCEc01 genomes 











Figure 6. Synonymous and non-synonymous SNPs present in 70 APCEc01 genomes 






























Table 5. Cases in which two different SNPs were found at the same site and SNPs 
which introduced or involved stop codons.  











Phage rIIA lysis 
inhibitor 
(14883-17096) 
































18633 (+) A→C Threonine Threonine 68 
Putative tail fiber 
protein 
(26377-29427) 



















53678 (+) C→T Glutamine Stop codon 1 
Phage protein 
(117777-118463) 
118117 (+) T→A Leucine Stop codon 26 
Phage protein 
(143308-143547) 
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Increasing levels of bacterial resistance to many common and last resort 
antibiotics has increased interest in finding new treatments. The low rate of approval 
of new antibiotics has led to the search for new and alternative antimicrobial 
compounds. Bacteriophages (phages) are bacterial viruses found in almost every 
environment. Phage therapy was historically investigated to control bacterial 
infections and is still in use in Georgia and as a treatment of last resort. Phage therapy 
is increasingly recognised as an alternative antimicrobial treatment for antibiotic 
resistant pathogens. A novel lytic Klebsiella aerogenes phage N1M2 was isolated 
from maize silage. Klebsiella aerogenes, a member of the ESKAPE bacterial 
pathogens, is an important target for new antimicrobial therapies. Klebsiella aerogenes 
can form biofilms on medical devices which aids its environmental persistence and for 
this reason we tested the effect of phage N1M2 against biofilms. Phage N1M2 
successfully removed a pre-formed Klebsiella aerogenes biofilm. Biofilm assays were 
also carried out with Staphylococcus aureus and Phage K. Phage K successfully 
removed a preformed Staphylococcus aureus biofilm. Phage N1M2 and Phage K in 
combination were significantly better at removing a mixed community biofilm of 
Klebsiella aerogenes and Staphylococcus aureus than either phage alone. 
 
Introduction 
Bacteriophages (phages) are viruses that require bacteria as a host for 
replication. Studies suggest that in many environments phages outnumber bacterial 
and archaeal cells 25:1 (1). Phages have been studied using culture based techniques 
since their independent discovery by Twort and D’Herelle in 1915 and 1917, 
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respectively. More recently, phages have been studied using culture independent 
methods such as the sequencing of environmental metagenomes which include 
bacteria, eukaryotic viruses and phages but also in studies of the virome alone (2). 
Interest has been growing in the role of phages in general human health (3) but also in 
specific conditions such as IBD (4). Despite the rise in viral metagenomics, cultivated 
phages are required for the development of interventions for use in phage therapy (5), 
food safety (6), and molecular biology (7). 
The acronym ESKAPE has been applied to six bacterial pathogens that are of 
concern due to their ability to cause hospital acquired infections and the difficulty in 
treating them due to antibiotic resistance (8). The ESKAPE pathogens have shown 
increased incidence as causative agents in human disease and have increased 
antimicrobial resistance and negative outcomes. In 2017 the WHO compiled a global 
priority pathogens list prioritising the development of new antibiotics (9). The 
pathogens were chosen based on ten criteria; mortality, association with issues in 
healthcare settings and communities, the frequency of resistance, a 10-year trend of 
resistance, ease of transmission, how they could be prevented in hospital and 
community settings, and their current treatment. This list included critical priority 
targets carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant 
Pseudomonas aeruginosa and carbapenem-resistant and 3rd generation 
cephalosporin-resistant Enterobacteriaceae (including Klebsiella pneumoniae, 
Escherichia coli, Enterobacter spp., Serratia spp., Proteus spp., and Providencia spp, 
Morganella spp). Klebsiella aerogenes was previously classified as Enterobacter 
aerogenes (10). 
The rise in antibiotic resistance has led to a need for new antimicrobial 
compounds; however, the number of drug applications and approvals for antibiotics 
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has dropped significantly (11). For example, 19 new antibiotic applications were 
lodged in the early 1980s but only one was lodged between 2010 and 2012. This 
shortage of newly developed antibiotics has led to research into alternative 
antimicrobials (12). Western societies lost interest in phage therapy during World War 
II with the discovery of antibiotics but interest has been renewed due to the need for 
new antimicrobials. Phage therapy is currently used in Georgia against a range of 
pathogens, including Shigella sonnei, Escherichia coli, Staphylococcus aureus and 
Pseudomonas aeruginosa. Randomised controlled trials using phage therapy have 
been carried out such as PhagoBurn to treat burn wounds infected by Pseudomonas 
aeruginosa and the use of Biophage-PA to treat chronic otitis caused by antibiotic-
resistant P. aeruginosa (13, 14). In the food industry, consumer distrust has increased 
towards chemical and artificial preservatives, leading to increased interest in 
alternative natural methods (15). Phages can also be used in food safety to reduce 
contamination from livestock during production, disinfect plants and equipment, 
reduce bacterial load on food at processing and during storage. 
Much work has been carried out isolating phages from different sources. 
Faeces is a common source of phages, such as from ducks (16), cattle (17), pigs (18) 
and from sewage (19). Phages have been isolated from human sources, such as saliva 
(20), sputum samples, catheter tips and pleural effusions (21). Phages have also been 
isolated from environmental samples, such as seawater, from river estuaries (22), 
Arctic sea ice and melt ponds (23), soil (24), and yogurt and cheese factories (25). 
The aim of this study was to isolate and characterise phages that could 
potentially be used for phage therapy or in food safety. A total of 163 bacterial strains 
were isolated from a healthy human faecal sample and used in conjunction with a bank 
of 79 known bacterial strains as prospective hosts for phages. These strains were 
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screened for phages against a human faecal filtrate and environmental samples 
collected from a nearby farm. Farm areas tested for phages were from cow slurry (n = 
2), sheep faeces (n = 2), maize silage (n = 1) and grass silage (n = 1). A selection of 
phages were sequenced and analysed. One phage isolated on a Klebsiella aerogenes 
host, named phage N1M2, was chosen for further study as it had not been previously 
sequenced or described. Genomic and phylogenetic analysis revealed it to be a highly 
novel jumbo phage distantly related to Pseudomonas phage OBP, a phage previously 
described to possess homology to the PhiKZ-like jumbo phages (26). 
Medical device-related infections are associated with increased morbidity, 
mortality and healthcare costs. Biofilms, which are commonly associated with medical 
devices, require treatment with antimicrobials in higher levels than planktonic cells 
(27). Phages have been investigated in human cases and mouse models of medical 
device infections. For example, phage coating significantly reduced the bacterial load 
and inflammation in a mouse model of MRSA orthopaedic implant infection (28). 
Moreover, phage significantly reduced bacterial numbers in a mouse model of implant 
infection caused by biofilm forming P. aeruginosa (29). Combinations of phage and 
antibiotics have also been successful in the treatment of a recurrent infection 
associated with a left ventricular assist device (30). In a case study, a combination of 
phage and antibiotics successfully treated a multidrug-resistant P. aeruginosa 
periprosthetic joint infection (31). The rationale behind the inclusion of phage was to 
aid in the breakdown of a biofilm matrix on the implant.  
Urinary tract infections are a common nosocomial infection. K. aerogenes 
strains capable of biofilm production have been isolated from urinary catheters (32), 
and has also been found to be the causative agent in central venous catheter-related 
bloodstream infections (33). The effectiveness of phage N1M2 was therefore 
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investigated in biofilms. Mixed community infections are commonly associated with 
medical devices. Hola et al. found 465/534 urinary catheters were colonised by more 
than one bacterial strain (32). For this reason mixed community biofilms were also 
investigated. Staphylococcus aureus was chosen because it is one of the most 
commonly isolated bacteria from catheter-related urinary tract infections and 
bloodstream infections and methicillin-resistant S. aureus (MRSA) is one of the most 
feared hospital acquired infections (27). The antimicrobial potential of Phage K 
against S. aurerus is well documented (34). Phage K belongs to the family of 
Herelleviridae and falls within the genus of Kayvirus (35). Given the data to date more 
intensive research into the effectivity of phages in nosocomial infection is warranted 
especially given the current status of antimicrobial resistance to commonly used 
antibiotics. 
 
Materials and methods 
Isolation of bacterial hosts 
Written consents were given according to study protocol APC055, approved by 
the Cork Research Ethics Committee (CREC). A healthy human faecal sample (1 g) 
was suspended in 5 ml of 1 X phosphate buffered saline (PBS) and 5 ml 40% glycerol 
and homogenised by vortexing for 5 min. Bacterial strains were isolated by diluting 
the faecal suspension in PBS and spread plating 100 µl of dilutions 10-3-10-8 on 
MacConkey agar (Merck), Violet Red Bile agar (Merck), Brain Heart Infusion agar 
(Oxoid), MRS agar (Oxoid) and LB agar (Oxoid). Agar plates were incubated at 37˚C 
aerobically, and also under facultative anaerobic conditions using a gas jar with an 
Anaerocult A (Merck). Colonies of different morphology, size and colour were 
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isolated from the various different agar plates. Strains were streaked on their respective 
agar plates in triplicate to purify cultures for phage screening. A bank of known strains 
was also selected to be used for screening (Supp. Table 1). Bacterial strains were 
identified by 16S rRNA sequencing analysis using BLASTn. The 16S rRNA DNA 
was amplified by colony PCR using primers: F8-Fw: 5’-
AGAGTTTGATCMTGGCTC-3’ and R1509-Rv: 5’-GNTACCTTGTTACGACTT-
3’. 
Isolation and purification of phages 
Human faecal and farm environmental samples (2 cow slurry, 2 sheep faeces, 1 
maize silage and 1 grass silage) were collected and lysates were prepared immediately. 
Supernatants were prepared from samples using the following method. Sample (1g) 
was suspended in 10 ml of SM buffer (50 mM Tris-HCl; 100 mM NaCl; 8.5 mM 
MgSO4; pH 7.5). Samples were homogenised by vortexing for 5 min, before 
centrifuging twice at 4,700X g for 10 min at 4˚C in a swing-bucket centrifuge to 
remove large particulates and bacterial cells. Supernatants were filtered twice through 
a 0.45 µm pore diameter filter. Bacterial strains were grown overnight in BHI at 37˚C 
with shaking (for aerobes) or without shaking (for facultative anaerobes). The overlay 
method was used for spot and plaque assays. BHI (1% agar w/v) was used as the base 
agar in a 100 mm X 15 mm petri dish. Plaque assays were performed by adding 400 
µl of 1M CaCl2 (final concentration 10mM), 100 µl of phage lysate and 100 µl of an 
overnight culture of bacterial host to 4 ml of soft BHI agar (0.5% agar w/v) kept at 
50˚C. This mixture was poured on top of the BHI (1% agar w/v) base agar and allowed 
to solidify. Spot assays were performed by adding 400 µl of 1M CaCl2 (final 
concentration 10mM) and 200 µl of an overnight culture of bacterial host to 4 ml of 
soft BHI agar (0.5% agar w/v) kept at 50˚C. This mixture was poured on top of the 
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BHI (1% agar w/v) base agar and allowed to solidify. 10 µl of phage sample lysates 
were pipetted on the agar and allowed to dry. Plates were incubated at 37°C for 24 to 
48 h. Single plaque purification by propagation of a single plaque and plaque assay 
was carried out 3 times. 
Viral DNA extraction, amplification, library preparation and sequencing  
A 20 ml phage lysate with 4 ml of 2.5M NaCl and 50% polyethylene glycol 
(PEG) solution (final conc 0.4M NaCl and 8% (w/v) PEG) added was stored at 4˚C 
on ice overnight. Samples were centrifuged at 4700X g for 20 min at 4˚C in a swing 
bucket rotor. Supernatants were removed and pellets were dried for 5 min by inverting 
tube. Pellets were resuspended in 400 µl SM buffer (50 mM Tris-HCl; 100 mM NaCl; 
8.5 mM MgSO4; pH 7.5). 40 µl of 10X Nuclease Buffer (50 mM CaCl2; 10 mM 
MgCl2), was added and treated with 20 U of DNase I and 10 U of RNase I (final 
concentrations; Ambion) for 1 hr at 37˚C. Nucleases were inactivated at 70˚C for 10 
min before samples were treated with 2 µl of freshly prepared 20 mg/µl Proteinase K 
for 20 min at 56˚C. Phage DNA extractions were performed using Norgen BioTek 
Corp Phage DNA Isolation Kit as described by the manufacturer starting at addition 
of Lysis Buffer B. The Elution Buffer (50 µl) was passed through the column twice to 
maximise DNA recovery. Viral DNA concentrations were equalised before paired-
end Nextera XT library preparation (Illumina, San Diego, CA, USA) as described by 
the manufacturer. Metagenomic sequencing was performed using the Illumina MiSeq 
(Illumina Inc., San Diego, CA, USA) by generating 300 bp paired-end read libraries 





Transmission electron microscopy  
Phage lysate was concentrated by ultracentrifugation at 40,000 RPM for 2 hours 
at 4˚C. 180 ml of phage lysate was concentrated to 6 ml. The resulting phage 
preparation was placed on to a CsCl step gradient composed of 1.3, 1.5, and 1.7 g/ml 
layers and ultracentrifuged at 40,000 RPM for 3 hours at 4˚C. Resulting phage bands 
were collected and subjected to dialysis with two changes of SM buffer at 4˚C. 5 µl 
aliquots of the viral fraction were applied to Formvar/Carbon 200 Mesh, Cu grids 
(Electron Microscopy Sciences) with subsequent removal of excess sample by 
blotting. Grids were then negatively contrasted with 0.5% (w/v) uranyl acetate and 
examined at UCD Conway Imaging Core Facility (University College Dublin, Dublin, 
Ireland) by transmission electron microscope. 
Bacterial DNA extraction, library preparation and sequencing 
N1 DNA was extracted from an overnight culture using a Qiagen DNeasy Blood 
and Tissue kit as per the manufacturer’s instructions with pre-treatment for Gram-
negative bacteria. N1 DNA was sequenced using the Oxford Nanopore MinION as per 
manufacturer’s instructions.  
Phage propagation and plaque assays 
After isolation of phage N1M2 propagation was carried out in Tryptic Soy Broth 
(TSB) with calcium boroglucinate (final concentration 10mM). Plaque assays were 
carried using 1% Tryptic Soy Agar (TSA) base agar and 0.4% TSA overlay with 
calcium boroglucinate (final concentration 10mM). Phage N1M2 host range was 
established on 1.5% LB base agar and a 0.2% LB agarose overlay with CaCl2 (final 
concentration 10mM) by carrying out plaque assays against a range of bacteria. The 
efficiency of plaquing was calculated by dividing the titre of phage N1M2 on the strain 
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to be tested by the titre of phage N1M2 on strain N1. For host range assay bacteria 
were grown overnight in LB broth at 37˚C under aerobic conditions. Phage K 
propagation was carried out in TSB with calcium boroglucinate (final concentration 
10mM). Phage K plaque assays were carried using 1% TSA base agar and 0.4% TSA 
overlay with calcium boroglucinate (final concentration 10mM). 
N1 Bioinformatic analysis 
K. aerogenes N1 draft genome and K. aerogenes KCTC 2190 genome were 
compared using Easyfig v2.2.2 (57). Genomes were compared using BLASTn with 
default settings except for minimum length and minimum identity which were 
changed to 100 bp and 50% respectively. PHASTER was used to predict possible 
prophage regions in N1 and KCTC 2190 (58). JGI IMG/M genome browser was used 
to analyse function of KTCT 2190 genes (59).  
Phage N1M2 Bioinformatic analysis 
Sequencing reads of phages were quality filtered and assembled into contigs 
using SPAdes meta (60). BLASTn NT database was used to ensure the phage N1M2 
sequence was not similar to that of a known phage (61). Phage N1M2 genome was 
annotated using VIGA (https://github.com/EGTortuero/viga; (62)). Functional 
annotation of ORF gene products and amino acid identity was established using 
BLASTn and InterProScan (63). Transmembrane helices in proteins were predicted 
using TMHMM (64). LipoP (65) was used for predictions of lipoproteins. The 
molecular weights and isoelectric points of the predicted ORFs were determined using 
https://web.expasy.org/compute_pi/. Amino acid and codon usage statistics were 
determined using the University of Georgia online tool 
(http://www.cmbl.uga.edu/software/codon_usage.html). The presence of transfer 
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RNA genes was determined using tRNAscan-SE (http://lowelab.ucsc.edu/tRNAscan-
SE/; (66) and ARAGORN (http://130.235.46.10/ARAGORN/; (67)). BLASTn search 
(evalue cut-off 1e-10) was performed against NCBI nt database and bacterial section 
of NCBI RefSeq genomes database release 89 to align to bacterial tRNAs. Potential 
Rho-independent terminators were identified using ARNold (http://rna.igmors.u-
psud.fr/toolbox/arnold; (68)) and then confirmed with MfoldQuikFold 
(http://unafold.rna.albany.edu/?q¼DINAMelt/Quickfold; (69)) using RNA energy 
rules 3.0. Potential promoters were identified by extracting sequences 100 bp upstream 
of each ORF using FeatureExtract 1.2L (light) Server 
(http://www.cbs.dtu.dk/services/FeatureExtract/; (70)) and submitting these 
sequences to MEME (Multiple Em for Motif Elicitation) (http://meme-
suite.org/tools/meme; (71)). MEME discovers novel, ungapped motifs of recurring 
and fixed-length patterns between submitted sequences. In this case it looked for 
similar motifs in the sequences submitted, 100 bp upstream of each ORF, where 
promoters would be found. The annotated genome was visualised using GView (72). 
Multiple sequence alignment was carried out with MEGA7 (73) using MUSCLE (74). 
Phylograms were then constructed using the major capsid protein, the large terminase 
and DNA polymerase being used among phage N1M2 and other jumbo phages. The 
evolutionary history of phage N1M2 was inferred by using the Maximum Likelihood 
method based on the JTT matrix-based model (75) in MEGA 7. The bootstrap 
consensus tree inferred from 1000 replicates was taken to represent the evolutionary 
history of the taxa analysed (76). The whole genome phylogenetic trees based on 
nucleotides and amino acid sequences were generated by Victor (77) using the 
Genome-BLAST Distance Phylogeny (GBDP) (78) method under settings 
recommended for prokaryotic viruses. Bacterial CRISPR spacer database (made in 
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house using PILER-CR v1.06 from NCBI RefSeq genomes database, release 89) was 
used as a query for BLASTn search (evalue cut-off 1e-5) against the phage genome.  
Biofilm assays 
96-well plates were filled as follows based on Dalmasso, et al. (20). Each well 
was filled with 200 µl TSB with or without 1% glucose inoculated at 1% with an 
overnight culture of the relevant strain. For mixed biofilms 1% of an overnight culture 
of N1 and 1% of an overnight culture of DPC 5247 (Methicillin sensitive) was added. 
Plates were incubated at 37˚C for 48 h to allow the biofilm to form. Broth containing 
planktonic cells was carefully removed to avoid disruption of the formed biofilm. 100 
µl TSB containing 20mM calcium boroglucinate and 100 µl of phage dilution was 
added to each well. SM buffer was added to control wells. Plates were incubated at 
37˚C for 48 hr as indicated. 24 h biofilm formation was also tested as was phage 
addition for 72 hr.  For investigating stopping the formation of a biofilm 50 µl phage 
was added at the same time as the 200 µl overnight culture of the relevant strain. After 
incubation, broth containing planktonic cells was carefully removed. Wells were 
washed twice with 150 µl phosphate buffered saline (PBS). An XTT/menadione assay 
was carried out as follows. XTT/menadione solution was prepared by adding 0.01 g 
XTT to filter sterilised water and filter sterilising using a 0.22 µm filter. 0.027 g 
menadione was added to 10ml acetone. 10 µl of menadione acetone solution was 
added to 20 ml of XTT solution. 100 µl of XTT/menadione solution was added to each 
well of the 96-well plate and incubated at 37˚C in the dark for 2 hours. The absorbance 
was then measured at a wavelength of 492nm in a plate reader. The XTT/menadione 
assay relies on the reduction of tetrazolium salt 2,3-bis[2-methyloxy-4-nitro-5-
sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT) by metabolically active cells to 
200 
 
an orange/yellow water-soluble formazan derivative that can be quantified 
colorimetrically meaning only live cells are counted (79). 
N1 and DPC 5247 numbers were quantified in a mixed biofilm. The 
experiment was carried out once but counts were carried out in duplicate. Biofilms 
were formed and treated as previously described. After incubation, broth containing 
planktonic cells was carefully removed. Wells were washed twice with 150 µl PBS. 
200 µl PBS was added to each well and mixed by pipetting up and down. All the wells 
in a row were combined and serially diluted 1:10 in PBS. 100 µl of the relevant dilution 
was spread plated on UTI ChromoSelect agar. Plates were incubated at 37°C for 24 
hours. 
Statistical analysis 
For XTT assays 2 rows per 96-well plate were used per condition to be tested 
and all experiments were independently performed 3 times. For enumeration of N1 
and DPC 5247 the experiment was carried out once but counts were carried out in 
duplicate. Graphs were prepared using GraphPad Prism and are presented as mean 
values of a single experiment that represent the trend seen in the triplicate experiment. 
Error bars in the figures indicate standard error of the mean. 1 way ANOVA was used 
to determine the significance of differences between controls and treated samples. 
 
Results  
Genome information of strain N1 
Bacterial strain N1 was isolated from a healthy human faecal sample using 
MacConkey agar and identified as Klebsiella aerogenes by 16S rRNA sequencing. It 
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was then genome sequenced using the Oxford Nanopore MinION. This was classed 
as a draft genome due to the high error rate associated with MinION sequencing (36). 
Strain N1 has a chromosome of 5167877 bp with a GC content of 55.3%. The 
chromosome encodes 14509 predicted open reading frames (ORFs) ranging in size 
from 90 to 3315 bp. N1 contained two plasmids of 72172 bp and 51484 bp with GC 
contents of 43.6% and 47.2% respectively. Plasmid 1 encoded 158 ORFs ranging in 
size from 93 to 636 bp. Plasmid 2 encoded 123 ORFs ranging in size from 114 to 660 
bp. No resistance genes or tRNA were predicted in plasmids 1 and 2. Twenty-four 
tRNA genes were predicted in the chromosome (Table 1). N1 was compared to the 
reference genome Klebsiella aerogenes KCTC 2190. KCTC 2190 and N1 are similar 
in gene order with no inversions or large areas of difference (Fig. 1A). Two intact 
prophage regions were predicted in KCTC 2190 while one intact, two questionable, 
and two incomplete prophage regions were predicted in N1 (Fig. 1B). The Pfam 
categories of KCTC 2190 encoded functions were used as indicators of the functions 
associated with N1 due to their similarity (Fig. 1C). Almost 12% of KCTC 2190 genes 
were of unknown function which is a common occurrence. KCTC 2190 included a 
number of antibiotic resistance genes and a number of different antibiotic resistance 
genes were predicted in the N1 genome confirming its importance in the rise of 
antibiotic resistance and as an ESKAPE pathogen (Supp. Table 2). Genes encoding 
MarR, EmrR, and AcrA are present in N1 and all have been linked to multidrug 
resistance in Enterobacteriacae (37). AcrA has been associated with resistance to 
carbapenem antibiotics. A number of efflux pumps were present in N1 and these are 





General information and characterisation of phage N1M2 
Phage N1M2 was isolated against Klebsiella aerogenes N1 from maize silage. 
Phage N1M2 had a genome size of 253367 bp, placing it among the double stranded 
DNA jumbo phages. The mean GC content is 40.9%. EM showed phage N1M2 to be 
a Myoviridae phage as evidenced by the long contractile tail (Fig. 2A). Broken tail and 
head structures were visible. The contraction of the tail sheath made the tail core 
visible (Fig. 2B). No tail fibers were visible in the EM images. The average capsid 
size was 113 nm (± 6 nm) X 101 nm (± 7 nm) (N=7). The average tail size was 158 
nm (± 11 nm) X 21 nm (± 1 nm) (N=7). 
The host range of phage N1M2 was tested against a range of bacterial strains 
(Table 3). In addition to Klebsiella aerogenes phage N1M2 also infected Klebsiella 
aerogenes NCIMB 10102 and Klebsiella pneumoniae NCIMB 13218. Plaque 
morphology was similar on all three strains but the efficiency of plaquing was much 
lower for Klebsiella pneumoniae NCIMB 13218 compared to N1 and Klebsiella 
aerogenes NCIMB 10102 (0.017 ± 0.009 compared to 1 ± 0 and 0.667 ± 0.17, 
respectively). 
The genome of phage N1M2 
The phage N1M2 genome is comprised of 257 ORFs of which 39 are encoded 
on the minus strand (Supp. Table 3). The putative gene products ranged in size from 
29 to 3375 amino acids. All ORFs were predicted to start with AUG. Based on a 
combination of BLAST and InterProScan 85 putative gene products were identified. 
Of the 172 unidentified putative gene products 106 aligned to unnamed protein 
products in Pseudomonas phage OBP. Of the unnamed protein products of 
Pseudomonas phage OBP the identity ranged from 21-88%. Three tRNA genes were 
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predicted and all were contained within a 947 bp region located between 249035 bp 
and 249982 bp (Table 1). The tRNA genes were similar to those found in Escherichia 
species, Salmonella enterica, Shigella species and Stx2-converting phage, and an 
Enterobacteria phage. No integrase, excisionase or repressor genes were identified, 
suggesting that the phage follows a lytic lifestyle (Supp. Table 3). 
The potential promoter 
TBYAWWWWWTTTCARRYAKATATTATYWAAGTGWA was identified at 31 
locations in the genome (Supp. Table 4). The promoter was compared to similar 
promoters in jumbo phages related to phage N1M2 (Table 2). Fifty-six potential rho-
independent terminators were predicted throughout the genome of phage N1M2 
(Supp. Table 5).  
At the DNA level phage N1M2 was found to have little homology to phage 
genomes available on public databases, with the closest match being the 
aforementioned Pseudomonas phage OBP (BLASTn analysis coverage: 55%, 
identity: 72.73%). The majority of proteins which aligned to known proteins on 
BLAST aligned to this phage (Supp. Table 3) (Fig. 3B). To investigate the relationship 
of phage N1M2 to other phages phylogenetic trees were constructed using the 
nucleotide and amino acid whole genome sequences (Fig. 4). To further characterise 
the relationship between phage N1M2 and some of these phages phylogenetic trees 
were constructed using the amino acid sequences of the major capsid protein, large 
terminase and DNA polymerase (Fig. 5).  
Single strain biofilms using strain N1 
Biofilms of K. aerogenes N1 were formed under various conditions and XTT 
assays were used to assess the efficiency of phage N1M2 in destroying existing 
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biofilms and preventing biofilm formation (Fig. 6). Biofilm experiments were 
performed three times with duplicate readings and the data from one experiment is 
presented as a representative of the triplicate results. Phage N1M2 at an MOI of 10 or 
100 for 48 hours reduced an N1 biofilm formed in the presence of glucose over 48 
hours but this did not achieve significance (P>0.05) (Fig. 6A). Phage K at an MOI of 
10 and 100 also had no significant effect on the N1 biofilm (Fig. 6A) which was 
expected since phage K does not infect strain N1. Similarly, phage N1M2 at an MOI 
of 10 or 100 for 48 hours did not significantly reduce an N1 biofilm formed without 
glucose over 48 hours (P>0.05) (Fig. 6B). However, phage N1M2 applied at an MOI 
of 10 or 100 for 72 hours significantly reduced an N1 biofilm formed over 48 hours 
without glucose (P<0.001 and P<0.05 respectively) (Fig. 6C). The reduction by phage 
N1M2 at an MOI of 10 or 100 was not significantly different. Phage K at an MOI of 
10 applied for 72 hours did not reduce the N1 biofilm (Fig. 6C). In an N1 biofilm 
formed over 24 hours without glucose phage N1M2 applied at an MOI of 10 for 48 
hours once again significantly reduced the biofilm (P<0.001) (Fig. 6D). Once again 
Phage K had no effect. 
As well as destroying preformed biofilms the ability of phage N1M2 to impede 
the formation of biofilms was investigated. To do this phage N1M2 was added when 
the bacteria was inoculated. Phage N1M2 applied at an MOI of 10 did not prevent a 
biofilm from forming or reduce the level of biofilm formed. This was seen in biofilms 
formed with (Fig. 6E) and without glucose (Fig. 6F).  
Single strain biofilms using DPC 5247 
Biofilms of S. aureus DPC 5247 were formed under various conditions and the 
impact of Phage K was measured using XTT assays (Fig. 7). Phage K at an MOI of 
205 
 
10 or 100 applied for 48 hours significantly reduced a DPC 5247 biofilm formed in 
the presence of glucose over 48 hours (P<0.001) (Fig. 7A). Phage N1M2 at an MOI 
of 10 had no effect on the DPC 5247 biofilm (Fig. 7A) which was expected since 
phage N1M2 cannot infect DPC 5247. The reduction due to Phage K at an MOI of 10 
was significantly better than that of Phage K at an MOI of 100 (P<0.001). Phage K at 
an MOI of 10 applied for 48 hours also significantly reduced a DPC 5247 biofilm 
formed without glucose over 48 hours (P<0.001) (Fig. 7B). Phage N1M2 at an MOI 
of 10 applied for 48 hours had no significant effect on a DPC 5247 biofilm formed 
without glucose over 48 hours.  
Mixed community biofilms using N1 and DPC 5247 
Mixed community biofilms of N1 and DPC 5247 were formed and treated with 
phage N1M2 and Phage K alone and in combination. XTT assays were carried out to 
assess their effect (Fig. 7). Phage N1M2 and Phage K at MOIs of 10, alone and in 
combination, applied for 48 hours did not significantly reduce a mixed biofilm of N1 
and DPC 5247 formed in the presence of glucose over 48 hours (P<0.001) (Fig. 7C). 
Equally, in a mixed community biofilm of N1 and DPC 5247 grown for 48 hours 
without glucose phage N1M2 alone and Phage K alone at MOIs of 10 applied for 48 
hours did not significantly reduce the biofilm. However, phage N1M2 and Phage K at 
MOIs of 10 in combination significantly reduced the biofilm (P<0.001) (Fig. 7D). 
Untreated and phage-treated biofilms were quantified by dilution and spread 
plating on UTI ChromoSelect agar (Supp. Figure 1). N1M2 and Phage K at MOIs of 
10, alone and in combination, did not reduce the N1 portion of the community. 
However, Phage K at an MOI of 10 and N1M2 and Phage K at MOIs of 10 in 




Phage N1M2 is the first jumbo phage identified which kills Klebsiella 
aerogenes. Jumbo phages have a number of common properties which differentiate 
them from smaller phages (38). Jumbo phages are tailed phages with genomes larger 
than 200000 bp with large virions. The genes are distributed throughout the genome 
rather than in organised blocks as is typical of smaller phage genomes. Also jumbo 
phages contain more genes associated with biological processes such as genome 
replication, nucleotide metabolism, and lysis of host cell peptidoglycan than smaller 
phages. Some jumbo phages have more than one DNA polymerase or RNA 
polymerase gene. Jumbo phages are phylogenetically unrelated to smaller phages. 
This was evident in our analysis as phage N1M2 showed no similarity to small K. 
aerogenes phages and was most closely related, albeit only distantly, to other jumbo 
phages (Fig. 3). Jumbo phages are isolated more rarely than smaller phages for a 
number of reasons related to their large size. Jumbo phages often cannot diffuse in 
semi-solid media meaning they are not always visible as plaques. Their large size also 
means they can be removed when filtering out bacteria as they cannot pass through 
smaller filter pores. 
The genome of phage N1M2 was suggested to be circularly permuted based 
on its similarity to Pseudomonas phage OBP, its closest relative (26). Pseudomonas 
phage EL, the closest relative of Pseudomonas phage OBP, is also circular permuted. 
When aligned using Mauve, phage N1M2 and OBP showed two areas of similarity, a 
short region and a long region, although within these similar regions are a number of 
regions with no homology (Fig. 3B). The areas of phage N1M2 that align to OBP 
ranged from 21-88% identity. In the whole genome trees at nucleotide and protein 
level phage N1M2 and Pseudomonas phage OBP formed a separate, strongly 
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bootstrapped clade (Fig. 4). The major capsid protein, large terminase and DNA 
polymerase trees supported these whole genome trees (Fig. 5).  
A potential promoter TBYAWWWWWTTTCARRYAKATATTATYWAA-
GTGWA was identified at thirty-one locations in the phage N1M2 genome (Supp. 
Table 4). A possible -10 sequence, KATA, was present but unclear. MEME uses K to 
signify that G or T could be present in a position of the motif identified. No conserved 
-35 sequence was present. No known sigma factors were present in the N1M2 genome 
(Supp. Table 3). Similar sequences have been identified in OBP and Pseudomonas 
phage 201phi2-1 (26), Pseudomonas phage EL (39) and Pseudomonas phage phiKZ 
(40). The promoter found in phage N1M2 was most similar to that of OBP but also 
similar to the TATATTAC block found in phiKZ (Table 2). The OBP promoter was 
suggested as phage specific based on its lack of similarity to sequenced Pseudomonas 
genomes and was deemed to be an early promoter as they were located at the start of 
operons associated with early genes but not middle or late genes (26). The potential 
promoter was situated before ORFs with predicted products with unknown functions 
but also with predicted products such as RNA polymerase beta subunit, putative virion 
structural protein, and putative lytic murein transglycosylase.  
Despite the clinical importance of K. aerogenes little work has been carried 
out isolating and characterising K. aerogenes phages. There are only four phage 
genomes publically available: vB_EaeM_φEap-1 (NC_028772), F20 (JN672684) 
(41), vB_EaeM_φEap-2 (NC_028695) (42) and vB_EaeM_φEap-3 (KT321315) (43). 
K. Verthe, et al. (44) also isolated UZ1 K. aerogenes phage but no genome sequence 
is available. None of these phages are jumbo phages, ranging from 39133 bp to 175814 
bp. The host range of phage N1M2 was tested against a range of bacterial strains 
selected based on these publications. It is difficult to establish the host range of K. 
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aerogenes phages in general based on this small amount of data. So far the host range 
of K. aerogenes phages appears to vary. In some cases it is limited to a single K. 
aerogenes strain, although only a small number of strains were tested (44). In other 
cases it can include multiple K. aerogenes strains but no other genera or species (42, 
43). Phage N1M2 infected the two K. aerogenes strains tested and also Klebsiella 
pneumoniae, although the efficiency of plaquing of phage N1M2 was much lower on 
Klebsiella pneumoniae 13218 (Table 3). Infection outside of the genus has not been 
previously seen in K. aerogenes phages. Klebsiella pneumoniae is a leading cause of 
hospital acquired infections and has been linked to a number of illnesses such as 
wound infections, soft tissue infections, urinary tract infections, pyogenic liver 
abscess, pneumonia, meningitis and neonatal sepsis (45). The emergence of multi 
drug-resistant Klebsiella pneumoniae has made it of critical concern for human health 
and the fight against antibiotic resistance. Phages have been investigated for the 
treatment of experimentally induced Klebsiella pneumoniae burn wound infections 
and pneumonia (46, 47). Phages have also been used to successfully treat a multi-drug 
resistant Klebsiella pneumoniae wound infection (48). Phage N1M2 showed no 
homology to known jumbo phages Klebsiella phage K64-1 and vB_KleM-RaK2 
which both infect Klebsiella strains. 
It is possible that the increased host range of phage N1M2 is related to the 
presence of tRNA along with the increased number of genes for genome replication, 
nucleotide metabolism and host cell-wall lysis (38). For example the entire genome of 
Pseudomonas aeruginosa Phage KZ can be transcribed using its own RNA 
polymerase with no significant contribution from the host RNA polymerase (49). 
tRNAs in phages correspond to codons that are more commonly used in the phage 
than their bacterial host, especially in genes encoding structural proteins. This reduces 
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the phages reliance on the host cell machinery for replication and increases host range 
(50). The presence of tRNAs for codons that are preferentially expressed in phage 
N1M2 compared to N1 was apparent in two out of three cases in phage N1M2 (Table 
1). Phage N1M2 has three tRNAs for the codons CAT, TCT and GTT. The codon 
usage of CAT (for Histidine) by phage N1M2 is less than that of N1, 1.04% and 1.23% 
respectively, with a ratio of phage/host of 0.85. Phage N1M2 uses codon TCT (for 
Serine) at a frequency of 2.13% while N1 uses TCT at a frequency of 0.73% with a 
ratio of phage/host of 2.92. Phage N1M2 uses codon GTT (for Valine) at a frequency 
of 3.40% while N1 uses GTT at a frequency of 1.43% with a phage/host ratio of 2.38. 
The jumbo phages also have a number of genes involved in nucleotide 
metabolism such as thymidylate synthase, thymidylate kinase, ribonucleoside 
diphosphate reductase, NrdB, and dihydrofolate reductase and multiple genes 
encoding β and divided β’ subunits specific for multisubunit bacterial RNA 
polymerases and virion associated RNA polymerases (26). These genes can aid or 
replace the function of host genes. Of these phage N1M2 contained genes for 
thymidylate synthase (ORF 184), thymidylate kinase (ORF 249 but of low homology), 
ribonucleotide diphosphate reductase beta subunit NrdB (166), and dihydrofolate 
reductase (ORF189). Phage N1M2 contained three genes for RNA polymerase β 
subunits (ORF37, ORF51 and ORF52) and three putative virion-associated RNA 
polymerase beta subunits (ORF64, ORF222 and ORF223). Phage N1M2 also 
contained genes for thymidine kinase (ORF196). A putative electron carrier 
glutaredoxin (ORF253) was present which could support NrdB function. Again all of 
these genes showed similarity to OBP.  
Phage N1M2 applied for 48 hours had no significant effect on a 48 hour 
preformed biofilm (Fig. 6A). Phage N1M2 could also not stop a biofilm from forming 
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over 48 hours (Fig. 6E). However, phage N1M2 applied for 72 hours reduced a biofilm 
formed over 48 hours and phage N1M2 applied for 48 hours reduced a biofilm formed 
over 24 hours (Fig. 6C and Fig. 6D). The importance of allowing an adequate time for 
phage to have an effect can be seen. Hosseinidoust, et al. found that after the addition 
of phage biofilms increased in some cases up to five times that of untreated controls 
after 24 hours but phage treated biofilms at 48 hours and 72 hours were similar to 
untreated controls (51). They also found that phage did not significantly reduce 
biofilms until 48 or 72 hours after phage application, before this point the phage treated 
biofilm was equal to or greater than an untreated biofilm. In some circumstances phage 
treatment can cause an increase in viable cell counts of biofilms. González, et al. found 
that phage treatment, using a phage that did not infect E. faecium or L. plantarum, of 
mixed biofilms formed over 5 hours significantly increased viable cell counts of E. 
faecium and L. plantarum while in 24 hour biofilms L. plantarum was slightly 
decreased and E. faecium was similar to untreated controls (52). Mixed species 
biofilms are often more resistant to antibiotics than single species biofilms. 
We tested 48 hours of phage application to a 48 hour mixed species biofilm to 
determine if the inclusion of another phage could improve the activity of phage N1M2 
in a situation where it had previously been ineffective. Phage K alone could effectively 
reduce S. aureus DPC 5237 in a single species biofilm (Fig. 7B). The reduction by 
Phage K of biofilms has been previously seen (53, 54). Phage N1M2 alone could not 
reduce N1 numbers in a mixed biofilm. This was expected as phage N1M2 alone could 
not reduce N1 numbers in a single species biofilm. In XTT assays a combination of 
phage N1M2 and Phage K was more effective than Phage K alone (Fig. 7D). 48 hours 
of phage application to a 48 hour biofilm was quantified to see if the inclusion of 
another phage could improve the activity of N1M2 in a situation where it had 
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previously been ineffective (Supp. Figure 1). Phage K alone could effectively reduce 
DPC 5247 numbers in a mixed biofilm as expected since it reduced DPC 5237 in a 
single species biofilm. The reduction by Phage K of biofilms has been previously seen 
(53, 54). N1M2 alone could not reduce N1 numbers in a mixed biofilm. This was 
expected as N1M2 alone could not reduce N1 numbers in a single species biofilm 
under the same conditions. In XTT assays a combination of N1M2 and Phage K was 
more effective than Phage K alone but this was not seen when quantifying the biofilm. 
A discrepancy between XTT results and quantification was previously seen in a study 
of the effect of antibiotics on biofilms (55). For some strains rifampicin significantly 
reduced cellular viability in a biofilm as measured by plating but not by XTT and vice-
versa. In a study of the antimicrobial activity of plant extracts Bacillus subtilis growth 
was reduced by 100% according to XTT assays but only 60% by plating (56). XTT 
values were from two separate experiments while viable count values were from three 
separate experiments.   
In conclusion, a novel bacteriophage was isolated against a clinically important 
bacterial pathogen that is of great interest in the fight against antimicrobial resistance. 
Phage N1M2 was characterised as a jumbo phage with little homology to other K. 
aerogenes phages and jumbo phages. The most related phage was the jumbo phage 
Pseudomonas phage OBP. Interest is growing in the use of phages in place of 
antibiotics. K. aerogenes can be found as a constituent of biofilms on medical devices. 
Phage N1M2 was found to be effective at reducing preformed biofilms but not in 
stopping the formation of biofilms. Biofilms on medical devices often contain mixed 
bacterial communities. S. aureus DPC 5247 was used in biofilms in combination with 
K. aerogenes N1. Phage N1M2 in combination with Phage K were significantly better 
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Tables and figures 
Table 1. Codon usage and tRNA present in phage N1M2 and N1. Codon usage was 
determined using the University of Georgia online amino acid and codon usage 
statictics online tool. The presence of transfer RNA genes was determined using 
tRNAscan-SE and ARAGORN. 

















GCG 0.57 4.13 0.14 0 0 
CGA 0.29 0.82 0.35 0 0 
CGC 0.60 3.11 0.19 0 0 
CGG 0.16 1.62 0.10 0 0 
AGG 0.17 0.38 0.45 0 0 
TGC 0.24 1.13 0.21 0 0 





GGC 0.84 3.84 0.22 0 0 
GGG 0.77 1.32 0.58 0 0 
CAC 0.74 1.11 0.67 0 0 
CAT 1.04 1.23 0.85 1 
(249035-249111) 
0 
CTC 0.73 1.23 0.59 0 0 
CTG 2.25 4.95 0.45 0 0 
CCC 0.16 0.83 0.19 0 0 
CCG 0.55 3.10 0.18 0 1 
(926231-926307) 
TCC 0.81 1.04 0.78 0 0 
TCG 0.31 1.38 0.22 0 0 
AGC 0.62 2.08 0.30 0 0 
ACC 1.75 2.51 0.70 0 0 
ACG 0.44 1.44 0.31 0 0 
TGG 1.22 1.54 0.79 0 0 
GTC 0.94 1.74 0.54 0 1 
(962722-962798) 
GTG 0.84 2.31 0.36 0 1 
(926098-926174) 
Phage=Host 
GAC 1.90 1.83 1.04 0 0 
GAG 1.64 1.75 0.94 0 0 
GGA 0.86 0.86 1.00 0 0 
CTA 0.57 0.60 0.95 0 0 
TTT 1.88 2.08 0.90 0 0 
Phage>Host 
GCA 1.77 1.25 1.42 0 0 






CGT 2.56 1.66 1.54 0 0 
AGA 0.72 0.39 1.85 0 0 
AAC 3.15 2.08 1.51 0 0 
AAT 2.68 1.41 1.90 0 0 
GAT 4.63 2.79 1.66 0 2 
(786427-786503) 
(966444-966520) 
TGT 0.62 0.53 1.17 0 1 
(778986-77906) 
CAA 1.79 1.15 1.56 0 2 
(331627-331705) 
(440212-440130) 
GAA 4.86 2.86 1.70 0 1 
(610794-610869) 
GGT 4.15 1.68 2.47 0 1 
(778693-778620) 
ATA 0.71 0.58 1.22 0 0 
ATC 3.32 2.60 1.28 0 0 
ATT 3.08 2.15 1.43 0 0 
CTT 1.55 1.01 1.53 0 0 
TTA 1.62 1.02 1.59 0 0 
TTG 1.45 1.27 1.14 0 1 
(925945-925873) 
AAA 4.40 2.82 1.56 0 0 
AAG 2.44 1.30 1.88 0 0 
ATG 2.49 2.16 1.15 0 0 





CCA 1.58 0.73 2.16 0 1 
(962668-962592) 
CCT 1.83 0.70 2.61 0 0 
TCA 0.88 0.78 1.13 0 0 
TCT 2.13 0.73 2.92 1 
(249512-249588) 
0 
AGT 1.23 0.58 2.12 0 0 
ACA 1.25 0.48 2.6 0 0 
ACT 3.02 0.68 4.44 0 0 
TAC 1.43 1.23 1.16 0 0 
TAT 2.69 1.50 1.79 0 0 
GTA 1.77 0.94 1.88 0 1 
(778891-778975) 































Figure 1. A. Comparison of N1 draft genome and K. aerogenes KCTC 2190 B. 
Prophages predicted using PHASTER in N1 and K. aerogenes KTCT 2190 C. Pfam 








Figure 2. EMs of phage N1M2. A. Empty phage capsid (black arrow), broken phage 
tail (white arrow), and fully formed phage particle (black triangle). B. Contracted tail 
sheath (white arrow) with tail core (black arrow). C. Phage N1M2 with uncontracted 





Table 2. Predicted promoter of phage N1M2 compared to predicted promoters of 
Pseudomonas phage OBP, Pseudomonas phage 201phi2-1, Pseudomonas phage EL 
and Pseudomonas virus phiKZ. Bases coloured red match the sequence of the 
predicted promoter of OBP promoter. Bases coloured blue match the sequence of the 
predicted promoter of phiKZ. 
 
  
Phage  Promoter sequence 
N1M2     TBYAWWWWWTTTCARRYAKATATTATYWAAGTGWA 
OBP     BSHAWWWWWTTTYARRYAKATATTATYWWADTG 
2012-1 TTAWTAVAA_HYWTTTRARR_BTATATTACDWHDGTG 
EL             WTTTYAAACCTACATTATY 
phiKZ                       TATATTAC 
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Table 3. Host range of phage N1M2. Efficiency of plaquing is represented as a fraction 
with SEM of 3 separate experiments. If no N1M2 plaques formed on a strain efficiency 
of plaquing is represented by (-). 
Strain Efficiency of plaquing 
Klebsiella aerogenes N1 1 ± 0 
Klebsiella aerogenes NCIMB 10102 0.667 ± 0.17 
Klebsiella pneumoniae NCIMB 13218 0.017 ± 0.009 
Enterobacter gergoviae DPC 6436 - 
Enterobacter cloacae DPC 6437 - 
Pseudomonas aeruginosa PAO1 - 
Escherichia coli 0157 ΔStx - 
Escherichia coli APC 106 - 
Acinetobacter johnsonii  - 






Figure 3. A. Genome map of phage N1M2. On the outer ring blue arrows represent 
genes on the forward strand, red arrows represent genes on the reverse strand, and 
black arrows represent hypothetical proteins. The inner ring represents GC skew 
compared to the average GC content of phage N1M2. B. Mauve alignment of phage 






Figure 4. Victor-generated phylogenomic Genome-BLAST Distance Phylogeny 
(GBDP) trees of K. aerogenes phage N1M2 and other jumbo phages inferred A. using 
nucleotide identity and the formula D6 and yielding average support of 88%. B. using 
amino acid identity and the formula D6 and yielding average support of 86%. The 
numbers above branches are GBDP pseudobootstrap support values from 100 



















Figure 5. Phylogenetic analysis of amino acid sequences of K. aerogenes phage N1M2 
and other jumbo phages using maximum likelihood (Whelan and Goldman 
substitution model), with 1000 bootstrap replicates of A. major capsid protein B. large 
terminase and C. DNA polymerase. 
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Figure 6. Effect of phage N1M2 on biofilms formed by N1 K. aerogenes. Biofilm 
metabolic activity was assessed by OD492nm measures after treatment with XTT 
supplemented with menadione. A. 1% glucose 48 hr biofilm, 48 hr phage B. No 
glucose 48 hr biofilm, 48 hr phage C. No glucose 48 hr biofilm, 72 hr phage D. No 
glucose 24 hr biofilm, 48 hr phage E. 1% glucose stop biofilm formation over 48 hr F. 





Figure 7. Biofilm metabolic activity was assessed by OD492nm measures after 
treatment with XTT supplemented with menadione. A. Effect of Phage K on biofilms 
formed by DPC 5247 S. aureus. 1% glucose 48 hr biofilm, 48 hr phage B. Effect of 
Phage K on biofilms formed by DPC 5247 S. aureus. No glucose 48 hr biofilm, 48 hr 
phage C. Effect of phage N1M2 and Phage K on mixed biofilms formed by N1 K. 
aerogenes and DPC 5247 S.aureus. 1% glucose 48 hr biofilm, 48 hr phage D. Effect 
of phage N1M2 and Phage K on mixed biofilms formed by N1 K. aerogenes and DPC 




Supplementary table 1. A bank of known strains was selected to be used for phage 
screening. 
Strain designation  Other designations Strain 
APC 53 DPC 6085, NCIMB700577, NCDO0577 Bacillus cereus 
APC 54 DPC 6086, NCIMB700578, NCDO0578 Bacillus cereus 
APC 55 DPC 6087, NCIMB700579, NCDO0579 Bacillus cereus 
APC 56 DPC 6088, NCIMB700827, NCDO0827 Bacillus cereus 
APC 57 DPC 6089, NCIMB8079, ATCC7004 Bacillus cereus 
APC 58 DPC 6334, Bel 17Bc Bacillus cereus 
APC 59 DPC 6336, Bel Bc33 Bacillus cereus 
DPC 8079  Bacillus cereus 
APC 1762 UCC 5002 Bacillus subtilis 
APC 1640  Enterococcus casseliflavus 
APC 1039 EC618 Enterococcus faecalis 
APC 1749 DPC 5152 Enterococcus faecalis 
APC 1025 EC251 Enterococcus faecium 
APC 1026 EC289 Enterococcus faecium 
APC 1029 EC300 Enterococcus faecium 
APC 1030  EC357 Enterococcus faecium 
APC 1031 EC520 Enterococcus faecium 
APC 1032 EC533 Enterococcus faecium 
APC 1035 EC548 Enterococcus faecium 
APC 1036 EC562 Enterococcus faecium 
APC 1038 EC587 Enterococcus faecium 
APC 1043 EC725 Enterococcus faecium 
APC 1044 EC748 Enterococcus faecium 
APC 1641  Enterococcus faecium 
Lactobacillus salivarius 6482 Lactobacillus salivarius 
APC 317  DPC 5245 S. aureus 
APC 993 ST290 S. aureus 
APC 994 ST291 S. aureus 
APC 995 ST295 S. aureus 
APC 996 ST299 S. aureus 
APC 998 ST355 S. aureus 
APC 1003  ST528 S. aureus 
APC 1004 ST530 S. aureus 
APC 1007 ST535 S. aureus 
APC 1009 ST544 S. aureus 
APC 1010 ST550 S. aureus 
APC 1012 35197 S. aureus 
APC 1019 25949 S. aureus 
APC 1022  Newman S. aureus 
APC 1024 RF122 S. aureus 
APC 1055 LMG14694, ATCC 13813, CCRC 
10787, CCUG 4208, CIP 103227, DSM 
2134, JCM 5671, NCFB 1348, NCTC 
8181 
Streptococcus agalactiae 
APC 1759   Streptococcus agalactiae 
APC 1755  Streptococcus dysgalactiae 
APC 119 DPC 6143, 4001 Streptococcus mutans 
APC 120 DC 6144, 4021 Streptococcus mutans 
APC 121 DPC 6145, 4070 Streptococcus mutans 
APC 122 DPC 6150, 4009 Streptococcus mutans 
APC 123 DPC 6151, 4030 Streptococcus mutans 
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APC 124 DPC 6152, 4037 Streptococcus mutans 
APC 125 DPC 6153, 4039 Streptococcus mutans 
APC 126 DPC 6154, 4040 Streptococcus mutans 
APC 127 DPC 6155, 4055 Streptococcus mutans 
APC 128 DPC 6156, 4058 Streptococcus mutans 
APC 129 DPC 6157, 3007 Streptococcus mutans 
APC 130 DPC 6158, 3013 Streptococcus mutans 
APC 131 DPC 6159, 3017 Streptococcus mutans 
APC 132 DPC 6160, 1038 Streptococcus mutans 
APC 133 DPC 6161, 1054 Streptococcus mutans 
APC 134 DPC 6162, NCTC10449, ATCC 25175, 
SIMS, DSM 20523, ATCC 25175, IFO 
13955, NCDO 2062 
Streptococcus mutans 
APC 135 DPC 6543 Streptococcus mutans 
APC 1756 DSM 2071 Streptococcus pyogenes 
APC 1757 DSM11728 Streptococcus pyogenes 
APC 1758 NCDO2381 Streptococcus pyogenes 
APC 104 DPC 6009 Escherichia coli 
APC 105 DPC 6050 Escherichia coli 
APC 106 DPC 6051 Escherichia coli 
APC 109 DPC 6054, P1432 Escherichia coli 
APC 110 DPC 6055, AR12900 Escherichia coli 
APC 115 DPC 6472 Escherichia coli 
APC 1220 HM605 Escherichia coli 
Escherichia coli 042 Escherichia coli 
Escherichia coli Nissle  Escherichia coli 
Esherichia coli UTI89 Escherichia coli 
APC 1977 MG1655 Escherichia coli 
APC 176 DPC 6452 Salmonella typhimurium  
APC 181 DPC 6547 Salmonella typhimurium  





Supplementary table 2. Resistance genes present in K. aerogenes N1 draft genome. 
Start End Strand Size 
(bp) 
Protein  
366872 367006 + 135 Multidrug resistance protein MdtM 
367003 367434 + 432 Multidrug resistance protein MdtM 
367400 367756 + 357 Multidrug resistance protein MdtM 
367741 367899 + 159 Multidrug resistance protein MdtM 
375134 375493 - 360 Fosfomycin resistance protein FosA 
395992 396282 + 291 Small multidrug resistance family (SMR) 
396382 396648 + 267 Small multidrug resistance family (SMR) 
594242 594364 + 123 RND efflux system, membrane fusion protein 
594373 594609 + 237 RND efflux system, membrane fusion protein 
594740 594925 + 186 RND efflux system, membrane fusion protein 
595140 595373 + 234 Bacteriocin/lantibiotic efflux ABC transporter, 
permease/ATP-binding protein 
595333 595560 + 228 Bacteriocin/lantibiotic efflux ABC transporter, 
permease/ATP-binding protein 
595535 595828 + 294 Bacteriocin/lantibiotic efflux ABC transporter, 
permease/ATP-binding protein 
595825 596058 + 234 Bacteriocin/lantibiotic efflux ABC transporter, 
permease/ATP-binding protein 
596018 596341 + 324 Bacteriocin/lantibiotic efflux ABC transporter, 
permease/ATP-binding protein 
596494 597003 + 510 Bacteriocin/lantibiotic efflux ABC transporter, 
permease/ATP-binding protein 
596996 597163 + 168 Bacteriocin/lantibiotic efflux ABC transporter, 
permease/ATP-binding protein 
1013381 1013539 - 159 Multidrug resistance protein MdtL 
1013536 1013667 - 132 Multidrug resistance protein MdtL 
1013682 1014032 - 351 Multidrug resistance protein MdtL 
1014085 1014483 - 399 Multidrug resistance protein MdtL 
1062821 1063504 - 684 Multidrug resistance protein EmrD 
1063461 1063679 - 219 Multidrug resistance protein EmrD 
1063631 1063930 - 300 Multidrug resistance protein EmrD 
1092936 1093298 - 363 Drug resistance transporter EmrB/QacA subfamily 
1093298 1093591 - 294 Drug resistance transporter EmrB/QacA subfamily 
1096061 1096552 - 492 RND efflux system, membrane fusion protein 
1096673 1096924 + 252 RND efflux system, membrane fusion protein 
1096899 1097234 + 336 RND efflux system, membrane fusion protein 
1097188 1097952 + 765 RND efflux system, inner membrane transporter 
1097989 1098135 + 147 RND efflux system, inner membrane transporter 
1098149 1098739 + 591 RND efflux system, inner membrane transporter 
1098711 1099190 + 480 RND efflux system, inner membrane transporter 
1099212 1099739 + 528 RND efflux system, inner membrane transporter 
1099718 1100335 + 618 RND efflux system, inner membrane transporter 
1232604 1232894 + 291 Putative resistance protein 
1232860 1233060 + 201 Putative resistance protein 
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1233035 1233139 + 105 Putative resistance protein 
1233139 1233561 + 423 Putative resistance protein 
1233524 1233646 + 123 Putative resistance protein 
1233697 1233840 + 144 Putative resistance protein 
1487046 1487204 - 159 RND efflux system, inner membrane transporter CmeB 
1487295 1488350 - 1056 Multidrug efflux system AcrEF-TolC, inner-membrane 
proton/drug antiporter AcrF (RND type) 
1488379 1488789 - 411 Multidrug efflux system AcrEF-TolC, inner-membrane 
proton/drug antiporter AcrF (RND type) 
1488756 1489157 - 402 Multidrug efflux system AcrEF-TolC, inner-membrane 
proton/drug antiporter AcrF (RND type) 
1489157 1489447 - 291 Multidrug efflux system AcrEF-TolC, inner-membrane 
proton/drug antiporter AcrF (RND type) 
1489545 1489910 - 366 Multidrug efflux system AcrEF-TolC, inner-membrane 
proton/drug antiporter AcrF (RND type) 
1490001 1490222 - 222 Multidrug efflux system AcrEF-TolC, inner-membrane 
proton/drug antiporter AcrF (RND type) 
1490236 1490601 - 366 Multidrug efflux system AcrEF-TolC, membrane fusion 
component AcrE 
1490598 1490858 - 261 Multidrug efflux system AcrEF-TolC, membrane fusion 
component AcrE 
1490827 1491378 - 552 Multidrug efflux system AcrEF-TolC, membrane fusion 
component AcrE 
1943717 1944244 - 528 Multidrug resistance outer membrane protein MdtP 
1944216 1944545 - 330 Multidrug resistance outer membrane protein MdtP 
1944565 1944981 - 417 Multidrug resistance outer membrane protein MdtP 
1977822 1978478 + 657 Permease of the drug/metabolite transporter (DMT) 
superfamily 
2167705 2168190 - 486 Multidrug efflux system EmrAB-OMF, inner-membrane 
proton/drug antiporter EmrB (MFS type) 
2168181 2168408 - 228 Multidrug efflux system EmrAB-OMF, inner-membrane 
proton/drug antiporter EmrB (MFS type) 
2168384 2168506 - 123 Multidrug efflux system EmrAB-OMF, inner-membrane 
proton/drug antiporter EmrB (MFS type) 
2168559 2168675 - 117 Multidrug efflux system EmrAB-OMF, inner-membrane 
proton/drug antiporter EmrB (MFS type) 
2168659 2169288 - 630 Multidrug efflux system EmrAB-OMF, inner-membrane 
proton/drug antiporter EmrB (MFS type) 
2169588 2170187 - 600 Multidrug efflux system EmrAB-OMF, membrane fusion 
component EmrA 
2170301 2170513 - 213 Multidrug efflux system EmrAB-OMF, membrane fusion 
component EmrA 
2170656 2170772 - 117 Multidrug resistance regulator EmrR 
2170931 2171053 - 123 Multidrug resistance regulator EmrR 
2171077 2171268 - 192 Multidrug resistance regulator EmrR 
2206785 2207132 + 348 Multidrug resistance protein ErmB 
2207174 2207566 + 393 Multidrug resistance protein ErmB 
2207603 2207902 + 300 Multidrug resistance protein ErmB 
2395428 2395754 - 327 Aminoglycosides efflux system AcrAD-TolC, inner-
membrane proton/drug antiporter AcrD (RND type) 
2395871 2396503 - 633 Aminoglycosides efflux system AcrAD-TolC, inner-
membrane proton/drug antiporter AcrD (RND type) 
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2396461 2397096 - 636 Aminoglycosides efflux system AcrAD-TolC, inner-
membrane proton/drug antiporter AcrD (RND type) 
2397099 2397434 - 336 Aminoglycosides efflux system AcrAD-TolC, inner-
membrane proton/drug antiporter AcrD (RND type) 
2397455 2397658 - 204 Aminoglycosides efflux system AcrAD-TolC, inner-
membrane proton/drug antiporter AcrD (RND type) 
2397721 2398134 - 414 Aminoglycosides efflux system AcrAD-TolC, inner-
membrane proton/drug antiporter AcrD (RND type) 
2398107 2398478 - 372 Aminoglycosides efflux system AcrAD-TolC, inner-
membrane proton/drug antiporter AcrD (RND type) 
2630196 2630564 + 369 Multidrug resistance transporter - Bicyclomycin resistance 
protein Bcr 
2630564 2630755 + 192 Multidrug resistance transporter - Bicyclomycin resistance 
protein Bcr 
2630736 2630849 + 114 Multidrug resistance transporter - Bicyclomycin resistance 
protein Bcr 
2630876 2631007 + 132 Multidrug resistance transporter - Bicyclomycin resistance 
protein Bcr 
2630979 2631503 + 525 Multidrug resistance transporter - Bicyclomycin resistance 
protein Bcr 
2685749 2686591 + 843 Putative multidrug resistance outer membrane protein MdtQ 
2686554 2686691 + 138 Putative multidrug resistance outer membrane protein MdtQ 
2686721 2686951 + 231 Putative multidrug resistance outer membrane protein MdtQ 
2739525 2740010 - 486 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2739991 2740539 - 549 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2740586 2740711 - 126 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2740689 2740826 - 141 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2740831 2741127 - 297 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2741124 2741768 - 645 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2741807 2741935 - 129 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2741919 2742203 - 285 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2742223 2742621 - 399 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2742714 2742935 - 222 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2742932 2743837 - 906 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2743851 2744522 - 672 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2744562 2745701 - 1140 Multidrug efflux system MdtABC-TolC, inner-membrane 
proton/drug antiporter MdtC (RND type) 
2745674 2746384 - 711 Multidrug efflux system MdtABC-TolC, membrane fusion 
component MdtA 
2746392 2746817 - 426 Multidrug efflux system MdtABC-TolC, membrane fusion 
component MdtA 




3408960 3409220 - 261 Permease of the drug/metabolite transporter (DMT) 
superfamily 
3409183 3409347 - 165 Permease of the drug/metabolite transporter (DMT) 
superfamily 
3621902 3622261 + 360 Permease of the drug/metabolite transporter (DMT) 
superfamily 
3622271 3622723 + 453 Permease of the drug/metabolite transporter (DMT) 
superfamily 
3653646 3653867 + 222 Multiple antibiotic resistance protein MarR 
3654038 3654274 + 237 Multiple antibiotic resistance protein MarA 
3654229 3654357 + 129 Multiple antibiotic resistance protein MarA 
3654414 3654563 + 150 Multiple antibiotic resistance protein MarB 
3654560 3655003 - 444 Permease of the drug/metabolite transporter (DMT) 
superfamily 
3654981 3655451 - 471 Permease of the drug/metabolite transporter (DMT) 
superfamily 
3812304 3812795 + 492 Multidrug efflux transporter MdtK/NorM (MATE family) 
3812863 3813018 + 156 Multidrug efflux transporter MdtK/NorM (MATE family) 
3813088 3813321 + 234 Multidrug efflux transporter MdtK/NorM (MATE family) 
3813334 3813690 + 357 Multidrug efflux transporter MdtK/NorM (MATE family) 
3910878 3911066 + 189 RND efflux system, inner membrane transporter 
3996022 3996360 + 339 Small multidrug resistance family 
4022413 4022739 + 327 Permease of the drug/metabolite transporter (DMT) 
superfamily 
4022724 4023047 + 324 Permease of the drug/metabolite transporter (DMT) 
superfamily 
4023162 4023290 + 129 Permease of the drug/metabolite transporter (DMT) 
superfamily 
4096282 4096521 - 240 RND efflux system, inner membrane transporter 
4069566 4070015 - 450 RND efflux system, inner membrane transporter 
4069984 4070094 - 111 RND efflux system, inner membrane transporter 
4070094 4070222 - 129 RND efflux system, inner membrane transporter 
4070203 4071120 - 918 RND efflux system, inner membrane transporter 
4071172 4071354 - 183 RND efflux system, inner membrane transporter 
4071315 4071602 - 288 RND efflux system, inner membrane transporter 
4071605 4071736 - 132 RND efflux system, inner membrane transporter 
4071733 4071879 - 147 RND efflux system, inner membrane transporter 
4071940 4072116 - 177 RND efflux system, inner membrane transporter 
4072182 4072328 - 147 RND efflux system, inner membrane transporter 
4072312 4072449 - 138 RND efflux system, inner membrane transporter 
4072517 4072813 - 297 RND efflux system, membrane fusion protein 
4072837 4072959 - 123 RND efflux system, membrane fusion protein 
4072996 4073124 - 129 RND efflux system, membrane fusion protein 
4073121 4073657 - 537 RND efflux system, membrane fusion protein 
4150746 4150934 + 189 Multidrug resistance protein MdtH 
4150895 4151170 + 276 Multidrug resistance protein MdtH 
4151131 4151865 + 735 Multidrug resistance protein MdtH 
4158614 4158748 + 135 Multidrug resistance protein MdtG 
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4158762 4159766 + 1005 Multidrug resistance protein MdtG 
4195855 4196394 - 540 Permease of the drug/metabolite transporter (DMT) 
superfamily 
4195662 4196856 - 195 Permease of the drug/metabolite transporter (DMT) 
superfamily 
4471180 4471380 - 201 Macrolide-specific efflux protein MacA 
4471377 4472069 - 693 Macrolide-specific efflux protein MacA 
4472123 4472251 - 129 Macrolide-specific efflux protein MacA 
4519566 4519937 - 372 Multidrug translocase MdfA 
4519948 4520121 - 174 Multidrug translocase MdfA 
4520106 4520213 - 108 Multidrug translocase MdfA 
4520210 4520509 - 300 Multidrug translocase MdfA 
4520542 4520946 - 405 Multidrug translocase MdfA 
4912248 4912634 + 387 Fosmidomycin resistance protein 
4912741 4913205 + 465 Fosmidomycin resistance protein 
4929836 4930288 + 453 Multidrug efflux system AcrAB-TolC, membrane fusion 
component AcrA 
4930320 4930838 + 519 Multidrug efflux system AcrAB-TolC, membrane fusion 
component AcrA 
4930838 4930999 + 162 Multidrug efflux system AcrAB-TolC, membrane fusion 
component AcrA 
4931198 4931398 + 201 Multidrug efflux system AcrAB-TolC, inner-membrane 
proton/drug antiporter AcrB (RND type) 
4931395 4931748 + 354 Multidrug efflux system AcrAB-TolC, inner-membrane 
proton/drug antiporter AcrB (RND type) 
4931705 4932019 + 315 Multidrug efflux system AcrAB-TolC, inner-membrane 
proton/drug antiporter AcrB (RND type) 
4932016 4932243 + 228 RND efflux system, inner membrane transporter CmeB 
4932251 4932913 + 663 Multidrug efflux system AcrAB-TolC, inner-membrane 
proton/drug antiporter AcrB (RND type) 
4932974 4933099 + 126 Multidrug efflux system AcrAB-TolC, inner-membrane 
proton/drug antiporter AcrB (RND type) 
4933134 4933253 + 120 Multidrug efflux system AcrAB-TolC, inner-membrane 
proton/drug antiporter AcrB (RND type) 
4933324 4933905 + 582 Multidrug efflux system AcrAB-TolC, inner-membrane 
proton/drug antiporter AcrB (RND type) 
4933932 4934138 + 207 Multidrug efflux system AcrAB-TolC, inner-membrane 
proton/drug antiporter AcrB (RND type) 
242 
 
Supplementary table 3. ORFS table N1M2. Genes are colour coded. Structural proteins are shown in yellow, DNA replication genes are shown in 




ORF Start Stop Strand Start codon Stop codon Size (aa) pI kDa Function Best match (extent, % aa identity) Accession number e-value TMHMM LipoP InterProScan
1 51 425 + ATG TAA 124 5.05 14.13 Hypothetical protein 0 − −
2 403 819 + ATG TAA 138 6.95 15.73 unnamed protein product Pseudomonas phage OBP (36/139, 26%) YP_004957926.1 2.00E-08 0 − −
3 929 1561 + ATG TAG 210 7.57 24.9 Hypothetical protein 1 − −
4 1570 1821 + ATG TAA 83 8.39 9.82 Hypothetical protein 1 − −
5 2029 2724 + ATG TAA 231 9.21 26.12 unnamed protein product Pseudomonas phage OBP (55/230, 24%) YP_004957929.1 8.00E-15 1 − −
6 2803 3195 + ATG TAA 130 9.13 14.38 unnamed protein product Pseudomonas phage OBP (73/121, 60%) YP_004957931.1 1.00E-42 1 − −
7 3535 3798 + ATG TAA 87 9.43 10.05 Hypothetical protein 0 − −
8 3809 4168 + ATG TAA 119 4.83 13.62 Hypothetical protein 0 − −
9 4178 4432 + ATG TAA 84 4.68 9.81 Hypothetical protein 0 − −
10 4432 4812 + ATG TAA 126 9.21 14.48 Hypothetical protein 1 − −
11 4819 5175 + ATG TAG 118 4.55 13.74 Hypothetical protein 0 − −
12 5503 5991 + ATG TAA 162 9.86 19.24 unnamed protein product Pseudomonas phage OBP (42/135,31%) YP_004957941.1 2.00E-07 0 − −
13 6071 6340 + ATG TAA 89 7.78 10.6 Hypothetical protein 0 − −
14 6447 7058 + ATG TAA 203 5.37 22.91 Hypothetical protein 0 − −
15 7074 7706 + ATG TAA 210 8.82 23.93 Hypothetical protein 0 − −
16 7706 8026 + ATG TGA 106 9.19 12.24 unnamed protein product Pseudomonas phage OBP (58/106, 55%) YP_004957943.1 3.00E-31 0 − −
17 8023 8727 + ATG TGA 234 5.31 27.17 Hypothetical protein 0 − −
18 8729 9190 + ATG TAA 153 5.21 17.18 Hypothetical protein 0 − −
19 9242 9568 + ATG TAA 108 9.56 12.07 Hypothetical protein 0 − −
20 9578 10033 + ATG TAA 151 9.37 17.01 unnamed protein product Pseudomonas phage OBP (72/151, 48%) YP_004957947.1 2.00E-40 0 − −
21 10035 10538 + ATG TGA 167 5.54 19.1 unnamed protein product Pseudomonas phage OBP (49/158, 31%) YP_004957948.1 5.00E-13 0 − −
22 10646 10879 + ATG TAA 77 4.61 9.05 unnamed protein product Pseudomonas phage OBP (35/73, 48%) YP_004957949.1 2.00E-14 0 − −
23 10872 12623 + ATG TAA 583 5.17 66.47 Hypothetical protein 0 − −
24 12756 13196 + ATG TGA 146 5.59 16.57 Hypothetical protein 0 − −
25 13171 13545 + ATG TGA 124 9.66 14.48 unnamed protein product Pseudomonas phage OBP (61/118, 52%) YP_004957952.1 1.00E-36 0 − −
26 13535 13939 + ATG TAA 134 4.41 14.79 unnamed protein product Pseudomonas phage OBP (72/128, 56%) YP_004957953.1 6.00E-43 0 − −
27 14082 15032 + ATG TAA 316 4.95 35.36 unnamed protein product Pseudomonas phage OBP (202/317, 64%) YP_004957954.1 8.00E-145 0 − Tubulin/FtsZ, GTPase domain superfamily
28 15366 15842 + ATG TGA 158 4.56 18.12 unnamed protein product Pseudomonas phage OBP (89/159, 56%) YP_004957956.1 1.00E-52 0 − −
29 15811 16380 + ATG TAA 189 4.73 22.19 unnamed protein product Pseudomonas phage OBP (54/136, 40%) YP_004957957.1 2.00E-21 0 − −
30 16389 16691 + ATG TGA 100 4.93 12.11 unnamed protein product Pseudomonas phage OBP (63/93, 68%) YP_004957958.1 1.00E-38 0 − −
31 16672 16989 + ATG TAG 105 5.08 11.79 unnamed protein product Pseudomonas phage OBP (42/96, 44%) YP_004957959.1 1.00E-24 0 − −
32 16999 17613 + ATG TGA 204 4.14 23.34 unnamed protein product Pseudomonas phage OBP (64/214, 30%) YP_004957960.1 7.00E-19 0 − −
33 17610 18041 + ATG TAA 143 4.85 16.56 Putative virion structural protein Pseudomonas phage OBP (93/139, 67%) YP_004957961.1 9.00E-63 0 − −
34 18129 20207 + ATG TAA 692 6.85 79.71 T4-like DNA polymerase Pseudomonas phage OBP (549/692, 79%) YP_004957962.1 0.00E+00 0 − SUPERFAMILY SSF56672 (DNA/RNA polymerases)
35 20276 21367 − ATG TAA 363 8.86 42.38 Putative virion structural protein Pseudomonas phage OBP (207/360, 58%) YP_004957963.1 1.00E-146 0 − −
36 21625 23541 + ATG TAA 638 7.1 70.09 unnamed protein product Pseudomonas phage OBP (440/613, 72%) YP_004957964.1 0.00E+00 0 − −
37 23638 25227 + ATG TAA 529 5.96 61.1 RNA polymerase beta subunit Pseudomonas phage OBP (445/527, 84%) YP_004957965.1 0.00E+00 0 − RNA polymerase, alpha subunit (IPR000722
38 25227 25895 + ATG TAA 222 4.85 25.43 unnamed protein product Pseudomonas phage OBP (176/220, 80%) YP_004957966.1 5.00E-130 0 Yes −
39 25971 26396 + ATG TAA 141 5.92 15.91 unnamed protein product Pseudomonas phage OBP (70/106, 66%) YP_004957967.1 4.00E-40 0 − −
40 26400 26864 + ATG TAA 154 5.31 17.34 RNA ligase Pseudomonas phage OBP (96/150, 64%) YP_004957968.1 4.00E-64 0 − −
41 27010 27177 + ATG TAA 55 9.99 5.97 unnamed protein product Pseudomonas phage OBP (31/55, 56%) YP_004957969.1 5.00E-11 1 − −
42 27281 27688 + ATG TGA 135 5.4 15.33 putative virion structural protein Pseudomonas phage OBP (100/134, 75%) YP_004957970.1 8.00E-70 0 − −
43 27690 28493 + ATG TAA 267 4.5 30.65 unnamed protein product Pseudomonas phage OBP (176/267, 66%) YP_004957971.1 2.00E-123 0 − −
44 28520 29656 + ATG TGA 378 5.49 43.9 putative SbcD Pseudomonas phage OBP (292/373, 78%) YP_004957972.1 0.00E+00 0 − Metallo-dependent phosphatase-like (IPR029052)





46 30458 31225 + ATG TAA 255 8.5 28.61 unnamed protein product Pseudomonas phage OBP (156/201, 78%) YP_004957974.1 1.00E-109 0 − −
47 31406 33046 + ATG TAA 546 4.9 62.34 unnamed protein product Pseudomonas phage OBP (425/543, 78%) YP_004957976.1 0.00E+00 0 − −
48 33046 34590 + ATG TAA 514 4.36 56.38 unnamed protein product Pseudomonas phage OBP (372/513, 73%) YP_004957977.1 0.00E+00 0 − −
49 34613 36085 + ATG TAA 490 5.39 53.83 unnamed protein product Pseudomonas phage OBP (353/505, 70%) YP_004957978.1 0.00E+00 0 − −
50 36158 36493 − ATG TAA 111 5.61 12.97 unnamed protein product Pseudomonas phage OBP (80/111, 72%) YP_004957979.1 1.00E-56 0 − −
51 36573 38681 + ATG TAA 701 8.45 80.33 RNA polymerase beta subunit Pseudomonas phage OBP (559/694, 81%) YP_004957980.1 0.00E+00 0 Yes −
52 38650 40671 + ATG TAA 673 6.06 76.62 RNA polymerase beta subunit Pseudomonas phage OBP (551/673, 82%) YP_004957981.1 0.00E+00 0 − −
53 40709 41008 + ATG TAA 99 4.9 11.35 0 − −
54 41008 41310 + ATG TAA 100 8.05 11.13 unnamed protein product Pseudomonas phage OBP (51/93, 55%) YP_004957984.1 2.00E-29 0 − −
55 41358 41588 + ATG TAA 76 8.98 8.59 unnamed protein product Pseudomonas phage OBP (43/76, 57%) YP_004957986.1 6.00E-23 0 − −
56 41662 41931 + ATG TAA 89 5.61 10.18 unnamed protein product Pseudomonas phage OBP (33/87, 38%) YP_004957989.1 4.00E-12 0 − −
57 42089 43633 + ATG TAA 514 9.12 59.59 putative helicase Pseudomonas phage OBP (421/514, 82%) YP_004957991.1 0.00E+00 0 − Helicase superfamily 1/2, ATP-binding domain
58 43670 44095 + ATG TAA 141 4.4 15.85 unnamed protein product Pseudomonas phage OBP (53/119, 45%) YP_004957992.1 7.00E-28 0 − −
59 44175 44450 + ATG TAA 91 4.74 10.73 unnamed protein product Pseudomonas phage OBP (33/93, 35%) YP_004957993.1 2.00E-11 0 − −
60 44470 45030 + ATG TAA 186 4.23 20.81 unnamed protein product Pseudomonas phage OBP (99/181, 55%) YP_004957994.1 3.00E-53 0 − −
61 45098 45553 + ATG TAA 151 7.74 17.36 0 − −
62 45697 46146 + ATG TAA 149 7.05 16.76 0 − −
63 46348 47412 + ATG TAA 354 6.61 40.41 HNH endonuclease Erwinia phage vB_EamM_Joad (86/284, 30%) ASU03793.1 1.00E-20 0 − HNH nuclease (IPR003615)
64 47455 48762 − ATG TAG 435 4.87 25.22 putative virion-associated RNA polymerase beta subunit Pseudomonas phage OBP (337/436, 77%) YP_004957997.1 0.00E+00 0 − −
65 48755 49636 − ATG TAA 293 4.19 33.12 putative virion structural protein Pseudomonas phage OBP (178/295, 60%) YP_004957998.1 5.00E-124 0 − −
66 49674 50429 + ATG TAA 251 5.93 27.66 unnamed protein product Pseudomonas phage OBP (101/254, 40%) YP_004957999.1 3.00E-55 0 − −
67 50462 52075 + ATG TAA 537 5.01 61.68 unnamed protein product Pseudomonas phage OBP (313/537, 58%) YP_004958000.1 0.00E+00 0 − −
68 52186 52518 + ATG TAA 110 6.41 12.34 unnamed protein product Pseudomonas phage OBP (47/108, 44%) YP_004958001.1 4.00E-25 0 − −
69 52524 53066 + ATG TAA 180 9.24 20.97 unnamed protein product Pseudomonas phage OBP (91/183, 50%) YP_004958002.1 1.00E-52 0 − −
70 53170 53685 + ATG TAA 171 8.24 19.53 0 − −
71 53688 53966 + ATG TAA 92 5.84 9.99 unnamed protein product Pseudomonas phage OBP (64/82, 78%) YP_004958005.1 3.00E-40 0 − −
72 54000 54539 + ATG TAA 179 5.33 19.67 0 − −
73 54601 56340 − ATG TAA 579 6.15 66.62 T4-like DNA polymerase Pseudomonas phage OBP (526/582, 90%) YP_004958006.1 0.00E+00 0 − Ribonuclease H-like superfamily (IPR012337
74 56429 57772 + ATG TAA 447 5.69 49.74 putative virion structural protein Pseudomonas phage OBP (202/450, 45%) YP_004958007.1 6.00E-132 0 − −
75 57782 58216 + ATG TAA 144 4.79 16.63 putative virion structural protein Pseudomonas phage OBP (84/144, 58%) YP_004958008.1 2.00E-51 0 − −
76 58231 59811 + ATG TAA 526 5.98 58.94 putative virion structural protein Pseudomonas phage OBP (256/525, 49%) YP_004958009.1 5.00E-177 0 − −
77 59813 60466 + ATG TAA 217 5.13 25.18 unnamed protein product Pseudomonas phage OBP (108/217, 50%) YP_004958010.1 1.00E-71 0 − −
78 60514 63501 − ATG TAA 995 5.16 112.86 putative virion structural protein Pseudomonas phage OBP (695/994, 70%) YP_004958011.1 0.00E+00 0 − −
79 63510 64595 − ATG TAA 361 5.03 41.19 putative virion structural protein Pseudomonas phage OBP (289/359, 81%) YP_004958012.1 0.00E+00 0 − −
80 64622 65710 + ATG TAA 362 6.05 39.42 putative minor virion structural protein Pseudomonas phage OBP (270/363, 74%) YP_004958013.1 0.00E+00 0 − −
81 65713 66597 + ATG TAA 294 5.45 33.54 putative virion structural protein Pseudomonas phage OBP (174/294, 59%) YP_004958014.1 2.00E-124 0 − −
82 66581 67111 + ATG TAG 176 6.43 19.98 putative virion structural protein Pseudomonas phage OBP (113/176, 64%) YP_004958015.1 8.00E-82 0 − −
83 67101 68384 + ATG TAA 427 4.79 48.37 putative virion structural protein Pseudomonas phage OBP (254/420, 60%) YP_004958016.1 0.00E+00 0 − −
84 68374 69336 + ATG TAA 320 6.27 35.85 hypothetical protein PPEV_gp062 Pseudomonas phage EL (81/316, 26%) YP_418095.1 1.00E-21 0 − −
85 69374 70597 + ATG TAA 407 5.47 42.66 putative virion structural protein Pseudomonas phage OBP (128/416, 31%) YP_004958019.1 8.00E-47 0 − −
86 70706 71767 + ATG TGA 353 9.08 39.94 putative virion structural protein Pseudomonas phage OBP (168/358, 47%) YP_004958020.1 6.00E-101 0 − −
87 71764 72276 + ATG TGA 170 4.99 19.09 unnamed protein product Pseudomonas phage OBP (67/171, 39%) YP_004958021.1 1.00E-34 0 − −
88 72273 72881 + ATG TGA 202 4.78 22.96 unnamed protein product Pseudomonas phage OBP (66/201, 33%) YP_004958022.1 1.00E-14 0 − −
89 72850 73689 + ATG TAA 279 5.57 30.44 unnamed protein product Pseudomonas phage OBP (130/281, 46%) YP_004958023.1 7.00E-73 0 − −
90 73691 74398 + ATG TAA 235 5.57 26.69 unnamed protein product Pseudomonas phage OBP (88/233, 38%) YP_004958024.1 9.00E-44 0 − −
91 74661 76247 + ATG TGA 528 5.08 62.35 putative virion structural protein Pseudomonas phage OBP (350/526, 67%) YP_004958025.1 0.00E+00 0 − −
92 76216 77517 + ATG TAA 433 5.16 50.32 putative virion structural protein Pseudomonas phage OBP (294/433, 68%) YP_004958026.1 0.00E+00 0 − −
93 77528 78166 + ATG TAA 212 5.57 24.26 putative virion structural protein Pseudomonas phage OBP (130/211, 62%) YP_004958027.1 2.00E-90 0 − −
94 78166 79509 + ATG TAA 447 5.34 50.47 putative virion structural protein Pseudomonas phage OBP (293/445, 66%) YP_004958028.1 0.00E+00 0 − −
95 79558 81096 − ATG TAA 512 5.26 58.07 putative DNAB-like replicative helicase Pseudomonas phage OBP (437/512(85%) YP_004958029.1 0.00E+00 0 − −
96 81134 81685 + ATG TAA 183 5.55 21.18 unnamed protein product Pseudomonas phage OBP (126/183, 69%) YP_004958030.1 2.00E-89 0 − −
97 81802 83979 + ATG TAA 725 5.52 78.93 putative major capsid protein Pseudomonas phage OBP (563/720, 78%) YP_004958031.1 0.00E+00 0 − −
98 84397 85230 + ATG TAA 277 6.21 31.32 unnamed protein product Pseudomonas phage OBP (166/276, 60%) YP_004958032.1 3.00E-106 0 − −
99 85243 86937 + ATG TAA 564 8.7 65.36 unnamed protein product Pseudomonas phage OBP (497/563, 88%) YP_004958033.1 0.00E+00 0 − −
100 86941 89352 + ATG TAA 803 5.23 92.04 unnamed protein product Pseudomonas phage OBP (442/825, 54%) YP_004958034.1 0.00E+00 0 − −
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 101 89568 89996 + ATG TAA 142 9.41 16.59 unnamed protein product Pseudomonas phage OBP (32/69, 46%) YP_004958035.1 5.00E-13 0 − −
102 90008 90190 + ATG TAG 60 3.93 7.14 unnamed protein product Pseudomonas phage OBP (42/60, 70%) YP_004958036.1 7.00E-19 0 − −
103 90144 90533 + ATG TAA 129 5.36 14.95 0 − −
104 90623 91285 + ATG TAA 220 4.64 23.51 0 − −
105 91346 94234 − ATG TAA 962 4.96 108.25 putative portal protein Pseudomonas phage OBP (656/943, 70%) YP_004958039.1 0.00E+00 0 − −
106 94263 96383 + ATG TAG 706 5.6 82.05 putative virion structural protein Pseudomonas phage OBP (505/702, 72%) YP_004958040.1 0.00E+00 0 − −
107 96376 96714 + ATG TAA 112 6.51 13.17 unnamed protein product Pseudomonas phage OBP (73/108, 68%) YP_004958041.1 6.00E-42 0 − −
108 96721 97653 + ATG TAA 310 5.01 34.28 putative major virion structural protein Pseudomonas phage OBP (230/303, 76%) YP_004958042.1 1.00E-168 0 − −
109 97673 98290 + ATG TAA 205 5.74 23.32 unnamed protein product Pseudomonas phage OBP (100/193, 52%) YP_004958043.1 3.00E-63 0 − −
110 98295 98888 + ATG TAA 197 5.65 22.25 putative RuvC Pseudomonas phage OBP (145/188, 77%) YP_004958044.1 3.00E-105 0 − Ribonuclease H superfamily 
111 98848 99498 + ATG TAA 216 9.1 23.34 unnamed protein product Pseudomonas phage OBP (141/218, 65%) YP_004958045.1 4.00E-95 4 − −
112 99551 99799 − ATG TAG 82 4.55 9.13 lambda Rz1-like protein Pseudomonas phage OBP (43/67, 64%) YP_004958046.1 1.00E-22 0 − −
113 99846 100295 − ATG TGA 149 7.84 16.61 lambda Rz1-like protein Pseudomonas phage OBP (75/146, 51%) YP_004958047.1 7.00E-40 1 − −
114 100292 101521 − ATG TGA 409 7.2 47.37 putative virion structural protein Pseudomonas phage OBP (273/408, 67%) YP_004958048.1 0.00E+00 0 − −
115 101551 102315 + ATG TAA 254 5.15 28.29 putative virion structural protein Pseudomonas phage OBP (169/254, 67%) YP_004958049.1 7.00E-124 0 − −
116 102379 106098 + ATG TAA 1239 5.84 140.82 putative virion structural protein Pseudomonas phage OBP (561/1266, 44%) YP_004958050.1 0.00E+00 0 − −
117 106159 109923 + ATG TAA 1254 5.44 141.6 putative virion structural protein Pseudomonas phage OBP (625/1278, 49%) YP_004958051.1 0.00E+00 0 − −
118 109967 115864 + ATG TAA 1965 5.54 221.36 putative virion structural protein Pseudomonas phage OBP (807/1745, 46%) YP_004958052.1 0.00E+00 0 − Protein of unknown function DUF285 
119 115915 116910 − ATG TAA 331 5.09 35.87 putative phage baseplate assembly protein Pseudomonas phage OBP (221/330, 67%) YP_004958053.1 6.00E-166 0 − −
120 116932 119412 + ATG TAA 826 6.86 94.44 putative SbcC ATPase Pseudomonas phage OBP (531/826, 64%) YP_004958054.1 0.00E+00 0 − P-loop containing nucleoside triphosphate hydrolase
121 119451 120008 + ATG TAA 185 4.94 20.89 unnamed protein product Pseudomonas phage OBP (76/187, 41%) YP_004958055.1 2.00E-38 0 − −
122 120226 121035 + ATG TAA 269 9.92 30.38 putative lytic murein transglycosylase Pseudomonas phage OBP (135/258, 52%) YP_004958056.1 4.00E-87 1 Yes Lysozyme-like domain superfamily
123 121097 121360 + ATG TAA 87 5.41 9.43 unnamed protein product Pseudomonas phage OBP (42/87, 48%) YP_004958057.1 2.00E-21 0 − −
124 121427 122149 + ATG TAG 240 8.98 27.53 0 − −
125 122157 124130 + ATG TAA 657 5.27 73.98 putative NAD-dependent DNA ligase Pseudomonas phage OBP (347/651, 53%) YP_004958060.1 0.00E+00 0 − NAD-dependent DNA ligase 
126 124190 124513 + ATG TAA 107 5.61 12.07 0 − −
127 124513 125088 + ATG TAA 191 5.88 21.65 0 − −
128 125341 125712 + ATG TAA 123 9.25 14.17 putative ribonuclease H Pseudomonas phage OBP (90/108, 83%) YP_004958065.1 2.00E-58 0 − Ribonuclease H-like superfamily 
129 125740 127539 + ATG TAA 599 4.44 66.71 unnamed protein product Pseudomonas phage OBP (116/202, 57%) YP_004958068.1 5.00E-59 0 − −
130 127676 128989 + ATG TAA 437 5.47 49.72 0 − −
131 129132 129878 + ATG TAA 248 6.31 28.25 putative homing nuclease Pseudomonas phage OBP (137/245, 56%) YP_004958072.1 3.00E-91 0 − GIY-YIG endonuclease
132 129884 130171 + ATG TAA 95 9.93 10.15 0 − Lambda repressor-like, DNA-binding domain superfamily
133 130164 130529 + ATG TAA 121 9.75 13.71 0 − Lambda repressor-like, DNA-binding domain superfamily
134 130547 131530 + ATG TGA 327 7.03 37.72 unnamed protein product Pseudomonas phage OBP (68/195, 35%) YP_004958076.1 1.00E-21 0 − −
135 131530 131889 + ATG TAA 119 9.1 13.46 unnamed protein product Pseudomonas phage OBP (39/115, 34%) YP_004958077.1 2.00E-15 0 − −
136 131889 132581 + ATG TAA 230 6.92 25.56 0 − −
137 132615 133376 + ATG TAA 253 9.11 28.71 unnamed protein product Pseudomonas phage OBP (56/208, 27%) YP_004958081.1 3.00E-06 0 − −
138 133376 133663 + ATG TAA 95 5.69 10.78 hypothetical protein Acinetobacter phage ABPH49 (23/62, 37%) AXN57887.1 9.00E-05 0 Yes −
139 133894 134316 + ATG TAA 140 9.74 15.85 0 − −
140 134316 134543 + ATG TAA 75 9.16 8.79 2 − −
141 134566 134706 + ATG TAA 46 9.82 5.09 hypothetical protein EHM17_17180 Verrucomicrobiaceae bacterium (32/43, 74%) RPJ30187.1 5.00E-13 0 − −
142 134766 135125 + ATG TAA 119 7.86 13.68 0 − −
143 135112 135453 + ATG TGA 113 5.37 13.1 unnamed protein product Pseudomonas phage OBP (40/109, 37%) YP_004958087.1 2.00E-13 0 − −
144 135450 135734 + ATG TAA 94 9.7 10.47 1 Yes −
145 135745 136203 + ATG TAA 152 7.77 17.27 unnamed protein product Pseudomonas phage OBP (39/155, 25%) YP_004958089.1 2.00E-04 0 − −
146 136282 136500 + ATG TAA 72 9.1 8.32 0 − −
147 136493 137872 + ATG TAA 459 5.75 50.72 unnamed protein product Pseudomonas phage OBP (160/505, 32%) YP_004958090.1 3.00E-37 0 − −
148 137884 138576 + ATG TAA 230 5.01 26.16 unnamed protein product Pseudomonas phage OBP (151/225, 67%) YP_004958091.1 5.00E-108 0 − −
149 138704 139018 + ATG TAA 104 6.07 12.36 0 − −
150 139048 139533 + ATG TGA 161 9.27 18.61 0 − −
151 139533 139745 + ATG TAA 70 9.7 8.41 0 − −
152 139756 139995 + ATG TAA 79 10.61 9.16 0 − −
245 
 
 153 140045 140674 + ATG TAA 209 5.73 24.07 unnamed protein product Pseudomonas phage OBP (122/205, 60%) YP_004958100.1 1.00E-85 0 − −154 140674 141009 + ATG TAA 111 5.91 12.85 unnamed protein product Pseudomonas phage OBP (85/110, 77%) YP_004958101.1 3.00E-57 0 − −
155 141040 141387 + ATG TAA 115 5.01 12.8 0 − −
156 141387 141713 + ATG TAA 108 10.39 12.34 0 − −
157 141727 143034 + ATG TAA 435 5.94 48.6 unnamed protein product Pseudomonas phage OBP (37/110, 34%) YP_004958106.1 3.00E-05 0 − −
158 143065 143412 + ATG TAA 115 6.71 12.24 unnamed protein product Pseudomonas phage OBP (48/116, 41%) YP_004958109.1 1.00E-26 1 Yes −
159 143473 143661 − ATG TAA 62 8.01 6.94 0 − −
160 143755 145923 − ATG TAA 722 4.55 78.47 unnamed protein product Pseudomonas phage OBP (60/150, 40%) YP_004958112.1 6.00E-22 0 − −
161 145938 149954 − ATG TAA 1338 5.24 144.28 unnamed protein product Pseudomonas phage OBP (148/492, 30%) YP_004958113.1 6.00E-42 0 − −
162 150579 160706 − ATG TAA 3375 4.77 372.47 unnamed protein product Pseudomonas phage OBP (1062/2918, 36%) YP_004958114.1 0.00E+00 0 − −
163 160820 163636 − ATG TAA 938 6.1 105.58 unnamed protein product Pseudomonas phage OBP (203/973, 21%) YP_004958115.1 2.00E-09 0 − −
164 163715 164380 − ATG TAA 221 5.4 24.83 unnamed protein product Pseudomonas phage OBP (72/204, 35%) YP_004958116.1 1.00E-25 0 − −
165 164495 165292 − ATG TAA 265 9.09 29.76 putative HNH homing endonuclease Erwinia phage vB_EamM_Special G (113/244, 46%) ANJ64902.1 1.00E-66 0 − HNH nuclease 
166 165344 166477 − ATG TAA 377 4.94 43.24 putative NrdB Pseudomonas phage OBP (311/377, 82%) YP_004958118.1 0.00E+00 0 − Ribonucleotide reductase small subunit family
167 166781 167635 + ATG TAA 284 5.26 31.73 unnamed protein product Pseudomonas phage OBP (49/126, 39%) YP_004958122.1 3.00E-19 0 Yes −
168 167790 168416 + ATG TAA 208 9.07 22.83 1 − −
169 168432 168827 + ATG TAA 131 9.81 14.73 1 − −
170 169056 169331 + ATG TGA 91 5.71 10.36 MULTISPECIES: hypothetical protein Burkholderia WP_023842450.1 5.00E-08 1 − −
171 169352 169639 + ATG TAA 95 8.68 10.11 1 Yes −
172 169723 170124 + ATG TAA 133 6.3 15.42 unnamed protein product Pseudomonas phage OBP (71/133, 53%) YP_004958125.1 9.00E-48 0 − −
173 170126 170410 + ATG TAA 94 5.44 11.11 hypothetical protein Aeromonas phage SD04 (35/74, 47%) AWY07228.1 9.00E-07 1 − −
174 170619 170831 + ATG TAA 70 5.25 8.24 0 − −
175 170842 171006 + ATG TAA 54 10.69 6.04 0 − −
176 170996 171766 + ATG TAA 256 5.83 29.77 unnamed protein product Pseudomonas phage OBP (75/237, 32%) YP_004958130.1 5.00E-29 0 − −
177 171777 172196 + ATG TAA 139 4.85 16.28 unnamed protein product Pseudomonas phage OBP (55/146, 38%) YP_004958131.1 2.00E-21 0 − −
178 172196 172654 + ATG TAA 152 5.37 17.78 unnamed protein product Pseudomonas phage OBP (63/153, 41%) YP_004958132.1 2.00E-36 0 − −
179 172725 173330 − ATG TAA 201 5.15 22.06 unnamed protein product Pseudomonas phage OBP (111/200, 56%) YP_004958133.1 3.00E-74 0 − −
180 173450 173905 + ATG TAA 151 8.49 17.8 unnamed protein product Pseudomonas phage OBP (61/125, 48%) YP_004958134.1 4.00E-05 0 − −
181 173881 174285 + ATG TAA 134 4.86 15.86 0 − −
182 174297 174824 + ATG TGA 175 7.17 20.22 putative serine/threonine protein phosphatase Pseudomonas phage OBP (123/167, 74%) YP_004958136.1 4.00E-93 0 − Metallo-dependent phosphatase-like
183 174799 175026 + ATG TAA 75 11.43 8.83 2 − −
184 175231 176421 + ATG TAA 396 6.35 46.49 putative thymidylate synthase Pseudomonas phage OBP (247/396, 62%) YP_004958141.1 0.00E+00 0 − Thymidylate synthase/dCMP hydroxymethylase superfamily
185 176501 176725 + ATG TAA 74 6.8 8.63 2 − −
186 176736 177635 + ATG TAA 299 8.64 32.95 0 − −
187 177776 178126 + ATG TAA 116 8.01 12.92 unnamed protein product Pseudomonas phage OBP (53/115, 46%) YP_004958144.1 1.00E-24 0 − −
188 178213 178860 + ATG TAA 215 5.41 25.39 unnamed protein product Pseudomonas phage OBP (77/201, 38%) YP_004958146.1 9.00E-36 0 − HAD-like superfamily. Phosphoglycolate phosphatase-like, domain 
189 178863 179486 + ATG TAA 207 8.54 23.37 putative dihydrofolate reductase Pseudomonas phage OBP (92/201, 46%) YP_004958148.1 1.00E-47 0 − Dihydrofolate reductase
190 179503 179757 + ATG TAA 84 10.02 9.31 unnamed protein product Pseudomonas phage OBP (24/59, 41%) YP_004958149.1 6.00E-10 0 − −
191 179851 179940 + ATG TAG 29 10.02 3.45 0 − −
192 179971 180618 + ATG TGA 215 5.56 24.4 0 − Clp protease proteolytic subunit /Translocation-enhancing protein T
ATP‐dependent Clp protease proteolytic subunit  
193 180645 181037 + ATG TAA 130 9.53 15.07 hypothetical protein pf16_08 Pseudomonas phage pf16 (29/59, 49%) AND74931.1 1.00E-04 2 − −
194 181086 182645 + ATG TAA 519 5 57.41 putative chaperonin GroEL Pseudomonas phage OBP (339/541, 63%) YP_004958153.1 0.00E+00 0 − Chaperonin Cpn60/TCP-1 family. Chaperone tailless complex polype
195 183006 183287 + ATG TAA 93 8.66 10.96 unnamed protein product Pseudomonas phage OBP (50/88, 57%) YP_004958155.1 2.00E-31 1 − −
196 183304 183888 + ATG TGA 194 8.19 21.83 thymidine kinase Psychromonas sp. psych-6C06 (120/198, 61%) WP_101107339.1 2.00E-86 0 − Thymidine kinase 
197 183979 184326 + ATG TAA 115 5.68 11.65 unnamed protein product Pseudomonas phage OBP (38/82, 46%) YP_004958157.1 1.00E-08 0 − −
198 184764 185486 + ATG TAA 240 5.28 27.65 unnamed protein product Pseudomonas phage OBP (91/233, 39%) YP_004958159.1 2.00E-28 0 − −
199 185617 186108 + ATG TAA 163 4.55 18.07 unnamed protein product Pseudomonas phage OBP (59/136, 43%) YP_004958161.1 3.00E-08 0 − −
200 186108 186599 + ATG TAA 163 9.77 18.74 0 − −
201 186599 187303 + ATG TAA 234 5.9 26.97 unnamed protein product Pseudomonas phage OBP (66/138, 48%) YP_004958163.1 8.00E-22 0 − −
202 187331 187906 + ATG TAA 191 8.89 22.65 unnamed protein product Pseudomonas phage OBP (58/196, 30%) YP_004958164.1 6.00E-17 0 − −




204 188599 189930 − ATG TGA 443 5.14 50.58 putative virion structural protein Pseudomonas phage OBP (339/447, 76%) YP_004958166.1 0.00E+00 0 − −
205 189985 190389 + ATG TAG 134 7.92 16 unnamed protein product Pseudomonas phage OBP (89/136, 65%) YP_004958167.1 1.00E-65 1 − −
206 190450 191871 + ATG TAA 473 8.22 54.23 unnamed protein product Pseudomonas phage OBP (364/456, 80%) YP_004958168.1 0.00E+00 0 − −
207 191928 193016 − ATG TAA 362 5.52 39.72 putative virion structural protein Pseudomonas phage OBP (124/379, 33%) YP_004958169.1 7.00E-19 0 − −
208 193020 195119 − ATG TAA 699 6.37 81.32 putative virion-associated SNF2-domain containing helicase Pseudomonas phage OBP (513/706, 73%) YP_004958170.1 0.00E+00 0 − P-loop containing nucleoside triphosphate hydrolase
209 195137 196240 + ATG TAA 367 4.59 42.1 unnamed protein product Pseudomonas phage OBP (182/348, 52%) YP_004958171.1 2.00E-106 0 − −
210 196289 197068 − ATG TAA 259 5.72 28.89 putative virion structural protein Pseudomonas phage OBP (152/260, 58%) YP_004958172.1 7.00E-118 0 − −
211 197136 198605 + ATG TAA 489 6.01 55.81 putative UvsX Pseudomonas phage OBP (425/491, 87%) YP_004958173.1 0.00E+00 0 − −
212 198607 198969 + ATG TGA 121 4.56 13.71 unnamed protein product Pseudomonas phage OBP (78/12, 65%) YP_004958174.1 2.00E-62 0 − −
213 198969 199646 + ATG TAA 225 5.56 24.74 putative virion structural protein Pseudomonas phage OBP (184/225, 82%) YP_004958175.1 1.00E-170 0 − −
214 199646 200122 + ATG TAA 158 4.69 18.22 unnamed protein product Pseudomonas phage OBP (79/141, 56%) YP_004958176.1 5.00E-52 0 − −
215 200129 200857 + ATG TAA 242 5.53 28.16 unnamed protein product Pseudomonas phage OBP (171/246, 70%) YP_004958177.1 1.00E-151 0 − −
216 200906 201508 − ATG TAA 200 4.28 22.64 unnamed protein product Pseudomonas phage OBP (137/204, 67%) YP_004958178.1 2.00E-112 0 − −
217 201618 202169 + ATG TGA 183 5.1 21.25 unnamed protein product Pseudomonas phage OBP (114/189, 60%) YP_004958179.1 7.00E-86 0 − −
218 202162 202572 + ATG TAA 136 9.52 15.66 unnamed protein product Pseudomonas phage OBP (99/136, 73%) YP_004958180.1 8.00E-70 0 − −
219 202642 203757 + ATG TAA 371 4.51 40.46 putative virion structural protein Pseudomonas phage OBP (255/369, 69%) YP_004958181.1 0.00E+00 0 − −
220 203816 206020 − ATG TAA 734 5.42 79.74 putative virion structural protein Pseudomonas phage OBP (578/740, 78%) YP_004958182.1 0.00E+00 3 − −
221 206060 213247 − ATG TAA 2395 8.14 260.37 putative structural lysozyme Pseudomonas phage OBP (1376/2449, 56%) YP_004958183.1 0.00E+00 0 − Lysozyme-like domain superfamily
222 213278 214894 + ATG TAA 538 5.41 60.58 putative virion-associated RNA polymerase beta subunit Pseudomonas phage OBP (454/519, 87%) YP_004958184.1 0.00E+00 0 − −
223 214894 219234 + ATG TAA 1446 5.49 163.48 putative virion-associated RNA polymerase beta subunit Pseudomonas phage OBP (1057/1451, 73%) YP_004958185.1 0.00E+00 0 − −
224 219237 220103 + ATG TAA 228 8.75 32.28 hypothetical protein PPEV_gp188 Pseudomonas phage EL (114/287, 40%) YP_418221.1 3.00E-52 0 − −
225 220131 220298 + ATG TGA 55 4.57 6.16 putative virion structural protein Pseudomonas phage OBP (41/50, 82%) YP_004958187.1 4.00E-20 0 − −
226 220295 221812 + ATG TAA 505 4.66 56.69 putative virion structural protein Pseudomonas phage OBP (300/504, 60%) YP_004958188.1 0.00E+00 0 − −
227 221812 222549 + ATG TAA 245 5.19 27.26 putative virion structural protein Pseudomonas phage OBP (196/245, 80%) YP_004958189.1 9.00E-144 0 − −
228 222551 223399 + ATG TAA 282 5.57 31.91 putative virion structural protein Pseudomonas phage OBP (205/283, 72%) YP_004958190.1 3.00E-153 0 − −
229 223503 224102 + ATG TAA 199 5.09 22.56 putative virion structural protein Pseudomonas phage OBP (94/159, 59%) YP_004958191.1 4.00E-63 0 − −
230 224210 224596 + ATG TAA 128 4.79 14.25 unnamed protein product Pseudomonas phage OBP (47/115, 41%) YP_004958198.1 4.00E-15 0 − −
231 224603 225136 + ATG TGA 177 5.79 20.26 0 − −
232 225387 225803 + ATG TAA 138 5.04 15.73 unnamed protein product Pseudomonas phage OBP (44/130, 34%) YP_004958198.1 8.00E-15 0 − −
233 225913 226365 + ATG TAA 150 5.17 16.61 0 − −
234 226405 226842 + ATG TAA 145 4.98 16.48 unnamed protein product Pseudomonas phage OBP (96/147, 65%) YP_004958202.1 2.00E-59 0 − −
235 226907 227308 + ATG TAA 133 10.21 15.64 0 − −
236 227259 227669 + ATG TAA 136 8.99 16.29 unnamed protein product Pseudomonas phage OBP (68/128, 53%)  YP_004958206.1 1.00E-44 0 − −
237 227660 228118 + ATG TAA 152 8.61 17.72 unnamed protein product Pseudomonas phage OBP (38/98, 39%)  YP_004958207.1 2.00E-13 0 − −
238 228118 228720 + ATG TGA 200 6.98 23.44 unnamed protein product Pseudomonas phage OBP (140/200, 70%) YP_004958208.1 1.00E-104 0 − −
239 228795 229334 + ATG TAA 179 5.7 19.74 unnamed protein product Pseudomonas phage OBP (76/186, 41%) YP_004958209.1 3.00E-36 1 Yes −
240 229431 230072 + ATG TAA 213 5.49 23.06 unnamed protein product Pseudomonas phage OBP (79/215, 37%) YP_004958210.1 9.00E-34 1 Yes −
241 230112 230786 + ATG TAA 224 5.29 24.24 unnamed protein product Pseudomonas phage OBP (102/228, 45%) YP_004958213.1 5.00E-64 0 Yes −
242 230931 231635 + ATG TAA 234 5.4 27.17 putative metal-dependent phosphohydrolase Pseudomonas phage OBP (171/233, 73%) YP_004958214.1 3.00E-121 0 − −
243 232568 233470 − ATG TAA 300 5.98 33.49 putative tail tube Pseudomonas phage OBP (271/300, 90%) YP_004957908.1 0.00E+00 0 − −
244 233482 235677 − ATG TAA 731 4.92 80.78 putative major tailsheath Pseudomonas phage OBP (561/733, 77%) YP_004957909.1 0.00E+00 0 − −
245 235785 236660 + ATG TAA 291 8.4 32.27 putative virion structural protein Pseudomonas phage OBP (233/291, 80%) YP_004957910.1 1.00E-177 0 − −
246 236688 239501 + ATG TGA 937 5.22 107.84 putative virion structural protein Pseudomonas phage OBP (667/938, 71%) YP_004957911.1 0.00E+00 0 − −
247 239494 241236 + ATG TAA 580 5.44 65.13 putative virion structural protein Pseudomonas phage OBP (443/578, 77%) YP_004957912.1 0.00E+00 0 − −
248 241285 244695 − ATG TAA 1136 8.38 130.91 putative terminase large subunit Pseudomonas phage OBP (483/599, 81%) YP_004957913.1 0.00E+00 0 − Homing endonuclease. Hint domain superfamily 
249 244825 245451 − ATG TAA 208 5.85 23.43 putative thymidylate kinase Pseudomonas phage OBP (78/199, 39%) YP_004957915.1 9.00E-39 0 − Thymidylate kinase
250 245451 246917 − ATG TAA 488 6.2 56.88 putative virion structural protein Pseudomonas phage OBP (379/484, 78%) YP_004957916.1 0.00E+00 0 − −
251 246917 247594 − ATG TAA 225 7.72 24.98 putative virion structural protein Pseudomonas phage OBP (189/225, 84%) YP_004957917.1 1.00E-138 0 − −
252 248377 248889 + ATG TGA 170 9.1 18.92 0 − −
253 248953 249192 − ATG TAA 79 4.99 8.61 putative glutaredoxin Pseudomonas phage OBP (46/64, 72%) YP_004957919.1 9.00E-24 0 − Thioredoxin-like superfamily 
254 249816 250403 − ATG TAA 195 9.47 21.69 hypothetical protein SHAb15599_00126 Acinetobacter phage SH-Ab 15599 (58/150, 39%) AXF41482.1 2.00E-31 0 − −
255 251200 251439 − ATG TAG 79 5.73 9.1 hypothetical protein SopranoGao_55 Klebsiella phage SopranoGao (32/73, 44%) ASV45078.1 2.00E-10 0 − Protein of unknown function DUF2829
256 252260 252874 + ATG TAA 204 7.72 23.63 putative virion structural protein Pseudomonas phage OBP (62/197, 31%) YP_004957923.1 1.00E-28 0 − −
257 252889 253245 + ATG TAG 118 7.76 13.99 unnamed protein product Pseudomonas phage OBP (40/62,65%) YP_004957924.1 3.00E-10 1 − −
247 
 
Supplementary table 4. MEME predicted promotors in Klebsiella aerogenes phage 
N1M2 shared with Pseudomonas phage OBP. 
 
  
Promoter  Start  End  Sequence E value 
   TBYAWWWWWTTTCARRYAKATATTATYWAAGTGWA 3.5e-093 
pORF 9 4117 4152 CTCATCAATAATCAAATCGAGATCTTGAAAATCTT 8.9e-5 
pORF 14 6381 6417 CTTATTTGTTTTGAAATAGATATTATTAGATTGAA 1.6e-10 
pORF 24 12701 12735 GTTATAAAATTTCAAACAAATATTATCCTCATGTA 7.4e-12 
pORF 41 26928 26963 TGTATTTCATTTCAGACCTATATTACTTAAGTGAT 1.0e-12 
pORF 47 31335 31370 TCTAAAAATGTTTAGGCAGATATTATTAGAGTGTA 3.1e-14 
pORF 50 36515 
complement 
36550 TACATATAGATAATATCTGTCTGATTATCTTTGGC 5.5e-13 
pORF 51 36515 36550 GCCAAAGATAATCAGACAGATATTATCTATATGTA 5.5e-13 
pORF 56 41620 41655 GTAATAAATTTTTAAGTAGATATTATTTATAGGAG 3.0e-10 
pORF 70 53113 53149 TCTATTGATTTTCAAGCAGATATTATTAACATGTA 4.6e-15 
pORF 85 69322 69357 AACAATTTAATTAAATCGTTTTAACTCTTTCTATA 4.0e-6 
pORF 104 90554 90589 TGAAAGAAATTTCAGGTCTATATCATCTAAGTGTA 6.8e-12 
pORF 122 120146 120181 GTCACATATTTTCAGGCAGATATTATCATTATGTA 2.8e-13 
pORF 131 129052 129087 TGCATATAAGTTTAAGCAGATATTATCACAGTGTA 2.7e-14 
pORF 149 138627 138662 TGTATTTATTTTTGGACTTATATTATCTAAGTGTA 1.7e-12 
pORF 167 166693 166728 TCCAAATCTTTTCAGGTAGATATTATTAAAGTGAA 8.6e-16 
pORF 168 167710 167745 TGCATTTCATTTTAAACCGATATTATTAACGTGAG 2.3e-13 
pORF 179 173383 
complement 
173418 TACATAATGATAATATCTGTCTATTTTTATTTGAA 2.1e-11 
pORF 180 173383 173418 TTCAAATAAAAATAGACAGATATTATCATTATGTA 2.1e-11 
pORF 187 177684 177720 TGTATTTCTTTTCAGACATATATAATTAAAGTGTA 8.5e-15 
pORF 192 179906 179941 GGTAAAATTTTTCAAACAGATATTATCTAAGTAGT 4.0e-12 
pORF 197 183895 183930 TGTATCTTATTTCAGACATATATCATTTAAGTGAA 2.5e-13 
pORF 199 185535 185570 TCTATTTTAAAACAGATAGATATTATCATAGTGTA 6.1e-13 
pORF 216 201530 
complement 
201565 TCTACTTTGATAATATTTGTTTGAAATATAATAGT 3.4e-11 
pORF 217 201530 201565 ACTATTATATTTCAAACAAATATTATCAAAGTAGA 3.4e-11 
pORF 219 202605 202640 CTCTTTTAAATAATTTATTTTTTTTTAGGATTAAT 3.7e-5 
pORF 230 224133 224168 GCTATTTAATTTCAAGCAGATATTATTAACGTGTT 2.0e-15 
pORF 233 225820 225854 GCCAAAATGCTTCAGGTATATATTATTACCGTGAA 1.3e-11 
pORF 239 228726 228761 TACATTCATAGTCAGGTCTATATTATCTAAGTGTA 1.0e-11 
pORF 240 229336 229371 TGAATACAAATTCAGAAATATATAATCTAATTGAT 3.2e-10 
pORF 242 230861 230895 TTTAAAATTATTCAGACGTATATTATTAGCATGTA 4.0e-12 
pORF 256 252179 252214 TCCATTATTAAATAAATAGATATTATTAGATTGAA 6.0e-11 
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Supplementary table 5. Terminators of Phage N1M2 detected using ARNold and 
confirmed using Mfold Quikfold. Loops and stems are shown in red and blue 
respectively. 
Terminator  Start  End  Sequence ΔG 
kcal/mol 
tORF5 2731 2770 GGGGTGGTGGGTAAAACCGTCACCCCgTTTTGATACCAC -18.60 
tORF13 6347 6384 CTATCACCTCCAAAAGGGGTGATAGTTTTTAGTTCTT -14.10 
tORF14 7153 7189 TTGGTCTGGTGGTTATCAGATCAATTTACTTTCTGG -10.10 
tORF18 9195 9229 TGGGGAGGTCAACCCTCCCTAaTTTTAATAGATC -13.12 
tORF27 15041 15072 GCCCTGGCTAGTCCAGGGCTTTTTATATTGC -13.60 
tORF32 17679 17710 GCGCTCAATACAAGAGCGCTTTGATTACCGG -10.50 
tORF 23568 
complement 
23612 CAGAGAGGAGGGCTTTCACCCACCCTCTCTGTTAATTTAGTTAA -17.20 
tORF36 23582 23625 CAGAGAGGGTGGGTGAAAGCCCTCCTCTCTGTTGTTTTTATAGG -23.20 
tORF38 25903 25941 GCAATGGGGTGGAAACACCCTGTTGCTTTTATCAGGTT -21.40 
tORF 27171 
complement    
27213 CAGGATCTCCCGGTTAGGGGAGATCCTGgTTATGACTTATTT -22.00 
tORF41 27185 27226 CAGGATCTCCCCTAACCGGGAGATCCTGTTATTCTATACTT -20.60 
tORF50 36095 
complement    
36135 TACCACCTACTATAGAGTAGGTGGTAgTTATTTACATAAA -17.40 
tORF60 45037 45076 CTTACCCTTCCTAGTGGAGGGTAAGggTTATATGTTTAT -14.80 
tORF 46140 
complement    
46179 CTACTCACCCTTAATTGGGTGAGTAGgTATGTGTTATTT -18.90 
tORF64 47405 
complement 
47446 CCTCTACTCCCGTGATGGGAGTAGAGGTTATGTTTACTTA -20.60 
tORF63 47419 47457 CTCTACTCCCATCACGGGAGTAGAGgTCTGTTATGCTA -18.40 
tORF67 52161 52193 GCCGTCTTAGAAAGGCGGCTTTTCATGATCA -11.10 
tORF73 54535 
complement    
54578 CCCTACCCACTCCGAAAGGAGGGGTAGGGgTTATGTTTGTTAT -27.00 
tORF85 70629 70667 GAGTAGGGGCCTTCGGGCTCCTACTCTTATATGTTTGC -24.10 
tORF87 72330 72366 GCTTGGCTGCTAAACAAGCTAAGCTATCTGTTAATG -12.00 
tORF90 74598 74637 CTCTACTCCTTTTATCGGGAGTAGGGgTTTGATGTTATG -15.10 
tORF 94012 94044 CAGGTCATTATTGGCCTGaaTGTTATTACTGA -10.20 
tORF108 97725 97671 GACCACGGTTTCGGCCGTGGTCagTTCTATTTATGA -17.10 
tORF109 98249 98288 TGTATGGGGGTTATAAAACCCATGCAcTTTTTGTAGGAT -11.30 
tORF111 99509 99554 CCCTACCCCTCCAATTAAGGATGGGGTAGGGgTTATGCTTACTAT -23.50 
tORF 109916 
complement    
109945 GGGGAGTTTCCTCCCCaTTCTATTAACCT -11.50 
tORF117 109929 109957 GGGGAGGAAACTCCCCTTTCTTATTTAG -15.40 
tORF119 115859 
complement    
115903 CCCCTACCCCTCCGAAAGGAAGGGTAGGGAgTTTATGGTTTATA -24.50 
tORF118 115875 115915 CCTACCCTTCCTTTCGGAGGGGTAGGggTTATGTTTACTT -21.00 
tORF120 119412 119438 CCCCGGAAACGGGGTTTTATTCATTA -12.70 
tORF125 124134 127172 TAGGAGAGGGGAAACTCTCTCCTAcaTTTTTGTTTATA -19.10 
tORF127 125095 125135 CCTAGAGAGGGAATTCCCTCTCTAGGacTTTATATTGTTT -22.00 
tORF 134705 
complement    
134741 GAACCTACCTTAATCGGTAGGTTCTCTATTATGGTT -14.90 
tORF 14139 
complement    
141438 TGGGGGTTGGTTTTACCCAACCCTTGaTTCTTTCTAATA -13.40 
tORF161 150437 150467 GGGGACCGGAGTCCCCCCTTTTACATCAAC -10.70 
tORF163 160772 
complement    
160813 TGAGAGTCTGGGGTAACCTGGGCTCTCATTATTATGGTATG -19.50 
tORF164 163667 
complement 
163705 AGTCCCTGGGTTCGTCCAGGGACTcTTTATCAGATTCT -18.90 
tORF165 164443 
complement 
164479 GTAGGGTGGCCGAAGCCACCCTACTCTATGTTCGGA -19.80 
tORF171 169645 169686 AGAGAGGCTTCCGAAAGGAGGTCTCTCTcTTTTTGTACCTGA -22.70 
tORF179 172660 
complement 
172704 CCCTACCTAGCCCGCAAAGGCTAGGTAGGGaTTATGCATGTATT -24.40 
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tORF184 176430 176468 GCTAGGGGCTCTTAGGAGCCTTTAGCTTTTCAAGGTAT -17.50 
tORF 182639 
complement 
182678 CGAGCTGAGGTGTTACCCTCAGCTCGaTCTTAGTTATGC -19.00 
tORF 184319 
complement 
184355 CAGGCTACCCGAAGGTAGCCTGagTTTACTTATTCG -16.30 
tORF197 184344 184638 AGGCTACCTTCGGGTAGCCTgTTATTCGGTTCTT -17.10 
tORF203 187904 
complement 
187944 CCTACCCTTCCTTACGGAGGGGTAGGggTATTTTGTCGTT -21.00 
tORF206 191881 191920 CTTACCCTCCGCAAGGAAGGGTAAGggTTATATGTTTGT -18.00 
tORF210 196236 
complement 
196271 CTTCCTTGCGGAGGGTAAGGGAGTATGTTTGTTAT -11.30 
tORF220 203754 
complement 
203798 CCCTTACCCACTCCGTGAGGAGGGGTAAGGGTTATGCTTGTTTA -27.20 
tORF221 206022 
complement 
206057 TGAGGGGACTTCGGTCCCCTTAcTTTTAGAGGTAA -18.10 
tORF 214038 
complement 
214070 CTGTGACGTTATCGTCGCAGTTTTCTACTGAT -11.60 
tORF223 219297 
complement 
219328 AGGCCGTCAATGCGGCCTTTATATAGGGAAA -11.00 
tORF 222630 
complement 
222667 GTTGGGGATATTAAAACCCCCAGCgTTTAATTCATAC -11.80 
tORF228 223407 223443 GTAGGGGTCCTTCGGGATCTCTACTTATTTTGTTAT -18.20 
tORF243 232501 
complement 
232545 CCCCTACCCACTCCGAAAGGAGGGGTAGGGGTTTTATGTTGTTT -29.60 
tORF 247875 
complement 
247919 CCCTACTCCCTCCGAAAGGAAGGGGTAGGGgTTTATGTTTGTTT -24.60 
tORF 251572 
complement 


























Supplementary Figure 1. Effect of N1M2 and Phage K on mixed biofilms formed by 
N1 K. aerogenes and DPC 5247 S.aureus. No glucose 48 hr biofilm, 48 hr phage. N1 
and DPC 5247 were quantified in the biofilm by dilution and spread plating on UTI 
ChromoSelect agar. The experiment was carried out once but counts were carried out 
in duplicate. A. Count of N1 in mixed biofilm formed by N1 and DPC 5247. B. Count 









































































































Phages have myriad uses with some used more classically, such as in studies 
of co-evolution, and some due to the changing needs of the world. The changing 
attitudes of consumers towards traditional chemicals, a move towards more natural 
options, and the increase in resistance to well characterised antimicrobial compounds 
has reinvigorated the study of phages.  
 We showed that a commercially available phage reduced Listeria 
monocytogenes growth in coleslaw over a 10 day period at both high multiplicity of 
infection (MOI) and low MOI. The low MOI alone was as effective as a combination 
of the phage and a bacteriocin but the combination may be helpful in limiting the 
emergence of phage resistant mutants.  Although listeriosis is a serious illness many 
consumers are unaware of it or are uninformed about its mode of transmission. In a 
survey 78.9% of pregnant women reported awareness of L. monocytogenes but 
conversely 71.1% reported consuming high-risk food, suggesting a gap between 
recognition of a term and full understanding of the associated risks (1). This was 
despite the fact that pregnant women are ten times more likely to contract listeriosis 
than the general population and 14% of all listeriosis cases occur in pregnant women. 
In a separate study 80% of non-pregnancy associated listeriosis patients in Germany 
had never heard of the disease prior to their illness (2). Also only 6% of the 
immunocompromised control population knew about the foodborne nature of the 
disease. L. monocytogenes can grow at high salt concentrations, a wide pH range, and 
at refrigeration temperatures. L. monocytogenes are found in a range of environments 
including a wide diversity of foods, soil, water, vegetation, sewage, and animal faeces 
(3). The ability of L. monocytogenes to form biofilms is also important for its 
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persistence in the environment, including processing plants and contaminated food, 
and its subsequent spread (4). Phage and bacteriocins are being introduced as clean 
label antimicrobials in food processing. As mentioned in Chapter 1b the properties of 
foods can affect the activity of phages so the combination could be tested in foods of 
different pHs, textures, and at different storage temperatures. Phage concentration is 
vital to the success of phage application in food so a range of concentrations were 
investigated. Partial synergy between the two biological agents was achieved in the 
checkerboard assays but not in the food model but this could be investigated further 
by varying the concentrations used. As also discussed phage choice is important so an 
alternative phage, such as ListShield, could be applied. Similarly, variants of nisin 
with increased activity could be applied to the system (5).  
 No differences were found between the viromes of men and women or between 
any of the phases of the menstrual cycle. No differences were visible in the bacteriome 
as analysed by 16S rRNA data. Differences were visible between the viromes of 
women using hormonal contraception and women not using hormonal contraception. 
We believe this to be the first study of its kind. No published literature is available on 
the effect of hormonal contraception on the gut virome or bacteriome assessed by 
metagenomics sequencing. Inter-individual variation in the viromes of people and 
viral dark matter can mask differences between groups or individuals. Clustering was 
used to overcome this issue. Clustered virome data showed more pronounced 
differences than unclustered data. The gut microbiota can regulate hormones and 
hormones in turn can affect the gastrointestinal tract (6). The menstrual cycle, and its 
associated changes in hormone levels, can be associated with gastrointestinal 
symptoms (7). Changes in the menstrual cycle have been found in the year prior to 
irritable bowel disease diagnosis (8). The selection of healthy controls is vital to 
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establishing differences between groups in metagenomics studies. A number of factors 
must be taken into account when recruiting healthy controls. Further research should 
be carried out to determine if there are differences between users and non-users of 
hormonal contraceptives. This study was a pilot study carried out with a limited 
number of subjects and must be repeated with greater numbers. Also metagenomic 
sequencing of the bacteriome could establish if there were any differences between 
any of the groups and if links were visible between the bacterial and phage components 
of the microbiome that were not visible using 16S data. This could help to establish if 
the virome is more discriminatory than the bacteriome or if they reflect each other (9). 
Comparisons of the effect of different oral contraceptive types such as estrogen and 
progesterone combined and progesterone only should be carried out. Postmenopausal 
women receiving and not receiving hormone replacement therapy could also be 
investigated and a comparison of premenopausal and postmenopausal women. 
 When a healthy human faecal sample was screened for phages against 163 
bacterial strains isolated from the same sample no phages were isolated. One phage 
was isolated from the faecal sample against a well characterised strain after screening 
an additional panel of 77 bacterial strains available in the laboratory. However, 155 
phages were isolated from six environmental samples against the laboratory strains 
and the strains isolated from a human faecal sample. This highlights the importance 
of screening new and unrelated environments and of intelligent strain selection for 
phage screening (10). Of the 86 phages sequenced the majority were previously 
published, which draws attention to the difficulty in isolating new and novel phages 
(11). Single nucleotide polymorphisms (SNPs) analysis was carried out on 70 strains 
of a previously described phage compared to the original genome and to one another. 
Although these were strains of the same phage genetic differences were apparent. 
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SNPs introduced synonymous and non-synonymous changes and introduced stop 
codons. Some genes were found to only contain synonymous changes or low levels of 
SNPs which could indicate the need for conservation of these genes. It would be of 
interest to screen a sample for phages using a method including and excluding 
enrichment to establish how much more effective enrichment can be. However, it must 
be taken in to account that enrichment can bias isolation. A systematic review of 
literature could be carried out to try and establish the probability of isolating phages 
based on the number of sources screened, the number of strains used, the number of 
potential phages found, if enrichment was included, and the number of novel phages 
found in a multitude of studies. It would be interesting to assess the host range of the 
APCEc01 phage strains including against the original host and pinpoint which, if any, 
SNPs affected this. Transcriptomics or ribosome profiling could be used to try and 
establish roles for the uncharacterised, hypothetical proteins or phage proteins present 
in APCEc01 (12). Some genes which had a large number of SNPs had no annotated 
function so little could be learned from these areas. SNPs are commonly investigated 
during co-evolution experiments where phages and bacteria are cultured together for 
a number of generations. SNPs have previously been investigated by designing PCR 
primers to regions of DNA, amplifying the region, and then Sanger sequencing the 
region (13). Another option is using host range as an indicator by assessing infectivity 
towards the original host and hosts from different time points in the evolution (14). 
Bacteria can also be assessed in the same way. Whole genome sequencing as carried 
out in this study is also an option.  
A novel lytic jumbo phage, N1M2, targeting a Klebsiella aerogenes strain was 
isolated from maize silage. N1M2 could also infect a Klebsiella pneumoniae strain. 
The K. aerogenes strain was isolated from a healthy human faecal sample. K. 
255 
 
aerogenes is an ESKAPE pathogen and often found as a component of biofilms on 
medical devices. N1M2 at MOIs of 10 and 100 applied for 48 hours was not effective 
against biofilms formed over 48 hours. However, N1M2 applied at an MOI of 10 or 
100 for 72 hours significantly reduced a biofilm formed over 48 hours and similarly 
N1M2 applied at an MOI of 10 or 100 for 48 hours significantly reduced a biofilm 
formed over 24 hours. Phage K is a well-documented phage with activity against 
Staphylococcus aureus (15). Similar to K. aerogenes S. aureus is of great importance 
for antibiotic resistance and is found as biofilms on medical devices. In a mixed 
community biofilm of K. aerogenes and S. aureus grown for 48 hours N1M2 alone 
and Phage K alone at MOIs of 10 applied for 48 hours did not significantly reduce the 
biofilm. However, N1M2 and Phage K at MOIs of 10 in combination significantly 
reduced the biofilm. Antibiotic resistance is naturally occurring but rates have 
increased due to the over use and misuse of antibiotics in humans and animals (16). 
Antibiotics have been used as growth enhancers in livestock, as prophylactics for 
infections, and to treat already established infections. New treatments are required for 
treatment of bacterial infections due to this rapid and unrelenting rise. Phage therapy 
is a technique that has largely been unexplored in Western medicine but is now gaining 
interest. Further characterisation of N1M2 could be carried out including its stability 
at a range of temperatures and pHs, host range analysis using more bacterial strains, 
restriction enzyme analysis, and a one-step growth curve. Host range should be 
assessed using efficiency of plating to avoid false positives in the form of lysis from 
without. The antibiotic sensitivity of strain N1 could be assessed. N1 was sequenced 
using the MinION and was described as a draft genome and should be sequenced 
further using a different platform. K. aerogenes resistance to carbapenem antibiotics 
is commonly caused by the overexpression of efflux pumps, the modification of 
256 
 
porins, or the downregulation of porin synthesis (17). Biofilm assays should be carried 
out to compare the efficacy of antibiotics and N1M2 against K. aerogenes biofilms. 
Combinations of antibiotics and phage could also be investigated. This could include 
the eradication of pre-formed biofilms and inhibiting the formation of biofilms. 
Biofilm assays could also be performed with clinical isolates from biofilms or infected 
wounds. 
This thesis addressed a varied range of applications of phages. Phage was 
applied to food in combination with another natural food additive, a pilot study 
highlighted the need for further investigation in to the effect of hormonal contraception 
on the human gut virome and bacteriome, a novel jumbo phage was isolated and tested 
in a model system, and the difficulties associated with screening and single nucleotide 
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